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Abstract 
Background: 
Access to medicines is a basic human right. The World Health Organization (WHO) Model List of 
Essential Medicines was created in 1977, to promote access to essential medicines that satisfy the 
priority health care needs of the population. In this day and age, access to safe and affordable 
medicines is not guaranteed to all. There exists global inequality of access to lifesaving or essential 
medicines. This is referred to by the WHO as the ‘global drug gap’, in which approximately one 
third of the global population still does not have access to basic medicines.  
Contributing to the disparity in access, are rising pharmaceutical expenditures and globalisation of 
complex pharmaceutical supply chain networks. This has resulted in countries of all economies 
and geographical regions sourcing their medicines from common sources. Therefore, challenges 
accessing unavailable medicines have become a shared experience, as demonstrated by the 
relatively recent emergence and recurrence of global drug shortage crises. The WHO framework 
for access to essential medicines, which considers rational selection of medicines, affordable 
prices, sustainable financing, and reliable health and supply systems, was used as a theoretical 
framework to explore the gap in access to medicines. 
Aims and Objectives: 
Aim: To explore stakeholder views about the concept of essential medicines. 
Objectives: (1) To explore the application of the Essential Medicines List (EML) concept and how 
this was associated with access to essential medicines. (2) To explore the factors that influence 
access to essential medicines, and understand the roles of international key stakeholders involved 
in this process.  (3) To explore what constitutes an “essential” medicine, and how the EML 
concept functions in a high income country (HIC) context. 
Content of This Thesis 
This thesis is made up of 4 chapters. Chapter 1 contains the background and a review of the 
literature on access to essential medicines.  The challenges identified in chapter 1 lead to the 
exploration of global perspectives on the supply and management of essential medicines in 
chapter 2. The qualitative study in chapter 3 describes what constitutes an essential medicine for 
stakeholders in a high income country (HIC). Lastly, chapter 4 contains general discussions and 
conclusions from the work described in this thesis. 
Methods: 
A narrative literature review (chapter 1) was performed to explore how the application of the 
EML concept is associated with access to essential medicines. A search strategy developed from 
the principles of the WHO access to medicines framework was used to identify primary studies 
from Medline, Embase and PubMed.    
A qualitative study was conducted to explore perspectives of international (chapter 2) and 
Australian (chapter 3) key stakeholders about the pharmaceutical supply chain, on the application 
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and relevance of EML concept and what makes a medicine essential. Snowball sampling was used 
to recruit decision makers, leaders or senior managers involved in medicines decision making 
across seven stakeholder groups. Stakeholders included: government, health care providers, 
academics, consumer groups, non-profit organisations, pharmaceutical manufacturers and 
wholesaler/distributors.   
Forty-seven semi structured interviews were conducted face-to-face, via Skype or telephone, 
audio-recorded and transcribed verbatim. Interviews were conducted until thematic saturation 
was achieved. Data were analysed using a grounded theory approach. The comprehensive theory 
of collaboration was applied after the grounded theory analysis to organise and understand 
results within a management context. In addition, chapter 2 used the Ishikawa fishbone diagram 
to illustrate the complexities of the pharmaceutical supply chain. Meanwhile, chapter 3 illustrated 
the conceptual model derived from the results. 
Key Findings: 
Chapter 1- A literature review showed that there has been improved access to essential medicines 
for many populations.  Findings showed EMLs help promote advocacy and provide reliable 
evidence at the health systems level. However, there was variable use of EMLs at the health 
services delivery level (i.e. for a patient at the point of care). Decision making around standard 
treatment guidelines and EMLs were often not aligned with procurement and management 
strategies within the supply chain. The literature review showed that accessing medicines was 
complex. Studies were often not well-designed, had narrow research objectives and few 
qualitative studies were conducted. Studies focused on resource limited settings in LMICs and 
scarce data was available for EMLs in HICs. 
Chapter 2- Qualitative interviews with international stakeholders described the complexities 
involved in managing the global pharmaceutical supply chain. While stakeholders’ roles and 
responsibilities were inter-connected, therapeutic decision making was often separated from 
logistic management of the pharmaceutical supply chain due to potential conflicts of interest. This 
created many gaps and inconsistencies around pricing and costs, planning and reactivity, 
communication and transparency, and contributed to difficulties building trust and consistency 
between stakeholders.  
Adding to this complexity, individualised or patient-centred care approaches have emphasised the 
need for consumer choice and demand a wide range of products that has become increasingly 
challenging to manage. Therefore, drug shortages have highlighted the opportunity for 
collaborative alliances to identify, prioritise, and manage vulnerabilities in the supply chain to 
prevent or mitigate patient harm as a result of restricted access to medicines.  In particular, 
wholesalers and distributors were identified as potentially having more valuable roles in 
managing supply disruptions (e.g. redistribution) and facilitating information exchange  between 
stakeholders (e.g. forecasting or confirming at what level of the system a shortage occurs).  
Participants also suggested designating drug shortage experts or liaison to manage and 
communicate shortages, especially to consumers and health providers.  
xiv 
 
Chapter 3- Qualitative interviews with Australian stakeholders demonstrated that the different 
perceived functions of EMLs seemed to be stratified depending on whether the decision making 
context was at a health systems level or at an individual level (i.e., for a patient at the point of 
care). EMLs can function as reimbursement lists at the health systems level, or hospital 
formularies at the health services level. Meanwhile, non-reimbursed or off-formulary medicines 
were available to consumers who were willing and able to pay if they were deemed essential to 
individuals. Conversely, some medicines can be deemed essential but were not available or 
affordable to individuals. The wide range of views in this study, highlight the complexities of 
decision-making processes involved in developing and managing EMLs, which has been 
compounded by the expanding consumer need to have a range of therapeutic options.  These 
findings emphasise the context within the health system determines for whom a medicine is 
deemed essential. 
Conclusion: 
 
Prior to this thesis, EMLs have been studied with narrow research objectives and mainly in LMICs. 
This body of research was the first to explore how the application and management of EMLs 
effected access to medicines, from a broad range of stakeholder views involved in both 
therapeutic decision making and logistics management. Furthermore, it was also a rare study that 
examined the EML concept within HIC contexts. 
Findings from this body of work demonstrated different perceived functions of the EML.  
Furthermore, it also questioned whether the term ‘essential’ was appropriate and reflected how 
the EML was used. While EMLs can be useful to guide evidence based decision making for 
reimbursement at the systems level, the variations in the notion of essential at the individual level 
is influenced by an individual’s choice. Therefore, this highlights the importance of guiding (or 
limiting) consumer choice with appropriate and accessible information, to help individuals make 
informed and responsible decisions.  
This research confirmed that the access to medicines gap continues to be problematic.  The 
pharmaceutical supply chain has been unable to handle drug shortages adequately.  Therefore, in 
order to sustain patient-centred care practices, concessions by all stakeholders must be made if 
the supply chain is to withstand global economic, political, and ecological instability. Multi-
stakeholder engagement, transparent processes, innovative communication pathways, and EML 
approaches offer potential solutions to mitigate supply chain disruptions.  Future approaches 
should align decision making priorities with procurement practices. Decision makers and supply 
chain managers have a valuable opportunity to reflect and understand how the current system is 
functioning, in order to develop foundations for improved processes, and innovative and 
cooperative platforms to interact and network. 
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CHAPTER 1: BACKGROUND AND LITERATURE REVIEW ON ACCESS 
TO ESSENTIAL MEDICINES 
1.1 INTRODUCTION  
1.1.1 Access to Medicines 
Access to medicines is a basic human right, in line with food, water, housing, clothing and 
education.  Medicines that are lifesaving and commonly used to improve individuals’ quality of life 
should be available, affordable, of safe quality and appropriately used for all people (UN 1948).  
According to the 1978 Geneva Alma Ata Declaration on Health for all, medicines should be 
accessible worldwide to people of all gender, race, sexual orientation, socioeconomic status, 
political beliefs and religion (WHO 1978, Hogerzeil 2006). The responsibility to ensure the 
provision of basic health care and access to medicines has been entrusted to policy makers 
globally. As a result, medicines policies are critical components of all health care systems 
(Perehudoff, Laing and Hogerzeil 2010). As the global population continues to age and 
pharmaceutical expenditure rises, access to medicines has become a high priority on government 
health care agendas worldwide. 
1.1.2 The Essential Medicines List Concept 
The Essential Medicines List (EML) concept dates back to military tradition,  where  therapeutic 
supplies were essential to be carried by soldiers, field medics, and camp infirmaries into combat 
zones (Greene 2011). This concept was also applied to the rationalising of therapeutic restrictions 
necessary during wartime economy. Following the industrial revolution and after the invention of  
penicillin, which was used in World War II by military and aide organisations, governments began 
considering the importance of making lifesaving medicines available to the population (Greene 
2011).  In accordance with the Geneva 1978 Alma Ata Declaration on Health for all, access to 
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essential medicines was  a human right that needed to be acknowledged and upheld by society 
and governments (UN 1948, Hogerzeil 2006).   
In 1977, the WHO created the Model List of Essential Medicines (WHO EML) to establish 
international pharmaceutical standards and guidelines to improve access to medicines. The WHO 
defined essential medicines as:  
“those that satisfy the priority health care needs of the population. They are selected with 
due regard to disease prevalence, evidence on efficacy and safety, and comparative cost 
effectiveness.  Essential medicines are intended to be available within the context of a 
functioning health system, at all times, in adequate amounts, in the appropriate dosage 
forms, with assured quality, and at a price the individual and the community can afford” 
(WHO 2002, WHO 2015b).   
Modeled after hospital formularies that aligned with standard treatment guidelines (STGs), the 
WHO EML started with 186 lifesaving medicines (Greene 2011).  Nowadays, the WHO EML 
contains 409 active substances that are lifesaving and/or improve the quality of life for individuals 
(WHO 2015b). It consists of medicines needed for basic health care systems and also medicines 
that require specialised health facilities, services or are costly. The WHO EML has expanded over 
the years with updates made every two years. It now includes generic and patented high cost 
medicines, and has integrated EMLs for children and palliative care. It has been applied in both 
low and high income settings in 156 countries (WHO 2015b, WHO 2015a). 
The WHO EML was intended to provide a flexible framework to guide national medicines policy 
(Hogerzeil 2006). The WHO advocated that each country take responsibility for the selection, 
implementation and evaluation of their EML, and governments were encouraged to adapt the 
EML to their population’s  health needs (WHO 2000).   The EML was an especially useful tool for 
low to middle income countries (LMICs), defined by the World Bank as those economies with a 
gross national income (GNI) per capita less than $12,736 US dollars, who have difficulty accessing 
unbiased information about medicines (Brundtland 2002, WorldBank 2016).  However, the EML 
principles are universal and should benefit health systems in all economic settings to promote 
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cost-effective, sustainable and affordable access to medicines (Hogerzeil 2004, Stolk, Willemen 
and Leufkens 2006).  This includes high income countries (HICs) with a GNI per capita greater than 
$12,736 US dollars (WorldBank 2011, WorldBank 2016). 
1.1.3 The Global Drug Gap 
 While the practice and use of medicines varies by culture, in today’s age it seems unimaginable 
that people should die from lack of access to basic medical treatments or medicines. Yet in the 
21st century, access to safe and affordable medicines is not guaranteed to all. Global inequality of 
access to lifesaving or essential medicines still exists (WHO 2015b). The disparity of access to 
medicines has been referred to by the World Health Organization (WHO) as the ‘global drug 
gap’(WHO 2000).  According to the WHO, approximately one third of the global population still 
does not have access to basic medicines. This number rose to 50% in the poorest parts of Asia and 
Africa (WHO 2004). Adding to this complexity is the globalisation of pharmaceutical supply chain 
networks which has resulted in countries of all economies and geographical regions sourcing their 
medicines from common sources. This is accompanied by rising pharmaceutical expenditure 
(Schumock et al. 2014, Majchrzak–Smith et al. 2012, Knaul et al. , Lee et al. 2014). Therefore, 
challenges accessing unavailable medicines have become a shared experience, as demonstrated 
by the relatively recent emergence of global drug shortage crises (Fox, Sweet and Jensen 2014, 
Gray and Manasse 2012, Bogaert et al. 2015, Wilson 2012, Schulman and Sweet 2011, Cherici C 
2011).  
To address this wide gap in access to medicines, and in line with the Alma Ata Declaration to 
promote equitable access to medicines, the WHO has developed the framework for access to 
essential medicines (Hogerzeil 2006). This framework considers rational selection of medicines, 
affordable prices, sustainable financing, and reliable health and supply systems (WHO 2004, 
Wiffen et al. 2003). Therefore, the WHO Access to Essential Medicines Framework (characterised 
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as appropriate, available, affordable and safe quality medicines) was applied as a theoretical 
framework to conduct a critical review of the literature. The aim of this literature review was to 
explore how the application of the EML concept was associated with access to essential 
medicines. 
1.2  METHODS 
A narrative literature review was conducted to provide a broad and comprehensive background 
on the EML concept, which was useful in the development of a conceptual framework, discussed 
later in chapter three.  This narrative review was performed in accordance with Green et al.’s 
(Green, Johnson and Adams 2006) guidelines and follows the overview rating scale and narrative 
review checklist, described in Appendix A (Green et al. 2006, 2016). However, this type of 
approach has been criticised as more biased compared to systematic reviews, due to subjective 
selection of information from primary articles, lack of systematic critical appraisal of each study, 
and differences between study designs (Green et al. 2006). Therefore, to address some of the 
potential biases associated with narrative reviews, a search strategy was developed from the 
principles of the WHO Access to Medicines Framework (WHO 2004, WHO 2002, Hogerzeil 2006).   
The literature review was commenced in August 2012 and updated in October 2015, prior to 
thesis submission.  The search for relevant literature was performed in Medline, Embase and 
PubMed.  Search terms included ‘essential medicine/drug’ (OR related terms), AND ‘access to 
medicines’ (OR related terms), as described in Table 1.1. Primary studies included: those that 
were conducted in humans,published in peer-reviewed journals in English, and afterthe WHO EML 
was created in 1977. Additional searches included reference lists and grey literature from WHO 
archives, Health Action International (HAI), World Bank, USAID: Deliver Project and government 
and non-government organisation reports.  Abstracts were used to screen non-empiric data or 
studies that were not relevant to the application of EML in improving access.  Although a search 
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for literature pertaining to general access to medicines found many studies conducted in HIC, few 
were identified when searched in context of the EML concept (Table 1.1).   Summaries of the 
literature reviews and primary studies included in this review are available as supplementary 
material in Appendix B.  These summary tables describe study designs and relevance to the EML. 
Table 1.1: Database Search Terms 
Concept 1 AND Concept 2 
Essential Medicines Concept  Access to Medicines 
OR  OR 
Essential medicines  Rational use of medicines 
Essential Medicines List  Quality use of medicines 
Essential Drug  Selection of medicines 
Essential drugs list  Drug affordability 
National formulary  Affordability of drug 
Preferred drug  Drug pricing 
Preferred drug list  Cost effectiveness 
Vital medicines  Health technology assessment 
Prioritised medicines  Cost benefit analysis 
Priority medicines  Availability of medicines 
   Reimbursement 
   Evidence-based medicine 
   Availability of medicines 
   Disinvestment 
 
 1.3. RESULTS 
 A review of the literature was conducted to explore the EML concept and the relationship to 
access to medicines. This review found that limited evidence was available to evaluate the impact 
of the EML concept on access to essential medicines, through national EML policies. While there 
has been improved access to essential medicines in some LMICs, there remain challenges to using 
EMLs, and few studies conducted in HICs. Furthermore, variations in accessibility of medicines 
between countries made it difficult to generalise whether having an EML was associated with 
better access, since implementation and governance of EMLs differed for each country and health 
facility. 
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1.3.1 Appropriate Selection of Essential Medicines  
 The literature supports that the concept of essential medicines has evolved and broadened in 
scope, making it difficult to select and assess the appropriate use of essential medicines 
(Appendix B, Table B1).  Vargas-Peláez et al. (Vargas-Peláez et al. 2014) argued that EMLs 
supported the basic human right to medicine and improved stakeholder accountability to improve 
access.  This aligned with Greene’s (Greene 2011) historical description of how the evolution of 
societal needs, medical practices, and pharmaceutical markets have improved access to essential 
medicines. Although, he also argued that what medicines are deemed essential has become more 
difficult to define. Meanwhile, in the context of poor access to medicines, Van der Geest (Van der 
Geest 1982) argued that adequate education and training was needed to improve the inefficient 
delivery of essential medicines policies.  Similarly, a global study conducted by Holloway & Henry 
(Holloway and Henry 2014), suggested EML policies were associated with improved appropriate 
use of medicines in LMICs, especially in terms of following standard treatment guidelines (STGs) in 
education and training sectors.     
Furthermore, some studies examined specialty classifications in EMLs that addressed neglected 
populations and conditions (i.e. maternal and child health or palliative care) (Robertson and Hill 
2007, Hill, Yang and Bero 2012, Wang et al. 2014, Anson et al. 2012, Bazargani et al. 2014, De Lima 
2007). These studies showed low inclusion of these priority medicines on EMLs and low 
availability in health facilities; therefore, recognising the need for increased advocacy to support 
access at the patient level of care.  This also drew attention to the challenges surrounding the 
development and provision of specialised treatments often excluded from EMLs, including orphan 
medicines for neglected diseases. These lifesaving treatments often affected either neglected 
populations in LMICs or highly expensive individualised treatments.  In contrast, Vargas-Peláez et 
al. (Vargas-Peláez et al. 2014) cautioned that in some circumstances, the right to access essential 
medicines also deepened the existing inequality to accessing health care, focused on non-priority 
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demands, and threatened sustainable financing of the health system. For example, this occurred 
through judicial hearings that focused on individuals’ rights (mostly those with wealth) to obtain 
expensive non-reimbursed medicines that overlooked the common wealth of the population.  
This review included studies from HICs such as Croatia and Italy, where the EML concept helped 
apply appropriate use of evidence to guide reimbursement decisions; although, these processes 
were shown to be fragmented at different levels of the health care system (Kadić et al. 2014, 
Jommi et al. 2013, WorldBank 2011).  Mahmić-Kaknjo and Marušić (Mahmić-Kaknjo and Marušić 
2015) and   Kadić et al. (Kadić et al. 2014) showed that the WHO EML provided strong evidence for 
decision makers and acted as a quality assurance tool to ensure that selection of medicines for 
national reimbursement were appropriate. The use of the WHO EML offered a fair and 
transparent process for reimbursement decisions. In a study by Hettihewa and Jayarthna 
(Hettihewa and Jayarathna 2010)  knowledge of the content and selection process of the EML was 
helpful in guiding evidence-based prescribing. Therefore, these studies demonstrated that EMLs 
serve as powerful advocacy and evidence-based tools to influence policy makers.   
 In contrast, application of EML concepts can be fragmented and variable.   Jommi et al. (Jommi et 
al. 2013) demonstrated that decision-making and the medicine assessment process in HICs like 
Italy, was multi-tiered, fragmented, and offered poor transparency of decisions. Similarly, in 
LMICs such as Tanzania, Mori et al. (Mori et al. 2014) showed that decision-making favoured 
experience and discretionary judgment over evidence.   These studies showed that wider gaps in 
decision making became more apparent at the  local health facility level of care.  According to 
studies by Bertoldi et al. (Bertoldi et al. 2012, Bertoldi et al. 2008) and Mori et al. (Mori et al. 
2014), local formularies were favoured over national EMLs at the health facility level. 
Furthermore, in a study by Rico-Alba and Figueras (Rico-Alba and Figueras 2013), some EMLs were 
considered highly irrational, containing a wide range of treatments in some therapeutic areas, yet 
excluded some essential medicines.  In line with these results, findings from a study by Dal Pizzol 
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et al. (Dal Pizzol et al. 2010b) supported that non-essential medicines were needed because there 
was inadequate supply of essential medicines, with stakeholders believing the EML was not 
adequate at meeting all local concerns.  Therefore, this demonstrated that the EML was not 
useful in supply chain operations and logistics management, where decision making at the point 
of care was focused on individuals’ needs and less on population priorities (Albert, Fretheim and 
Maiga 2007)  
In line with the fragmented use of EMLs at the health facility level, Chen et.al’s (Chen et al. 2010) 
findings showed that listing on the EML did not influence manufacturers’ production or retail 
pharmacy procurement decisions. Instead, factors influencing procurement were market demand, 
production costs, price, profit margins, and market share. Even in hospitals, low purchasing of 
essential medicines was due to lack of clinical use and availability of clinical alternatives.  Hence, a 
study by Chen et al. (Chen et al. 2014), showed there were no changes in prescribing patterns 
after the implementation of a national essential medicines list (NEML) in China. Although, 
researchers did not determine whether this was a result of poor awareness and training around 
the EML, needing more time for integration into practice, or whether it was perceived as not 
useful. Therefore, the evidence available to policy makers showed that EML policies had not 
shown significant impact on quality use of medicines, questioning whether continued investment 
and support required to maintain and update EMLs were of value. 
1.3.2 Availability and Affordability of Essential Medicines  
The search strategy applied in this literature review found that there have been many medicines 
availability and affordability studies conducted in LMIC settings, but few in HICs.  Appendix B, 
Table B2, described variable access to essential medicines ranging from very poor to adequate 
access.  Since 2001, the WHO and Health Action International (HAI) developed a survey protocol 
to evaluate access to medicines within a country setting,  referred to as the WHO/HAI survey 
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(Madden et al. 2010, Cameron et al. 2009, Niëns et al. 2010, Niens et al. 2012). Studies using the 
WHO/HAI survey methodology comprise a significant proportion of the availability and 
affordability studies in the field of EML research (Cameron et al. 2009, Cameron et al. 2011, 
Mendis et al. 2007, van Mourik et al. 2010, Cameron et al. 2012, Babar et al. 2013).   
Many WHO/HAI studies found that EML policies increased affordability of medicines, especially in 
terms of pricing of generic medicines, providing medicines to individuals in the public sector at no 
or low cost, and bulk procurement (Wagner et al. 2011, Carapinha et al. 2011, Moon et al. 2011, 
Saleh and Ibrahim 2005, Dabare, Wanigatunge and Beneragama 2014).  These WHO/HAI studies 
were in line with other studies, which found adherence to the WHO EML provided good evidence 
for decision-making and offered greater procurement cost savings (Mahmić-Kaknjo and Marušić 
2015, Burapadaja and Chinawong 2010, Gitanjali and Manikandan 2011, Ganga Senarathna, 
Mannapperuma and Rohini Fernandopulle 2011, Cheraghali and Idries 2009, Cheraghali et al. 
2004a, Carasso et al. 2009, Mouala, Abeye and Goumba 2009, Bertoldi et al. 2012, Kadić et al. 
2014, Logez et al. 2004, Burapadaja et al. 2007, Zhu et al. 2008).  However, results were highly 
variable across countries due to differences such as governance, EML implementation policies, 
distribution and workforce capacity.  Therefore,  global studies generally showed low availability 
and lack of affordability of medicines in public sectors (Cameron et al. 2009, Cameron et al. 2011, 
Cameron et al. 2012, Mendis et al. 2007, van Mourik et al. 2010, Srivastava and McGuire 2014, 
Babar et al. 2013, Yang et al. 2010, Kotwani 2013). These studies highlighted that access was 
especially low in resource limited settings such as LMICs (Babar et al. 2007, Jiang et al. 2013, Khan 
et al. 2011, Kotwani et al. 2007, Kotwani 2009).  In addition, Nakyanzi et al (Nakyanzi et al. 2010) 
demonstrated that poor management of supplies may also lead to expiry and waste of medicines 
(Magadzire et al. 2014, Mikkelsen-Lopez et al. 2014).  
This review found several approaches have been applied to measure the affordability of 
medicines. For example, Niens et Al. (Niëns et al. 2010, Niens et al. 2012) measured the 
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affordability of medicines using expenditure data,  based on  the proportion of the population 
that would be pushed below the poverty level, or the proportion of the population whose 
resources would be catastrophically reduced by spending on medicines.  Therefore, these studies 
suggested that the purchase of medicines by individuals in LMICs could lead to impoverishment of 
a high proportion of the population.   
Alternatively, Maiga and Williams-Jones (Maiga and Williams-Jones, 2010) and Van Der Geest et 
al.’s (Van Der Geest et al. 2000) work on cost sharing and price regulation indicated that these 
approaches did not improve the availability of essential medicines. Therefore, due to poor 
availability of free or low cost medicines in the public sector, many individuals had to seek 
medicines in the private sector in which prices were higher, and incurred out-of-pocket 
expenditure (Wagner et al. 2011, Santos Pinto et al. 2010). In addition to these challenges to 
make medicines affordable, international trade agreements, like the Trade Related Aspects of 
International Property Rights (TRIPS), threatened to hinder access to affordable medicines.  TRIPS 
protected company patents, which keep essential medicine prices high and make them 
unaffordable to most LMICs, inhibiting  population access (Akaleephan et al. 2009).  In contrast, 
studies on the availability and affordability of essential medicines in HICs were not found. Instead, 
some literature examined the role of HICs (i.e. Canada), to facilitate access to lower cost essential 
medicines for LMICs through providing or advocating for compulsory licensing (Goodwin 2008). 
1.3.3 Quality of Essential Medicines  
This review also explored the t EML impact on quality of medicines (Appendix B, Table B3). 
Caudron et al. (Caudron et al., 2008), Khan et al. (Khan et al. 2011), and Lauffenburger et al. 
(Lauffenburger et al. 2011) found that  there was an alarming presence of poor quality medicines 
available on the global market.  These products were found in the form of substandard or 
counterfeit medicines, particularly in LMICs. In a study by Bevilacqua et al. (Bevilacqua, Farias and 
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Blatt 2011), bio-equivalency testing policy in Brazil led the number of registered products to fall 
from 98% to 25%. This prompted another round of bidding and resulted in dropping the test to 
prevent the health care system from collapsing.  This signaled that there may be a high proportion 
of medicines in the system that are substandard, and kept within the system because they are low 
cost despite their poor quality. In contrast, Patel et al. (Patel et al. 2012) argued that perception of 
quality was not always reflective of actual quality of medicines and required more consumer 
education.   
Overall, this literature search strategy did not identify many studies conducted in HIC countries, 
and none which investigated the quality of essential medicines. This could possibly be attributed 
to these countries having rigorous regulatory and quality assurance programs that prevent poor 
quality medicines from reaching the population.  However, in recent years, there has been a rise 
in the incidence of drug shortages in HICs (Bogaert et al. 2015). This phenomenon has occurred 
concurrently with the prevalence of poor quality medicines in the supply chain of LMICs. 
Therefore, results from Bevilacqua et al. (Bevilacqua et al. 2011) and drug shortage crises in HICs 
raise concerns about the security and sustainability of global pharmaceutical supply chains. 
1.4 DISCUSSION 
This review found that limited evidence was available to evaluate the impact of the EML concept 
on access to essential medicines. While there has been improved access to essential medicines in 
some LMICs, there remain challenges to using EMLs and few studies conducted in HICs. 
Furthermore, variations in accessibility of medicines between countries made it difficult to 
generalise whether having an EML was associated with better access, since implementation and 
governance of EMLs differed for each country and health facility. Furthermore, this review found 
that limited qualitative studies were conducted in this field, but offered in-depth insights into 
decision making around essential medicines and the challenges to using EMLs. Additionally, while 
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research was intended to target the access to medicines gap, findings highlighted that studies 
conducted in this field were biased to LMIC settings and lacked HIC data, despite the challenges in 
HICs to access medicines in rural and remote areas.(WHO 2004, Kadić et al. 2014, Jommi et al. 
2013, Hogerzeil 2004). 
This review showed the use of EMLs improved population access to essential medicines. In line 
with Holloway and Henry (Holloway and Henry 2014), EML policies improved quality use of 
medicines through the use of standard treatment guidelines in education and training sectors, 
provided good evidence for decision-making, offered greater procurement cost savings, and 
functioned as a powerful advocacy tool to influence policy makers (Hogerzeil 2006, Reidenberg 
2007, Magrini N 2014, Stolk et al. 2006, Shaw and Cook 2012, Kishore, Vedanthan and Fuster 
2011, Hettihewa and Jayarathna 2010, Hettihewa, Dadallage and Wimalasena 2013).  An example 
of improved population access to essential medicines was demonstrated by  multi-stakeholder 
advocacy, engagement and delivery of HIV/AIDs anti-retroviral medicines in LMICs like Brazil and 
many African countries (Nunn, Fonseca and Gruskin 2009, Gilliam et al. 2012). Furthermore, EMLs 
also provided a tool to evaluate whether accessible medicines in a country adhered to global 
standards.   
Conversely, specialised treatments and orphan medicines were shown to have low inclusion on 
EMLs.  In most circumstances, orphan medicines were difficult to procure and sustain in the 
supply chain due to limited and sometimes unpredictable demand (Stolk et al. 2006). Therefore, 
this challenged whether special funding arrangements are required to ensure availability and 
affordability of these medicines. An example of specialised funding programs available in HICs like 
Australia include the lifesaving drugs program, Special Access Scheme, and Section 100-highly 
specialised drugs program (TGA 2015, PBS 2015b, PBS 2015a, Cohen and Milne 2013).  
Unfortunately, due to the high costs of some of these medicines, they are often not listed on 
EMLs, thus unavailable to the individuals that need them in resource poor settings, particularly in 
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LMICs. However, as raised by Vargas-Peláez et al. (Vargas-Peláez et al. 2014), policies must be in 
place to protect population access to essential medicines and individuals whilst preventing 
inequalities of spending of scarce resources. 
Findings from this review demonstrated the challenges and complexities associated with EMLs.  
Firstly, the appropriate use of essential medicines was challenged with gaps in addressing 
neglected populations and conditions, lack of transparency around decision making, and 
fragmented processes. Furthermore, EMLs were often not perceived as being useful at the health 
services delivery level, not adequate at meeting local concerns, and did not influence prescribing 
patterns in some countries. In contrast to Holloway and Henry (Holloway and Henry 2014), 
Vargas-Peláez (Vargas-Peláez et al. 2014) claimed that EMLs had limited influence at the health 
facility level and patient point of care. Therefore, fragmented prescribing practices and 
implementation of policies has left many critics to question whether EMLs were useful. 
Particularly, when essential medicines were not available to individuals at the point of care, 
stakeholders preferred and used “non-essential” medicines (Bertoldi et al. 2012, Mori et al. 2014).  
This review found that much work remained to improve issues such as standardisation of 
processes, quality and interpretation of evidence, trust between stakeholders, logistics 
management and procurement practices.  
Secondly, low availability and affordability of essential medicines were found in some public 
sectors, especially in LMICs. Poor management of supplies often led to waste and expiry of 
medicines which could not be used by individuals and exacerbated in resource scarce situations. A 
high proportion of the population in LMICs was at higher risk of impoverishment due to 
purchasing medicines. Meanwhile, cost sharing and price regulation did not improve the 
availability of essential medicines, and international laws threatened to keep prices of essential 
medicines high and inaccessible to LMIC populations.  
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Furthermore, this review suggested that financial and ethical issues act as barriers to accessing 
essential medicines. Researchers, such as Akaleephan et al. (Akaleephan et al. 2009), have 
claimed that international trade laws have created challenges to access affordable medicines.  
Agreements surrounding intellectual property rights, such as the World Trade Organizations 
(WTO) Declaration of Health Action (DOHA Declaration) and the TRIPS agreement, have enforced 
patent laws to protect international property rights held by pharmaceutical companies (Gregson 
et al. 2005, Akaleephan et al. 2009, Cohen 2006, Grootendorst et al. 2011).  Unfortunately, this 
has created barriers to accessing affordable essential medicines, notably in LMICs, by keeping 
prices high (Martin, Sorenson and Faunce 2007).  The HIV/AIDS epidemic in the 1980s and 1990s, 
was a key example of high prices of medicines that was mostly unaffordable for populations in 
parts of Africa, Asia and South America. Instead, these countries benefitted from compulsory 
licensing agreements, which allowed contracts to be given to generic companies to manufacture 
medicines while a medicine was on patent. Without the ability to create generic alternatives for 
these populations to access, results may otherwise have been catastrophic (Nunn et al. 2009, 
Cohen 2006). 
Lastly, this review also raised concerns around the quality of medicines, highlighting the high 
proportion of low cost substandard and counterfeit medicines in the system and drug shortages. 
In contrast quality use of essential medicines focused perspectives, consideration of 
pharmaceutical supply chains also contribute to improved access to medicines (Caudron et al. 
2008, Pazirandeh 2011, Jahre et al. 2012, Meijboom, Schmidt-Bakx and Westert 2011, Homedes 
and Ugalde 2005). The advancements in technology and communication have facilitated 
transportation, storage, Internet access, tele-communication, reporting, and manufacturing 
capacity. While not perfect, there have been many benefits that have improved access to 
medicines.  However, globalisation has formed a new landscape for managing the pharmaceutical 
supply chain. Many processes, solutions, and challenges are shared throughout a complex and 
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intricate network.  According to Caudron et al. (Caudron et al. 2008), substandard and even 
counterfeit medicines can permeate a supply chain, causing serious risks to individuals within a 
population.   With the rise of manufacturing issues that have caused drug shortages in HICs, these 
supply chain issue needs to be addressed and further investigated (Bogaert et al. 2015). 
1.4.1 Types of Research on Essential Medicines 
To date, the range of evidence available to decision makers is limited in the field of essential 
medicines. Of the primary studies available, most have applied quantitative methods. However, 
few systematic literature reviews, qualitative and mixed methods studies were also identified.  
This review found an abundance of grey literature, but found few primary studies relevant to 
EMLs, and even fewer conducted with well-defined study designs.  These findings were reinforced 
by Ratanawijitrasin et al. (Ratanawijitrasin et al., 2001), Nunan and Duke (Nunan and Duke, 2011), 
and Nguyen et al. (Nguyen et al., 2012), all of whom criticised the quality, lack of standardised 
approaches and methods conducted in essential medicines policy research.    
Systematic reviews have been useful in identifying guidelines and assessment tools that can be 
used to guide EML policy. This was demonstrated through Newton et al’s (Newton et al. 2009) 
work on a medicine quality assessment reporting guidelines (MEDQUARG) checklist, used to guide 
quality assurance practices. Meanwhile, Tran and Bero (Tran and Bero, 2015) and Ridge et al. 
(Ridge et al., 2010) identified barriers and facilitators to quality use of medicine from the 
literature, and applied visual models like the Ishikawa framework approach to organise results.  In 
addition, Wilson et al. (Wilson et al. 2014) and Rico-Alba and Figureras (Rico-Alba and Figueras 
2013) have applied qualitative constant comparative approaches to systemic reviews to assess 
the rationality of decisions to list or de-list medicines. 
Meanwhile, the range of primary studies in this review applied quantitative, qualitative or mixed 
methods approaches to describe, explain or triangulate data (Khan et al. 2011, Magadzire et al. 
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2014, Patel and Pichardo 2012, Nakyanzi et al. 2010, Nilseng et al. 2014, Mujinja et al. 2014).  This 
review found that studies mostly applied quantitative methods, such as surveys. There were some 
key studies that used validated methods to evaluate global access to essential medicines.  For 
example, Cameron et al. (Cameron et al. 2009, Cameron et al. 2011) conducted WHO/HAI survey 
studies on global availability and affordability of medicines in a large number of LMICs.  Whereas, 
Holloway and Henry (Holloway and Henry 2014) used surveys to evaluate whether WHO EML 
policies were associated with better quality use of medicines (QUM).  To address the gaps in the 
literature from quantitative studies, particularly the variations at the local level, qualitative 
research has been recently included amongst the literature to enrich the depth of understanding 
in country specific settings (Chen et al. 2010, Van Der Geest et al. 2000, Mori et al. 2014, Wilson, 
Kohler and Ovtcharenko 2012, Albert et al. 2007, Mackintosh, Chaudhuri and Mujinja 2011).  
Results from these studies were often in contrast to the survey studies, which showed improved 
(albeit variable) population access and quality use of medicines. Instead, the views from these 
qualitative studies revealed that EMLs did not function adequately at addressing local needs at 
the patient point of care.  
This review found that quantitative studies were conducted with limited focus on one or two 
principles of the WHO access to medicines framework.  These studies also had limited utility in 
reporting access unless information could be provided continuously and seamlessly. Therefore, 
wide variability in the reporting of how EMLs have been utilised in different health systems have 
made it difficult to determine the impact of EML policies.  Most notably, quantitative studies 
following the WHO/HAI survey methodology accounted for a significant proportion of the 
availability and affordability knowledge in the field of EML research. This survey methodology was 
meant to serve as a standard protocol for measuring availability, price and affordability of 
medicines, and has been conducted in over 70 countries (Madden et al. 2010).  Therefore, this 
review considered these studies to be a prominent body of work that offered a snapshot of the 
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global access to medicines situation. Although performing these studies was costly and required 
funding and local endorsement, they helped quantify the gap in access to medicines and inform 
policy (Mendis et al. 2007).   
On the other hand, these WHO/HAI studies had limitations that only offered a description of the 
availability of medicines at one moment of time. This limitation was attributed to the dynamic 
nature of the pharmaceutical supply chain, where demand and supply can fluctuate seasonally 
and annually, Some of these design limitations included: limited generalisability of results, 
descriptive summary of a country’s availability and pricing of a drug on only one day of data 
collection in each facility, and poor consideration of logistical variations.  Examples of logistical 
variations include the likelier availability of malaria treatments (i.e. Artemesin base combination 
therapy (ACT)) during high risk wet versus dry season, or dwindled stocks closer to scheduled 
delivery dates from central medical store (e.g. monthly, or quarterly). Furthermore, geographic 
representation was variable, often restricted to urban centre proximity or systematically excluded 
remote areas and pharmacies, and included small samples of deliberately selected facilities (i.e. 
ranging from 6 to 129 health outlets). Therefore, this resource-intense approach had a limited 
ability to reflect the availability and affordability of medicines, other than at the time the study 
was conducted.   
Furthermore, these WHO/HAI survey studies offered limited understanding of the decision 
making process at the point of care that may have led to medicines becoming available or 
unavailable.   For example, data collection was restricted to originator brand and lowest priced 
generic (LPG) products, and products were limited to medicines within one therapeutic class 
according to standard treatment guidelines (STGs), which could not account for patients with co-
morbidities or prescriber preferences for other generic brands. Also, surveys did not consider 
differences in quality of medicines across products, patent status between countries, nor 
consideration of alternative dosage forms, products, or therapeutic alternatives which may have 
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influenced the decision to provide medicines at health facilities.  Finally, the affordability of 
medicines at the point of care was potentially skewed based on the point of references used. For 
example, the daily wage of the lowest paid government worker used in calculations risked 
overestimation of affordability. Furthermore, the reliability of the median price ratios as a metric 
was used to determine median international reference price for each medicine and can be 
skewed high or low, which varied depending on the average income of the population in each 
country. In summary, these many limitations warrant alternative methods to investigate the 
challenges and variations in decisions to utilise EMLs at the point of care. 
Lastly, medicines decision-making and communication throughout the pharmaceutical supply 
chain can be influenced by many subjective factors such as cultural, behavioural, sociological, 
environmental, and psychological experiences.  These influences can be explored through 
different research approaches. Most notably, qualitative methods have been recently adapted in 
the literature to explore the cultural and social variations within a country. While results from 
qualitative studies are not considered generalisable, they offer deeper exploration of the 
challenges to access essential medicines, especially in specific settings. Hence, qualitative 
methods have been shown to add to the richness of understanding in the field of essential 
medicines research by considering valuable stakeholder perspectives.  This may enhance our 
understanding of the impact of EMLs and what causes variations across health systems.  
1.4.2 Strengths and Limitations 
This review was the first to offer a broad comprehensive review of the literature, which included 
all four principles of the WHO access to medicines framework.  Previously, study designs focused 
on only one or two principles of the WHO Access to Medicines Framework (e.g. availability and 
affordability), due to the challenges and complexity of implementing EML policies. Under this 
broad search strategy, this review identified a lack of studies evaluating the impact of EMLs in 
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HICs. While HICs are generally perceived to have good access to medicines, rural and remote 
areas in these countries may also experience challenges to access (Fletcher and Guttmann 2013).   
Alternatively, the literature for HICs commonly showed studies on reimbursement lists, drug 
shortages, the role of evidence based medicine in decision making, drug formulary decisions, the 
cost-effectiveness of high cost medicines, upholding regulatory standards and good 
manufacturing practices.  Although these terms seemed synonymous with the essential medicines 
concept, the search strategy did not locate these studies.  This may imply that there were 
different descriptions for similar concepts within different country contexts, or the perception 
that EMLs were not used in HICs.  Therefore, this review was unable to identify studies to offer 
comparison of how LMICs and HICs implement their EML policies.  
Furthermore, while some researchers recommend that without explicit critical appraisal criteria, a 
narrative review would be extremely subjective and biased, others suggest they are not required. 
Instead, some researchers argued that, “since the narrative overview already includes the biases 
of the author, there is a limit to how much more bias may actually enhance the credibility of the 
overview” (Green et al. 2006). The aim of this literature review was to gain a broad 
comprehensive overview on the topic of EMLs, which was supported by a well defined search 
strategy. Therefore, a critical appraisal of each study was not deemed to enhance the credibility 
of the narrative review.  However, summaries of the papers included were made available as 
supplementary material, included in Appendix B.  These tables described study designs and 
relevance to the EML. 
1.5 CONCLUSION 
The universal EML concept has evolved and expanded since the inception of the WHO EML nearly 
40 years ago. While there have been improvements in global access to essential medicines, there 
remains a disparity in access by individuals and across populations. This review showed that the 
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access to medicines gap has been predominantly investigated in LMICs, which similarly reported 
low availability and affordability of essential medicines. Hence, perspectives and solutions to 
access issues appeared limited and repetitive. Instead, investigation in settings with higher access 
rates, such as HICs, could offer insight into how challenges are overcome and managed. The 
literature confirms that the use of EMLs was not consistent at all levels of the health system, and 
there was variation of needs at the health facility level which EMLs were unable to meet.  
Although the EML was shown to be a useful advocacy tool to influence policies, it appeared poorly 
applied and fragmented throughout the pharmaceutical supply chain, falling short in guiding 
procurement practices. Therefore, further investigation with qualitative methods is needed to 
determine what makes a medicine essential and the influences on stakeholders that facilitate or 
hinder access to these medicines.  This exploration would help define what variables contribute to 
access at different levels of the health system, and how EML policies can be supported 
throughout the pharmaceutical supply chain to support patient access at the point of care.   
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“You can save a life for less than you pay for a Mars Bar”  
–Health Provider, Physican, Western Pacific 
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CHAPTER 2- GLOBAL PERSPECTIVES ON THE SUPPLY AND 
MANAGEMENT OF ESSENTIAL MEDICINES 
2.1: INTRODUCTION 
2.1.1: The Pharmaceutical Supply Chain  
The vital role of essential medicines in society necessitates a reliable and sustainable 
pharmaceutical supply and distribution system (supply chain) (WHO 2003).  However, the 
pharmaceutical supply chain is a complex network of multiple stakeholders and management 
systems (Rossetti, Handfield and Dooley 2011). The provision of medicines involve an array of 
stakeholders (Lee and Whang 2000, Shah 2004).  For example, consumers, health care providers, 
wholesalers, distributors, government, third party insurers, procurement agencies, non-profit 
organisations, academic institutions, advocacy groups and the pharmaceutical industry participate 
in ensuring reliable, safe and efficient processes in delivering medicines to individuals.  
Meanwhile, the processes involved in the provision of medicines are complex. Prior to production, 
medicines innovation involves research and development (R&D) driven by advocacy, academic 
research and industry investment.  After discovery, medicines pass through intense economic 
analysis, clinical trials, regulatory approvals, and third party reimbursement assessments. Once 
these requirements have been met, medicines can be approved for production through the 
pharmaceutical supply chain (Greene 2011).  Afterwards, medicines enter manufacturing 
processes which begin with active pharmaceutical ingredients (API) and inactive ingredients, 
along with their chemical components, supplied to manufacturers who create the finished 
medicine product (Thaul 2013). This product then goes through packaging (sometimes 
repackaging), regulatory requirements to ensure quality, wholesale, distribution (sometimes 
redistribution to secondary warehouses), storage and dispensing at health facilities.  In brief, 
medicines travel through the pharmaceutical supply chain starting from raw materials, to 
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manufacturing, filing and packaging, to international and local distribution centres, wholesalers, 
and then delivered to health care facilities to dispense to patients (Figure 2.1) (McBeath 2012).     
Figure 2.1: The Pharmaceutical Supply Chain 
 
Complexity of the pharmaceutical supply chain can also challenge access to medicines. The 
processes and systems involved in delivering medicines has become more complex due to more 
products and therapeutic options available on the market, accommodation of broader individual 
needs, and the expansion of markets due to globalisation (Bhatia, Lane and Wain 2013). 
Globalisation in particular, has created many issues for all supply chains worldwide, and has led to 
volatility in supply chains caused by environmental, geopolitical, economic and technological 
disruptions (Bhatia et al. 2013, Hogerzeil and Laing 2009).  Hence, many things can go wrong 
along the way.  For example, a range of risks include: supplier failures (e.g. financial, production, 
design, facility, standards),  delivery delays (e.g. customs, accessible roads or repair); 
counterfeiting; theft; poor packaging; spoilage; improper handling or cargo placement; diversion 
or gray markets; and unanticipated demand surge or drop-off (McBeath 2012). In addition, 
unpredictable events may also cause supply disruptions in an already vulnerable supply chain.  
These can include: unanticipated supply constraints, allocation, or price increases; price, currency 
and interest rate fluctuations; political upheaval; infrastructure outages (e.g. fire in plant, power 
grid down); natural disasters; pandemic, work stoppages and labour disputes (McBeath 2012, 
Bhatia et al. 2013). Hence, these risks have become increasingly challenging to coordinate 
amongst multiple stakeholders (Craighead et al. 2007, Papageorgiou 2009, Koh et al. 2003).   
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Contributing further to these risks, were the recent management trends in global supply chains 
across all sectors. These trends include specialisation of services, complexity in processes and 
systems, decisions toward lean processes to improve efficiency (e.g. “just in time model”), 
information sharing or availability, and government legislation such as international trade 
agreements or change to regulatory requirements (Bhatia et al. 2013, Sousa et al. 2011).  
Therefore, global and local systemic risks flow down the supply chain, in which problems become 
magnified and can lead to supply disruptions such as drug shortages, recalls, and discontinuations 
of medicines by manufacturers (Bogaert et al. 2015, de Vries et al. 2011, Jahre et al. 2012, Fox et 
al. 2014, Abramowitz P.W. 2013, Wilson 2012, Woodend, Poston and Weir 2005, Lee Ventola 
2011, Quilty et al. 2011, Cherici C 2011). These supply chain vulnerabilities impact health systems 
and risk consumer safety. 
2.1.2: Unavailable Medicines in the Pharmaceutical Supply Chain  
 
Supply disruptions can result in unavailable medicines at the point of care.  One third of the global 
population does not have access to essential medicines, rising to 50% in low to middle income 
countries (LMICs) (WHO 2004). These health systems face resource, capacity, political, and 
infrastructure challenges, resulting in lower availability of medicines such as insulin, anti-
retrovirals (ARVs), tuberculosis medicines, magnesium sulphate, doxycycline, and 
hydrochlorthiazide (Stop-Stock-Outs 2015, Cameron et al. 2009).  Until recently, access to 
essential medicines in high income countries (HICs), has not received much focus; however, the 
drug shortage crises in the last few years have raised many concerns regarding the stability of the 
pharmaceutical supply chain  (Gray and Manasse 2012, Jahre et al. 2012, Bogaert et al. 2015, Yu 
et al. 2010, Koh et al. 2003, Craighead et al. 2007).  For example, in the United States, the number 
of new drug shortages quadrupled from approximately 60 in 2005, to more than 250 in 2011; and 
by the end of 2012, more than 300 shortages remained active (FDA 2013).   
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Drug shortages have been defined differently across health systems. According to the United 
States (US) Food and Drug Administration (FDA) a drug shortage is as, “a period of time when the 
demand or projected demand for a drug within the United States exceeds the supply of the drug” 
(FDA 2011, FDA 2013, Thakur 2013). Similarly, the European Public Health Alliances defined 
supply shortage as, “a situation in which the total supply of an authorised medicine or of a 
medicine used on a compassionate basis is inadequate to meet the current or projected demand 
at the patient level. The shortage may be local, national, European or international. This common 
position prioritises supply shortages that affect medically necessary medicines (also called 
essential medicines)” (Charnay-Sonnek et al. 2013). Whereas, the European Federation of 
Pharmaceutical Industries and Associations (EFPIA)  describes a drug shortage as, “a crisis 
situation caused by the inability of any market authorisation holder (MAH) to supply a medicine 
with a specific active pharmaceutical ingredient (API) to a market over an extended period of time 
resulting in the unavailability of this medication for patients” (Bogaert et al. 2015, EFPIA 2013).  
Time frames stipulating a shortage were variable among European countries, ranging from a 
minimum of 48 to 96 hours, and without mention of a maximum limit. Similarly, a stock-out, “is 
when a pharmacy (in a medical store or health facility) temporarily has no medicine on the shelf” 
(Stop-Stock-Outs 2015).  For the purposes of this thesis, drug shortages and stock-outs have not 
been differentiated; and drug shortages refer to the inability to dispense a medicine for an 
individual at any point of time, which may result in potential patient harm. 
The risks of drug shortages pose significant health threats to the provision of patient care, strain 
resources needed to manage medicine supplies, and corrupt systems by driving prices up with 
emerging grey markets (Akaleephan et al. 2009, Cherici C 2011, Lee Ventola 2011, Bogaert et al. 
2015, Gray and Manasse 2012, McBride et al. 2013, TGA 2013, GaBI 2012, Schulman and Sweet 
2011). Drug shortages can result in delaying or denying needed care to individuals and may cause 
health practitioners to prescribe an alternative therapy that may be less effective for the patient 
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or that poses greater risk. This has even disrupted clinical trials, potentially delaying research on 
important new therapies (FDA 2013). In HICs, even though clinically interchangeable substitutes 
were mostly available, the FDA reported 89% of drug shortages caused a safety issue or drug 
related problem (DRP) and 80% resulted in the delay or cancellation of a patient care intervention 
(FDA 2011). This was most concerning when essential medicines for life-threatening diseases, 
including some treatments for cancer and serious infections, were affected by drug shortages 
(e.g. morphine, gentamycin, naloxone, frusemide, cytarabine, adrenalin, and noradrenalin) (FDA 
2011).   
In light of these issues, the integrity and reliability of the pharmaceutical supply chain needs 
reinforcement. Ongoing supply disruptions threaten global access to medicines in the short and 
long term.   Therefore, response to these significant supply disruptions, requires a coordinated 
approach between multiple stakeholders (Rossetti et al. 2011).  However, the pharmaceutical 
supply chain is extremely complex. While there has been research on the supply chain, it has been 
studied in silos and focused on specific areas or practice settings (Bhakoo, Singh and Sohal 2012, 
Meijboom et al. 2011, Jahre et al. 2012, Ford and Hughes 2007). Therefore, further understanding 
is needed on how the different elements of the pharmaceutical supply chain and health systems 
operate and interact.  Investigation is required to explore how multiple stakeholders within the 
medicine supply continuum respond to supply disruptions, how these responses change 
depending on the context and work environment of each stakeholder, and how stakeholders 
interact or collaborate.  Exploring the dynamics of how stakeholders interact throughout the 
pharmaceutical supply chain could highlight management strategies that may reinforce and 
protect the supply of essential medicines.   
The objective of this qualitative study was two-fold. Firstly, this study aimed to explore key 
stakeholders’ perspectives of the factors that influence access to essential medicines; and 
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secondly, to understand the roles of international key stakeholders involved in access to essential 
medicines.   
2.2 METHODS 
2.2.1: Qualitative Semi-Structured Interview Framework  
Ethics approval was obtained from the University of Sydney Human Research Ethics Committee 
(HREC) (Appendix C). Participant consent was obtained, and confidentiality and anonymity was 
guaranteed (Appendix C,E). Research objectives and literature were used to design a qualitative 
semi-structured interview protocol based on the WHO access to medicines framework to address 
issues around access to essential medicines (WHO 2004).  The interview guide was pilot tested 
with a hospital pharmacist and researcher. As part of the consent process, the interview guide 
was provided to participants prior and during interviews. Reporting of the study adhered to the 
Coreq-32 checklist guidelines, included in Appendix F.   The interview guide, included in Appendix 
G, contained questions pertaining to participants familiarity and experiences with the EML 
concept, what their thoughts were on what made a medicine essential, facilitators and barriers to 
the provision of essential medicines, collaborations involved in delivering EMLs, and key issues 
surrounding essential medicines. Each area of appropriateness, affordability, availability and 
quality were explored according to each participant’s background and expertise. The data 
pertaining to Australian stakeholders only, have been published in a peer-reviewed journal, 
described in Chapter 3 (Duong et al. 2015). Subsequently, parts of the methods section overlap 
and have been repeated. This chapter included all interviewed stakeholders. 
2.2.2: Sampling  
Between October 2012 and January 2015, 47 stakeholders were recruited worldwide for in-depth 
interviews through purposive and snowball sampling approaches (Heckathorn 2011, Goodman 
1961).  Key stakeholders had experience in multiple country settings, including: Canada, United 
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States, Columbia, Netherlands, Denmark, Estonia, Latvia (and other Baltic countries), Tanzania, 
Zimbabwe, South Africa, Nigeria, Uganda, Namibia, Cameroon (and neighbouring French speaking 
African countries), India, Pakistan, Afghanistan, Bangladesh, Sri Lanka, Australia, New Zealand, 
Philippines, Fiji, Tonga, and Papua New Guinea. The broad range of expertise was representative 
of each WHO region, including: Pan America, Western Pacific, South East Asia, Africa, Eastern 
Mediterranean and Europe (WHO 2015c). While representation was highest in the western pacific 
region due to the nature of the snowball technique, at least one stakeholder was interviewed 
from each region. Of the 96 participants contacted to participate in the study, 23 declined to 
participate either due to perceived limitation of expertise or time constraints.  Ten of those who 
declined to participate referred a colleague, and a further 24 failed to respond to the invitation to 
participate.  
Stakeholders represented in this study were working in government, regulatory bodies, hospital 
practice, primary health care settings, the pharmaceutical industry, wholesale/distribution 
companies, medicines non-profit organisations, academia and consumer health groups.  The 
study targeted individuals with EML experience, medicines reimbursement and selection 
knowledge, or those with experience managing drug shortages.  Participants included were 
recognised as leaders, advisors and/or experts amongst colleagues or professional organisations 
in the area of quality use of medicines, medicines policy, medicine distribution, procurement 
management, manufacturing, or health economics.  Most participants had professional 
backgrounds as physicians or pharmacists. In addition, consumer representatives, chief executive 
officers, supply chain managers, and health economists were also included.  Most participants had 
broad experiences across multiple and overlapping sectors in high or low income countries, and 
often both settings.  A summary of participant demographics is illustrated in Table 2.1. 
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Table 2.1: Summary of Participant Demographics  
Demographic # of Participants 
(Total n=47) 
Region*  
Africa 4 
Europe 2 
Pan America 5 
South East Asia 1 
Western Pacific 35 
Profession*  
Physician 12 
Pharmacist 26 
Business Management 3 
Other: e.g. Sociologist, 
Psychologist, Scientist, Teacher 
6 
Gender  
Male 33 
Female 14 
Stakeholder Group*  
Government 10 
Consumer Group 4 
Health Provider 7 
Academia 11 
Pharmaceutical Industry 6 
Wholesaler/Distributer 5 
Nonprofit 4 
 
*There was overlap between participants, but for the purpose of Table 2.1, participants have been allocated to 
prioritised to region, profession and stakeholder groups 
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2.2.3: Data Collection 
In-depth, face-to-face, teleconference and Skype interviews were conducted with participants.  
Audio recordings of the interviews were de-identified, transcribed verbatim, and secondary 
verification of the transcripts was conducted by the researcher to ensure accuracy.  De-identified 
supplementary field notes were included in the data analysis.   Interviews were conducted until 
thematic saturation was achieved (when several participants repeated similar or recurrent 
concepts in their response), as described by Bazeley (Bazeley 2013).  Interviews lasted a median 
time of 60 minutes (IQR: 45 – 69).  
2.2.4: Data Analysis 
Interview transcripts and field notes were imported into the qualitative data analysis software 
program N-Vivo 10 for coding and data management (Welsh 2002).  Sequential analysis was used 
to explore relevant issues according to participants’ responses (Pope, Ziebland and Mays 2000).  A 
grounded theory approach was applied in data analysis to extract themes and key concepts using 
iterative constant comparative techniques (Strauss 1998). This well-established research method 
has been widely accepted and supported as a high standard of analysis used in interpreting and 
reporting qualitative research (Strauss 1998, Miles and Huberman 1994, Patton 2002, Creswell 
2013, Bazeley 2013).  
Additionally, to understand how multiple stakeholders engaged within the pharmaceutical supply 
chain, the comprehensive theory of collaboration was applied to assist in explaining results (Wood 
and Gray 1991, Bazeley 2013).  In other words, this underpinning theory provided a management 
context for themes to be considered as control mechanisms or contributing to the complexity of 
the situation (Wood and Gray 1991).  While the theory of collaboration provided a management 
context, thematic data analysis adhered to the grounded theory approach.  Therefore, open, axial 
and selective coding methods were used to identify and interpret emerging themes (Bazeley 
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2013). One researcher independently conducted the axial and open coding thematic content 
analysis to identify themes and concepts, which were then discussed and validated by the rest of 
the research team.  Final selective coding was performed as a team.   
To display the significance of stakeholders’ roles, themes were applied to the Ishikawa Fishbone 
diagram to explain the factors that contributed to access to medicines. The comprehensive theory 
of collaboration contextualised results according to control mechanisms and complexities faced 
by multiple stakeholders throughout the supply. The iterative consultative approach offered 
reflexivity and explored relationships between these themes and concepts.  As described by 
Patton (Patton 2002), reflexivity of data collection, interpretation and analysis was offered by the 
researchers’ broad experiences working across multiple pharmacy, patient care and 
administrative settings, with international experiences in both HICs and LMICs.  
2.3 RESULTS  
Results demonstrated perceived factors that influenced access to medicines (section 2.3.1) and 
explained stakeholder roles in the medicine supply chain (section 2.3.2).   
2.3.1: Factors and Influences Affecting Access to Medicines  
Participants had a broad range of views of what factors influenced access to essential medicines.  
Results demonstrated that fragmented management of essential medicines was driven by the 
underpinning principle of choice.  Four main concepts demonstrated this by illustrating the 
complexities involved in managing the pharmaceutical supply chain. Firstly, both international and 
local disruptions contributed to vulnerabilities in the pharmaceutical supply chain; there were 
gaps in communication between multiple stakeholders throughout the continuum of the 
pharmaceutical supply chain; there lacked a coordinated approach between stakeholders to 
manage supply disruptions throughout the pharmaceutical supply chain; and lastly, the current 
consumer driven “just-in-time” supply model must meet a wide range of individual needs that has 
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become increasingly difficult to sustain.  The following themes and quotes supported these 
concepts. 
2.3.1.1:  Theme 1- Both international and local disruptions contributed to 
vulnerabilities in the supply chain. 
Many stakeholders felt they had no control of supply disruptions, especially when they were 
caused outside their country.  
“The current inventory that's out there is dwindling. They haven't come back online yet. 
Doctors are starting to talk to their patients about, "we’ll, start doing half-dosing. The MS 
will probably come back, or the Crohn's disease will start getting some severe symptoms. 
But I have nothing to do for you until they fix this." Participant 42-Academic/ Government-
Pharmacist-Pan America 
 
 “...something like morphine, you'd think there'd be companies all around the world 
making the stuff?  But there was a problem looming.  The TGA [Therapeutics and Goods 
Administration, regulatory body], was able to enable a different preparation of morphine 
but we found it had an additive in it; and therefore, people [could not use this] into the 
spinal canal for epidurals.  This represents a safety issue. I'm still concerned that there 
may be an adverse event with this [new] morphine. But there's nothing we can do about 
that factory.” Participant 20-Government-Physician-Western Pacific 
 
Most participants viewed that supply disruptions were caused by manufacturing and distribution 
issues.   
 “Supply chain issues tend to be more of a problem from the manufacturing perspective 
than from the user end… producing enough or having the [drug] shortages based on 
contamination, [manufacturing plants] going down, supplies along the way being 
intercepted, and grafting corruption.” Participant 42-Academic/ Government-Pharmacist-
Pan America 
 
 
Many participants viewed that stakeholders had the capacity to address direct risks associated 
with their immediate work environments rather than the continuum of the supply chain.   
 “The national department co-ordinates policy and then the provinces are where policy is 
implemented. Some of the provinces have people other than pharmacists responsible for 
the pharmaceutical supply chain. You have efficiencies in some instances because those 
are finance people that might be efficient in ensuring that medicines are paid for in time. 
[They] do not order unless [there’s] money in the budget. [However], they do not 
understand the seasonal changes that will lead to a particular product being used more 
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than for the rest of the year and tend to react very slowly to those kinds of changes.” 
Participant 8-Non-profit-Pharmacist-Africa 
 
Some stakeholders described how sudden regulatory decisions and changes in requirements 
contributed to drug shortages.  
 “We basically make no API [active pharmaceutical ingredient] in Australia. We make a lot 
of our finished products overseas.  They have different quality standards.  The TGA 
[Therapeutic Goods and Administration] have very high standards.  We don't want to 
change them, but we want to be able to get some pro-activity around where they live.  So 
TGA is integral in this process.  Globally, we're raising our quality requirements, as soon as 
you get any variation from regulatory authorities and if it doesn't get through quality 
there's a batch that you write off and you have to make a new batch.  Go back to the API 
and you're chewing through wastage at that end.  There's a massive amount of wastage 
driven by quality.  Participant 18–Pharmaceutical Industry-Pharmacist-Western Pacific 
 
Many stakeholders discussed that governance and enforcement of ethical practices were variable 
and lacked transparency. Most notably in LMICs, concerns of corruption and financial 
inducements were hindrances to collaborative alliances. 
“Prescribers get financial incentives from pharmaceutical companies. Companies, [mostly] 
from India, come and induce through sponsorship, sometimes outright financial 
inducement; which is very unethical. Participant 6-Distributor-Pharmacist-Africa 
 
“We have the national tender system where every province is invited to submit the list of 
requirements with the numbers. But you also have provincial tender boards. Provinces 
have the freedom to decide not to procure a particular item on national tender and get it 
instead on provisional tender. We've seen many examples of the price of medicines 
doubling because they acquire it at the provisional tender. The difference obviously goes 
into people's pockets. So you have a lot of corruption in the procurement system. [And no] 
amount of consultancy or technical assistance is going to improve things if that continues. 
So it's a huge problem.” Participant 8-Non-profit–Pharmacist-Africa 
 
2.3.1.2: Theme 2:  There were gaps in communication between multiple 
stakeholders throughout the continuum of the pharmaceutical supply 
chain. 
According to some participants, wholesalers and distributors had the capacity and supply chain 
knowledge that could potentially facilitate or boost access to essential medicines.  
“One of the problems we have here [in Australia] because we’re such a big country, is you 
might have an out-of-stock situation at the manufacturing level but there’s plenty in the 
wholesale chain. There’s 50% of it [in Western Australia] and they use 5% of it a year. And 
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then none of its [in New South Wales] and you need a lot of it. You can get imperfections 
in the supply chain that creates artificial shortages, and similarly you’ve got 5,000 
pharmacies. Everyone has pharmacies [where they] might have one that they outsource 
stopped product. But how do they get it to the place where it’s needed?” Participant 26–
Pharmaceutical Industry-Pharmacist-Western Pacific 
 
“Availability is an issue because of underfunding, [and] management issues, [such as], late 
procurement, or deliveries.  [Even] if the drugs are there in the country in sufficient 
quantities; distribution inside the country is an issue sometimes.  [For example], Uganda 
and Tanzania migrated from a push system to a pull system.  Push system means that the 
pre-determined quantity you get [is] based on a number of parameter.  The reality is, 
morbidity is not evenly distributed and in every region there are so many factors that 
influence the requirements. You have districts where you have an oversupply and a district 
where you have under supply.  It’s so difficult to re-distribute from one district to another 
because of the administrative and logistic complications.  Availability is and going to 
remain an issue as long as we haven’t solved these management issues and the budget 
limitations.” Participant 2-Nonprofit-Pharmacist-Africa/Europe 
 
Wholesalers and distributors were identified by many stakeholders as not consulted in the 
decision making process, or lacked input in the process of managing and improving supply 
disruptions.  
“Looking back on it now particularly, with the experiences I've gained around the AIDS, 
the ACTs and the anti-malarial medicines; if I had my time again, I would have been much 
more active in involving the distributors and the local wholesalers for them to know what 
was the change [in therapeutic guidelines or procurement decisions].” Participant 43-
Academic/Government–Physician-Africa/Pan America. 
“When morphine was an issue, we [the wholesalers] were restricting morphine sales and 
drip feeding it out to stop people stockpiling. More and more manufacturers are asking us 
to restrict the supply out to hospitals because they know there’s going to be a shortage. 
They think we should have to do it based on our current fees which are being squeezed 
dramatically over the last five years.  I don't have an issue with the wholesaler doing it, 
because we're the ones that deal with hospitals, so we're the logical people to do it, but 
somebody’s got to pay for us to do it. At the moment, nobody wants to pay us to do it and 
that's the problem.”  Participant 29-Wholesaler/Distributor-Business Management-
Western Pacific 
 
All stakeholders expressed concern that there was poor communication between stakeholders 
and fragmented approaches within the system.  
“In practice, [the EML] is really not working effectively, but in theory it is. Because of 
changing governments, various governments come and go and there is no consistency in 
policy implementation. Because of that, you have a lot of problems in trying to get those 
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policies implemented. So you don't see the policy changes, the change of government or 
new minister comes with new ideas.” Participant 6-Distributor-Pharmacist-Africa 
 
“If you don’t communicate about that quality [of medicines] it will stay in the minds of 
people [that] cheap medicines are bad quality.” Participant 7-Distributor-Pharmacist-
Africa 
 
 
Additionally, many stakeholders described how tensions between stakeholders were caused by 
pricing of medicines and costs of services for a wide range of products; therein, putting much 
pressure on the system.   
“Most of the old generic drugs are being forced to become cheaper. And that’s causing the 
problem. [Today], ceftriaxone costs $1 per vial. So you can life-save for meningitis for less 
than you pay for a Mars Bar.”  Participant 15-Health Provider-Physician-Western Pacific 
 
“I think Australia is a disastrous example as far as the generic market is concerned. The 
prices paid compared to New Zealand and compared to just about every other country, 
middle and high income country in the world, is disastrous.” Participant 43–
Academic/Government-Physician-Africa/Pan America 
 
Most participants demonstrated that stakeholders had limited knowledge of how others managed 
supply disruptions.   
 “People worry drug shortages must be the company's fault? Sometimes it is. Sometimes 
companies screw up. But then other times there are actually drugs out there. The supply is 
there but it's not in that hospital's formulary. So is that the company's problem? Or is that 
the hospital formulary manager not anticipating, or he/she only realised the company 
wrote to them six months ago [saying], ‘you might want to start stocking up on your 
formularies’, and they didn't do it.” Participant 14-Pharmaceutical Industry-Business 
Management-Western Pacific 
 
Meanwhile, all stakeholders agreed information sharing was limited and inconsistent, sometimes 
due to the lack of trust or communication between stakeholders.  
“In the past, the manufacturers association was a member of the committee and it was a 
major battle. [They were] removed from the committee because of that conflict of 
interest. I don't see any conflict of interest with the public sector procurement agency 
because they have a responsibility for providing for the public sector. The distributors were 
a much more difficult issue. How we handled that was we shared the changes in the 
treatment guidelines in advance with the distributors and told them what the new 
treatment guidelines were and to be aware that there will be a change in the market.” 
Participant 43-Academic/Government-Physician-Africa/Pan America 
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“Industry wants decision-making more transparent. Transparency is a flexible term. 
Sometimes what that translates into is industry wants more of an ability to influence the 
decision makers. [For example], they want the ability to make direct presentations to 
committees, or an appeal mechanism if they’ve been turned down. It’s fair to industry to 
have a set of principles [for the] evidence that you have to provide, [and] the way we’re 
going to evaluate the evidence. That’s okay. [But] when industry talks about transparency 
as the ability to influence decisions, I’m not supportive of that.” Participant 41 - 
Academic/Health Provider/Government-Physician-Pan America  
 
“It’s particularly a challenge when the places you’re trying to harmonise are at different 
levels of development.  [For example], harmonising within Latin America is proving a lot 
easier with Anvisa in Brazil as the core, along with a few fairly similar regulators to share 
information and do joint inspections. The Southern African development community has 
14 countries, including the Democratic Republic of Congo who hasn’t got a regulator.  
[South Africa] has got some regulatory capacity, [but] how do you work with a place that 
has nothing, and how do you harmonise that?  It’s easier for us to harmonise with other 
PIC/S [Pharmaceutical Inspection Corporation Scheme] countries and share our 
inspections. That’s the nature of PIC/S. It’s about GMP inspection, recognising one 
another’s inspection reports and sharing inspection reports.  So you can all be at the same 
standard, applying the same rules, and then share results.” Participant 3– 
Academic/Government–Pharmacist-Africa 
 
Most participants claimed that prescribing practices did not provide a consistent pattern for 
procurement to follow due to many preferences and therapeutic options.  
“They came together as a committee to complain about stock-outs. The [cancer] 
specialists, wanted to treat everything, but were dealing with repeated stock-outs and 
shortages. They would initiate a patient on anti-leukaemia, lymphoma or Burkitts 
[treatment], but would run out and then the child would relapse and be resistant. They 
identified which were the priority conditions to start with. I said [to] look at the budget, 
you cannot have everything, and some medicines are more essential than others. Some 
medicines were better than others and you have to recognise it, and tell me what those 
medicines are so I can help you do the cost effectiveness analysis.  That moment, they 
could see that treating one patient with high-cost medicine, [meant] there were ten that 
were deprived of treatment under those circumstances. The essential medicines principles 
came across in a very effective way.  And, the chair of this committee was very successful 
in motivating all the specialists.” Participant 43–Academic/Government-Physician-
Africa/Pan America  
 
“I remember one person from one of the hospitals from the province saying, ‘You're 
putting a cost on survival?’ And I said, ‘a cost on life?  Absolutely.’  That's a public health 
approach, and this is what the essential medicines approach is. They came onboard 
because we convinced them that it was the stock-outs and [drug] shortages that were 
killing them.” Participant 43–Academic/Government-Physician-Africa/Pan America 
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2.3.1.3: Theme 3: Lack of a coordinated approach between stakeholders to 
manage supply disruptions throughout the pharmaceutical supply chain. 
All participants reported that supply chain stakeholders fixed their own problems instead of a 
cohesive approach with clear leadership.  
“Health professionals can be extremely good at getting stuff for their patients. To what 
extent do health professionals either ignore or actually circumvent the EMLs because their 
concern isn't so much about the politics or the financing of drugs for their country? Their 
concern is helping this person who's in front of them.”  Participant 42-Academic/ 
Government-Pharmacist-Europe/Pan America 
 
 “If there’s a supply issue and it’s a company that can’t supply, then the government 
should have in place alternative supply, particularly for essential medicines. We’re not 
talking about every medicine; we’re talking about penicillins and morphines. They should 
be able to access alternative suppliers and have that as a backup.” Participant 44-
Consumer-teacher-Western Pacific 
 
Some participants showed that timing and reducing the impact of short and long term shortages 
was a priority for stakeholders involved at the point of care.    
“We use mostly prednisone 5mg tablets in South Africa. The reason [suppliers] give is that 
the API is very expensive, it's not worth producing [because] the market is not big enough 
for it. The other one is chloramphenicol eye drops and eye ointment. It's those medicines 
that appear not to be very important because they are not used to treat the big disease 
categories. But, when they are not there, you really feel it because people just can't get 
access to those. Sometimes manufacturers will deliberately decide not to continue 
producing something.” Participant 8-Nonprofit-Pharmacist-Africa 
 
Some stakeholders discussed that accountability of supply disruptions required more clearly 
defined stakeholder roles and responsibilities in order to improve engagement and collaboration.   
“If nobody's in charge, it's going to be a big issue, that thorn in your side every day.  But if 
you dedicate a 0.1 FTE [full time employee] staff member for example, in your pharmacy, 
pharmacy group or organisation you can refer to the expert in drug shortages. That way 
the message is being delivered consistently all the time, and the patient [or physician] 
won't get mixed messages of what was available.  [Otherwise, this] can be very draining 
on people.  So it's about knowing your work environment, being able to have that 
organisational structure that says who's responsible for what, and then having the CEO 
ensure that proper training is done so that the people know who, when and how to do the 
referral piece.”  Participant 1-Health Provider/Nonprofit-Pharmacist-Pan America/Africa 
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Meanwhile, participants showed there were different (at times conflicting) priorities amongst 
stakeholders.  For example, most stakeholders demonstrated isolated management according to 
the specific needs and capacity of each practice setting, sometimes resulting in duplication of 
activities  
“The purchasing people in hospitals are working like many wholesalers and we don't see 
that as necessary to do.  We think there’s an opportunity to be more efficient with sharing 
data at the hospital level, the hospital to the wholesalers.  They can get more consistency 
back to the manufacturer, so they could manage the supply chain better.” Participant 29-
Wholesale/Distributor-Business Management-Western Pacific 
 
“There are a lot of people who sell medicines.  People import medicines and sometimes 
there’s no pharmacist.  Sometimes, [people] trust medicines but then they hear about the 
counterfeits, or something has happened.  After this, they don’t trust the system anymore.  
They will trust only the people they know, the pharmacies they know, to resolve their 
medical problem.” Participant 7-Distributor-Pharmacist-Africa 
 
However, most participants demonstrated that shared priorities were not identified or 
communicated between stakeholders. 
“When you talk to individuals who are coming from a clinic or small hospitals in rural 
areas, they know [there’s an] EML but it doesn't mean much to them. They're working 
from their formulary. There are many countries that don't even have EMLs. Should they? 
That ties into national drug policies that many countries don't have. Participant 42-
Academic/Government-Pharmacist-Europe/Pan America 
  
“The EML was never meant to support innovation in any sense. The idea [was] to provide 
access to medicines that were needed by the population.” Participant 41-
Academic/Government/Health Provider-Physician-Pan America 
 
“Eighty percent of people that die of non-communicable diseases live in developing 
countries. The EML may not efficiently and effectively, with the limited resources available, 
[offer] these treatment options to help people, and prioritise [medicines]. [For example] 
insulin [is on the EML], but funding levels are so low, [so] you then prioritise within your 
priorities.  [With] the EML you’ll find that they stratify according to categories of vital, 
essential, and non-essential.  So first, if your resources are limited you drop the non-
essential ones, then the essential ones, and the vitals you never touch.  But I’ve never seen 
a well organised approach towards dealing with limited resources, by having a fair 
composed group of people, committee, determining what [to] buy, what [not to] buy. As 
soon as you have an EML [where] you have to make selections within a selection, then it 
seems to be done at random.” Participant 2-Nonprofit-Pharmacist-Europe/Africa 
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2.3.1.4:  Theme 4:  The current consumer driven “just-in-time” 
pharmaceutical supply chain model must meet a wide range of individual 
needs that has become increasingly difficult to sustain. 
Many participants were uncertain whether consumers played a role in managing the supply chain.   
“The more you look at the supply chain, the more vulnerability you see.  We create some 
of our own vulnerabilities here with our just-in-time medication, and with our contracting 
processes.  ” Participant 20-Government–Physician-Western Pacific 
 
“For low [income individuals], and the lowest possible incomes are those who live on 
services from the state, up to one-fourth [25%] had said they can't always afford the 
medicines from the doctor.” Participant 16-Academic-Pharmacist-Europe 
 
 
Some participants acknowledged health provider concerns were unable to accommodate 
consumer demands. This also draws attention to the importance of well trained health providers 
who can communicate and advocate appropriate or cost-effective therapeutic options, despite 
pressures, in order to empower consumer choice.  
 “To some extent, we now influence non-essential medicines coming in. When a patient 
says, this is the prescription from my doctor and this is what I want, what would you do? 
You just have to find a way of getting it for them.  People go to the private sector for 
medicines if it's not covered under essential medicines. I know some government hospitals 
still insist on getting essential medicines, but the doctor will tell you this is what I want for 
my patient. And when he says that, there's nothing you can do, you have to look for it or 
you lose your customer, you lose your patients.” Participant 6-Distributor-Pharmacist-
Africa 
 
In contrast, some participants viewed that ordering, poor quantification and forecasting practices, 
especially from the health facilities, as major limitations to providing fluid and reliable supply.   
“The reasons for stock-outs in the Pacific are almost entirely due to bad management. 
They don’t have a culture of keeping records. In Cambodia, in the public sector, if they 
order something from the CMS [central medical store], they’re only likely to get half of it 
[even though] you may know that in the CMS it’s all there. The reason is that the CMS staff 
believed that the minister [of health] liked the CMS to [always] be full.” Participant 38-
Academic/Nonprofit-Pharmacist-Western Pacific 
 
“Generally, most medicines are available in the country. Every province has its own 
medicines depot. But availability in the medicines depot does not equate to availability in 
the facilities. The problem is that because of poor quantification, or poor forecasting [on 
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the part of] the facilities, other facilities will not have a drug, even if it's available at the 
medicines depot. They don't have enough skilled, experienced, qualified people to run the 
drug supply management chain. Of course, you do have companies that do not supply as 
they are supposed to. But in the system, there's been no provision for follow-ups for 
monitoring of the performance of the companies.” Participant 8-Nonprofit-Pharmacist-
Africa 
 
Many stakeholders expressed that there lacked cohesive and inclusive consultation between 
stakeholders regarding solutions to fix drug shortages or offer sustainable supply solutions.  
“You’ve got to get the six states and two territories to agree on the list.  If they don’t agree 
on the list, they’ll tend to do their own thing.  If they want consistency when there are 
shortages, they have to have a national approach how they’ll allow products to be drip fed 
out to the market nationally.  If they don’t get to a national arrangement and get those 
states to agree, they’ll all go do their own thing because there’ll be each state with one 
thing of their own essential product listing, which they essentially do now. They're all 
different, but 80-90% of it can be a combined list. Unless you get all the states together, 
nothing's going to change.” Participant 29-Wholesaler/Distributor-Business Management-
Western Pacific 
“In the public sector it’s very difficult not to adhere [to EMLs] because other medicines just 
simply aren’t there.  In South Africa and at primary care level, all medicines are free to 
uninsured patients, so there’s no co-payers, no consulting fee. But you can’t prescribe 
what’s not available, it’s quite simple.  On the private side you can deviate from those 
algorithms, and even if the insurer refuses to pay, the patient picks up the co-pay.” 
Participant 3-Academic/Government-Pharmacist-Africa 
 
Moreover, some highlighted that the availability of too many therapeutic options and market 
competition driven to meet a broad range of individual needs has consumed large amounts of 
resources.  
“Think about relativity. There's a valuation and people make those decisions. People say 
that medicines are expensive, and I'll grant you that there are some medicines that are 
very expensive and I don't understand why they're so expensive. But are they affordable? 
[I think] you can do anything you want to do, you just have to face the consequences.” 
Participant 1-Health provider/Nonprofit–Pharmacist-Pan America/Africa 
 
“I find the essence of the EML is defeated. It's not that they're not competent. Definitely 
those EMLs are there, but you see pressure coming from outside to use these products 
[and] a lot of irrational prescriptions coming from the prescribers, because the 
pharmaceutical companies are coming up with innovations, ideas, and puts pressure on 
them. [Some] doctors [might] say, ‘okay let me see how this [new medicine] is?’ In the 
private sector, they can make use of any medicine they want to use. But in the public 
sector, there's policy on essential medicines, and preference to essential medicines in 
43 
 
tenders in government hospitals. [But] policy is not implemented to the letter, so there's 
still room for non-essential medicines coming in, which is compounding the system.” 
Participant 6–Distributor–Pharmacist-Africa 
 
“We’re reimbursing sometimes because of political pressure. What becomes essential, 
cost effectiveness? The culture will influence what you think is essential to some degree. 
The other thing that influences essential is moral attitudes. [If] it’s quality of life, then how 
far do you want to go with that in terms of essential and not essential? Does that make 
enough difference to your quality of life that it should be on the list?” Participant 41-
Academic/Government/Health Provider–Physician-Pan America 
 
In addition, some participants explained the expiry and waste of medicines were costly 
consequences to providing essential medicine stockpiles or emergency use only medicines. 
“Everybody should adhere to the essential medicines concept, because we don’t need a lot 
of waste in the healthcare system even if you’re in a high resource place. Also, if this is 
strictly adhered, to as far as judging efficacy and safety in comparing one drug to another, 
making sure that you don’t need every alternative available but the best alternative, 
anyone [and] any country could benefit from that.”  Participant 40- 
Academic/Government–Scientist-Pan America 
 
“Stockpiling is extremely dangerous.  Stockpiling has [only] worked for anti-retrovirals in 
Africa.  IDA [International Dispensary Association] or the SCMS, [Supply Chain 
Management Systems] has stockpiles in South Africa that are able to supply to SCMS 
projects. It's a single payer. The US Government is paying for all those medicines, 
whichever country it goes to, so they are able to shift funds around.” Participant 43-
Academic/Government-Physician-Africa/Pan America 
 
2.3.2: The Roles of Stakeholders in the Pharmaceutical Supply Chain  
In addition to these influences, this study also explored the roles of supply chain stakeholders to 
understand how they interacted and engaged in decision making. The Ishikawa fishbone diagram 
has been used in studies to display barriers and facilitators (Ridge, Bero and Hill 2010, Tran and 
Bero 2015).  In line with the comprehensive theory of collaboration, the themes displayed in 
Figure 2.2 and 2.3 highlighted control mechanisms and complex challenges involved with each 
stakeholder’s role. Results showed that sometimes stakeholders’ intended control mechanism 
contributed to the complexity of the supply chain, and stakeholder roles sometimes overlapped.  
For example, providing quantification of medicine stock is a critical control mechanism needed for 
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the supply chain to run smoothly. Meanwhile, poor quantification frequently occurred due to 
capacity, resource or time limitations, resulting in complexities such as stockpiling, expiry of 
medicines, unavailable medicines, and delivery delays.   
Thematic analysis showed that logistics management and therapeutic decision making were 
managed separately by stakeholders in the supply chain.  As a result, these were displayed in two 
separate diagrams. The first fishbone diagram (Figure 2.2) shows stakeholders involved in decision 
making to facilitate access to medicines. The second fishbone diagram (Figure 2.3) shows 
stakeholders involved in pharmaceutical logistics to deliver access to medicines. 
45 
 
 
Figure 2.2: Stakeholders involved in decision making to facilitate access to medicines. 
Logistics management and therapeutic decision making were managed separately and displayed in separate diagrams. To simplify reporting of results, repetition of 
themes were not displayed in the fishbone diagram.  Instead, themes were arranged according to the stakeholder who was perceived to have the most influence 
(control) on the issue.   Furthermore, since managing drug shortages was explored in interviews, the analysis often reflected how unavailable medicines were managed 
in the supply chain. 
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2.3.2.1: Government Roles  
Stakeholders perceived that governments had significant leadership, facilitating, regulatory, 
enforcement, provision and funding roles.   
“People in leadership [positions] have the charisma and preparedness, to bring people 
together and share a combined vision.  At a national political level, it can make such a 
dramatic difference how a minister of health is appreciated, how much he /she advocates 
and [stands] behind these kinds of ideas to impact the willingness and preparedness to follow 
[through]. [However], knowing is different from doing. [For example], the Budget Declaration 
is a commitment by countries in Africa to spend at least 15% of the national budget on 
health care. Almost none of the African countries, except Botswana and Namibia, even reach 
10%.  Governments have to [set] their priorities right.” Participant 2-Nonprofit-Pharmacist-
Europe/Africa 
 
“[Nowadays], government hospitals have medicines available, [with] patients lining up for 
the services. [This did not happen] before, because there were no medicines [at the facility]. 
When the president made the mandate, the corresponding logistics, structure, and 
monitoring logistics were also done, [through the] political will of the insurance company, of 
the head of the department of health, and the regulatory agencies. I could not work well with 
them before, because our ideas clashed.  [Since] these administrative and executive orders 
[were passed within] a legal frame, [it allowed] everybody to really work [together].” 
Participant 4-Health Provider/Government–Pharmacist-Western Pacific 
 
Meanwhile, government involvement created complex environments and were challenged with 
issues around pricing, ensuring payments, regulatory changes, monitoring quality and safety of 
medicines and market influences. 
“The major reason for stock-outs is nearly always a failure or delay in paying for the 
medicines. In the US, the increasing quality standards [have created] a very competitive, very 
tight generic market where the insurers are ratcheting down the reimbursement price for 
products, while at the same time the FDA [US Food and Drug Administration] has raised 
standards. And so the cost of manufacturing has increased for what are often low-volume 
products, and that's the most frequent cause of shortages in middle and high income 
countries. In the low income countries, the vast majority of stock-outs and shortages have 
related to inadequate financing or inadequate financial management.” Participant 43–
Academic/Government-Physician-Africa/Pan America  
 
“Eighty percent of API for both brands and generics come from China or India. It doesn’t 
matter what country you’re in. In the US, the market competition drives the price for generics 
down extremely low. If you’re deciding what’s on the list just on the basis of price, than you 
may end up with shortages. If you pick a single supplier, this is typically if you’re tendering, 
you tender to the lowest bidder, but then something happens. [For example], the situation 
with the fire in the Sandoz plant in Quebec [Canada].  If that happens, then you could be in 
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trouble with shortages of what you deemed an essential drug because you’ve only got the 
one supplier.” Participant 41-Academic/Government/Health Provider-Physician-Pan America 
 
“If a regulatory authority such as the FDA has Okayed a particular product, some people will 
say why doesn't South Africa simply take their [decision] into consideration and give 
approval. To some extent, I think it happens on some of the medicines. But much [as] our 
regulatory authority is quite strong, certainly the strongest on the African continent, it's not 
efficient enough. [Therefore], companies complain that it can take up to five years, those are 
extreme cases, to have a product’s registration go through. Our government agreed to fast 
tracking the registration of certain medicines, if they are found essential and therefore 
required. [Regulatory requirements are] quite strict, but takes a long time, and companies 
complain they lose a lot of money waiting for registration to go through. If a company wants 
to register a drug in South Africa they have to have a presence in the country, even if it 
means initially opening an office and employ a pharmacist who's going to look after their 
interests. So [companies] start spending money long before the product is registered.” 
Participant 8-Nonprofit-PharmacistAfrica 
 
Furthermore, decisions around prioritising health needs and contingency planning were complex. 
“We assume that nothing is going to come to the committee unless there is at least marginal 
public health need. But I don’t think committees grapple very well with differentiating 
between something that’s going to be used by everybody versus a very small segment of the 
population.” Participant 40–Academic/Government–Scientist-Pan America  
 
At the same time, government roles were viewed as susceptible to coercion and corruption due to 
lack of transparency around decision making and handling of public funds. 
“In one province, the company that was supplying this only drug was not paid. The company 
then withheld supplies. But the province was given money to do a buyout, meaning buying 
that same product from the same company outside the tender process by paying a lot more 
money. The suspicion in fact was that officials in the department are paid to make sure that 
the companies are not paid so that they can sell them at the higher prices. So [companies] 
have all sorts of ways of ensuring that they make a lot more money, especially when they are 
single source suppliers.” Participant 8-Nonprofit–Pharmacist-Africa 
 
2.3.2.2: Academic Roles 
Academic stakeholders had a pivotal role in providing unbiased information that identified, and 
explained information sharing and interaction between stakeholders in the supply chain.  
“I think there is a sort of myth that the EML is for second class medicines, [as in] they’re not 
the best medicines. Really, they are the best medicines.”  Participant 40-
Academic/Government–Scientist-Pan America 
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“Consistent statistics management - it all boils down to components of information in the 
supply chain system.  In Kenya for example, in spite of insurmountable situations, local staff 
have come up with a logistics information system where somebody sitting in the capital city, 
Nairobi, in real time, can know what is going on in Nyanza province or anywhere else in 
Kenya. [They know] the consumption level and what the situation is there. They have time to 
even act upon any redistribution that may be needed from one province to another in case 
there's a shortage over there.  So when all that information comes upstream that can help 
them plan for a procurement cycle.” Participant 9-Nonprofit-Pharmacist-South East 
Asia/Africa 
 
“So a good example of how to deal [with] simple things and do them consistently is Namibia.  
They gather simple indicator data every six months and they report it every year, and they 
can see a percentage antibiotic use or what proportions of the population who leave a 
primary care facility have had an injection and they can track it over time.” Participant 3-
Academic/Government-Pharmacist-Africa 
 
However, some challenges academics faced were around providing and communicating information 
from different levels of the health care system to different stakeholders, engaging collaboratively 
with different stakeholders, and sharing and coordinating information in a timely and ethical 
manner.  
“I find it pointless when researchers try to have a consistent measure.  You just can't do that 
and studies cost money, time and resources.  The availability data that you might see from 
studies five years ago, well it changes. Even last year will change this year because it all boils 
down to pricing, supply chain information, quantification, and forecasting.” Participant 9-
Nonprofit-Pharmacist-South East Asia/Africa 
 
“We are gradually moving towards bringing about a connection between the procurement 
system and the selection system. You have the people on the [EML] committee simply 
choosing medicines based on efficacy, on suitability for treating the particular ailment or 
disease. The procurement people on the other hand, will look at the price. If the procurement 
[and] the selection processes did all of this together, then they'd be able to look at two 
[products] for the same ailment and then bring into the whole equation, availability, wide 
availability of the product. There are instances where other products which might not be as 
efficacious, but which is readily available and is produced by more than one company. That 
product could have been used and would have had better success.” Participant 8-Nonprofit-
Pharmacist-Africa. 
 
Further challenges that academics faced, included the lack of trust and conflict of interests between 
stakeholders. 
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“They won’t talk about the process, there’s a complete lack of transparency. It corrupts the 
whole system, because then you’re moving the medicines that are available to the 
practitioner further away from what’s on the EML, because you’ve had all these financial 
dealings behind the scenes. I mean why have an EML if you know people are going to go 
make these behind door deals and wind up with a small number of companies whose 
products are on their list?” Participant 40-Academic/Government-Scientist-Pan America 
 
These issues also raised concerns about the importance of training and qualified staff to interpret 
and disseminate evidence. 
“[Available] people who are able to interpret this and challenge poor quality modeling is 
scary.  Think of industry providing modeling to NICE [the National institute for Health and 
Care Excellence], how many times does NICE say we ran another model and we disagree with 
the one that was submitted to us?  The capacity do to that and to distinguish between good 
and bad public economic data is very limited.” Participant 3-Academic/Government–
Pharmacist-Africa 
 
“There’s this notion [of] providing treatment to the poor and treatment to the affluent.   I 
think education is core, it’s essential.  In medical schools they have to include this in the 
curriculum, to medical doctors, pharmacists, and nurses.  But, if these tools are out dated, it 
loses its value.  It depends on so many elements.  What is the culture in an institution, the 
university, the school of medicine in the university?  How much do people interact with each 
other and have faith and trust in each other?  That varies over time.” Participant 2-
Nonprofit-Pharmacist-Europe/Africa   
 
“I think the main difference is the [Health Technology Assessment] HTA process does have 
the formal cost effectiveness analysis. In the evidence review, they’re very similar in terms of 
efficacy and harm, but when we get to the cost data the HTA is a more formal process. Also 
the HTA doesn’t necessarily take into account public health need.”  Participant 40-
Academic/Government –Scientist-Pan America 
 
2.3.2.3: Consumer Group Roles 
Consumers were most concerned with having timely and affordable medicines available when they 
needed them.  
“What am I going to do? [The patient thinks] I need my pink pills or I go crazy, or I get hot 
flushes or I get this or that, or my kids are going to shoot me.  I have to focus on managing 
that process.  So every ounce of energy that I spend away from that focus is waste. So from a 
patient perspective, they may see that I'm really trying to help them.  I'm their advocate.  On 
the other hand, they could well be saying, ‘you're an idiot, I came last week and you didn't 
have them either’.” Participant 1-Health Provider/Nonprofit–Pharmacist-Pan America/Africa 
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There was emphasis on advocacy for access and the importance of having choices to meet their 
individual needs.   
“I think choice is very important and having as much information as possible in order to make 
an informed choice is actually more important. For consumers we have to think much more 
about the trade off in paying for very expensive medicines that don’t cure. That means other 
medicines that might be able to cure the people of other diseases may not be as affordable 
because we’re paying so much for these medicines that extend life.  Or it might mean that we 
can’t put as much money into other things like preschool education.” Participant 44-
Consumer-Teacher-Western Pacific 
 
“The industry argues innovation in the sense that every new drug is to some degree 
innovative because it’s a new molecule. It provides extra choice.” Participant 41-
Academic/Health Provider/Government-Physician-Pan America 
 
“It depends on people’s choice. Some people will want to not have medicines that prolong 
their lives for a short time because the side effects are so debilitating. They’d rather forego 
the treatment. Participant 44-Consumer-Teacher-Western Pacific 
 
While consumers provided demand, they were not seen to contribute to the supply chain 
management process. 
“If you pay for a service you have the right to demand something in return.  So you give a 
voice to people who have no voice.  If you get something for free in Africa, in a country like 
Tanzania; if you get health care for free, people, patients have no voice.  And the dynamics 
change if people have to pay for services.  That changes the dynamics in the system too.  
That’s not happening nowadays.  So free services for free, is never providing an incentive 
unless you have people with this intrinsic motivation out of their personal value system.  But 
reality tells you that as people, we all are in our own way, very selfish.” Participant 2–
Nonprofit-Pharmacist-Europe/Africa 
 
“I don’t know what [consumers] can do about [drug shortages]? Put pressure on the 
purchases of medicines? [Not having medicines available] can be devastating to people. But 
they have to know about it, and I don’t know who would take responsibility for informing 
people.” Participant 44-Consumer–Teacher-Western Pacific 
 
2.3.2.4: Non-Profit Organisation Roles  
Non-profit organisations had a role in providing advocacy for consumers and unbiased information 
to all stakeholders.  
“[There is a need] to disseminate information to the public, what is a medicine, why is it 
being used, what are the things you need to be careful about, and what information you are 
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to ask when you use this, because medicines are viewed as an ordinary commodity.” 
Participant 4-Health provider/Government–Pharmacist-Western Pacific 
 
Their involvement in various contexts offered reflection of challenges implementing policies on the 
ground level. 
“When people talk about all these policy things, the national drug policy and EMLs, it's the 
politicians and the NGO [non-government organisations] directors who are envisioning all 
these wonderful things. Then when you see what happens on the ground, in the field in some 
small village, it's a completely different world. Oftentimes I think WHO, Ministers of Health, 
NGOs, trainers, academics, don't do a very good job of educating people in those lower levels 
mostly in community settings or specific health settings, clinics and so forth. Both the 
providers and the patients, [need education] about essential medicines, and what this 
means, how are you going to implement it and use it in your particular setting?” Participant 
42-Academic/Government-Pharmacist-Pan America 
 
Non-profit organisations’ roles sometimes overlapped with other stakeholders in LMICs, when 
involved with the provision of care or managing donated or sponsored medicines; however, this was 
not addressed in these results. 
2.3.2.5: Hospital Health Care Provider Roles  
At the therapeutic decision making level, health providers determined health need priorities and 
processes based at the patient level, managed standard treatment guidelines (STGs) and 
procurement processes, and were at the front lines of managing therapeutic options for drug 
shortages.  
“The larger an EML gets, the larger and more complicated the procurement process and 
storage becomes.  The prescribing can become more complicated as well. Then you’ve got to 
look at the different dose forms and strengths that are available too. For example, 
pregabalin is available as 25mg, 75mg, 150mg and 300mg capsules. You need to have shelf 
space for four different strengths of the one drug if you’re going to have all four drug 
strengths on your hospital formulary. The cost of that has to be taken into account. So access 
is affected by the different levels of the supply chain. You’ve got impressed in the hospital, 
versus prescribing, versus supply as well. Participant 10-Health Provider-Pharmacist-Western 
Pacific 
 
“The only way we'll substitute a product is if the pharmacist from the hospital tells us what 
they want to buy. [The wholesalers] don't have clinical people.  Whatever they tell us we'll 
do.  Whatever the alternatives we’ve got in stock, we will supply that at the contract price if 
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it’s on tender and then charge the difference to the manufacturer.  That is totally embedded 
in our system.” Participant 29-Wholesaler/Distributor-Business Management-Western Pacific 
 
“The main thing that affects prescribing is what’s available to people to prescribe. If the EML 
was guiding purchasing and management of the supply more directly then maybe that could 
prevent some of those shortages particularly since the EML is focused on the medicines 
where we do know there’s a high public health need.” Participant 40-Academic/Government-
Scientist-Pan America 
 
However, these stakeholders felt the consequences of unavailable medicines through their inability 
to deliver patient care, and were crucial to relaying patient needs to other stakeholders. Therefore, 
the therapeutic decisions made at the patient level of care, mostly reflected the consumer demand 
in the supply chain. 
“Just because it's on the EML doesn't mean the company's going to keep providing it.” 
Participant 12-Health provider-Pharmacist-Western Pacific 
 
“Health professionals are people who want to help their patients. They care less about 
politics and lists and what WHO says. [The EML] is good guidance, especially if one doesn't 
have time to maintain their knowledge level for all the changes in medicine. But for the most 
part, they're just focusing on what my patients need from us as providers of healthcare. I 
remember where the government deemed [a medicine] to be an essential medicine and 
focusing on that word ‘essential’ and how loaded it is. But we can never get any at our clinic. 
So how essential is it really if they have it on a list but it's never or rarely available? Or when 
we can get it, it's really expensive?” Participant 42-Academic/Government-Pharmacist-
Europe/Pan America 
 
On the other hand, high variation in administration and management strategies, procurement, 
capacity, resources, budget constraints, variations in contracts and tenders, and payment practices 
created a high degree of inconsistencies throughout the supply chain.   
“I think they mostly budget properly. It's the budget allocation that's a problem, lack of skills 
to [prepare] proper forecasting or quantification, and the irrational failure to pay suppliers. 
But most medicines are generally available in the country. So it's the logistics system that 
leads to what we refer to as artificial stock-outs.” Participant 8-Nonprofit-Pharmacist-Africa 
 
“There's no pro-activity when we get past the wholesaler, and this is down to the end user 
perspective.  Stock control is a site-by-site level and only for those organisations that see it as 
a financial enabler, but there's no sharing of that information system-wide.  So when you 
hear [government] say we need to create a reserve of essential medicines, I completely and 
utterly disagree, because we need to actually understand where this resource is within the 
country so that we can best use it.” Participant 18-Industry-Pharmacist-Western Pacific 
53 
 
Figure 2.3: Stakeholders involved in pharmaceutical logistics to deliver access to medicines. 
Logistics management and therapeutic decision making were managed separately and displayed in separate diagrams. To simplify reporting of results, repetition of 
themes were not displayed in the fishbone diagram.  Instead, themes were arranged according to the stakeholder who was perceived to have the most influence 
(control) on the issue.   Furthermore, since managing drug shortages was explored in interviews, the analysis often reflected how unavailable medicines were managed 
in the supply chain. 
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2.3.2.6: Manufacturer Roles 
Manufacturers were accountable to stakeholders nationally and globally. They provided capacity, 
ensured reliability of supply, upheld quality standards, and communicated supply disruptions 
throughout the supply chain.   
“The system we've had in Australia has worked well for the last 50 years or more. Even 
though there have been drug shortages, you haven't heard about it, because the system 
worked.”  Participant 14-Pharmaceutical Industry-Business Management-Western Pacific 
 
“[Medicines] are commodities. The people who sell the commodity play all the games they 
play in sales and marketing to make money with these commodities.” Participant 42-
Academic/Government-Pharmacist-Pan America/Europe 
 
Due to globalisation, medicines were predominantly sourced out of country, and companies were 
expected to provide safe, reliable, and appropriate supplies of medicines.  
“Eighty percent of all those drugs are being manufactured out of India, so if something 
goes wrong with the Indian manufacturing system; it's going to have a massive issue with 
the shortage.  On top of that, any drugs, even these generic drugs, get solely listed on a 
tender even though they’ve got these issues, [and] they can broker by the brand one.  
There's more and more generic providers [that] get on the tender and they don't have 
stock here.  They cause all sorts of issues with out-of-stocks.  It’s more time consuming 
when you have product substitution and claim back the dollars.” Participant 29- 
Wholesaler/Distributor–Business Management-Western Pacific 
 
“About 90 percent of the medicines we use are imported, and the local production is not 
very effective. So a company importing this product wants their products to be sold, bring 
in new products, and to introduce new molecules.”  Participant 6–Distributor–Pharmacist-
Africa 
 
“The differences between little generic firms in developing countries and the big firms are 
beginning to merge.” Participant 3-Academic/Government–Pharmacist-Africa 
 
The ability to perform these roles made them the drivers of the medicine supply chain. However, 
unexpected natural or political disasters, manufacturing and delivery issues, international laws, 
and profit margins created volatility in the supply chain.  
“Low prices may also contribute to shortages because there’s less profit margin. The 
generic companies are looking at their range of products that they’re offering, and 
discontinue selling the ones they’re making [less] on to focus on the ones that they’re 
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making a higher profit margin.” Participant 41-Academic/Government/Health Provider–
Physician-Pan America 
 
“There's an example where a company in Australia will have responsibility [as] the only 
company that imports in Australia. Not that they've got an exclusive contract, they just 
happen to be the only company. They rely on another separate company to supply the 
main board for that company there. If that first company doesn't tell the second company, 
then there's one example where they go raise the talk. Where company x is relying on 
company y overseas to do it in Europe. Company x bought it off company y. Company y 
had decided to refurbish its factory or do something but they didn't bother telling 
company x. So company x who is operating here in Australia suddenly goes what do you 
mean you can't supply anymore? So company x had to deal with company y's [issue] - 
anyway that happens.” Participant 14-Pharmaceutical Industry-Business Management-
Western Pacific 
 
Furthermore, the provision within the supply chain was complicated by market competition, 
manufacturing issues or disruptions, meeting regulators quality requirements, fragmented 
management and response, operational costs, profit targets, investment costs and the 
discontinuation of products.  
“Where we have a single source product, as in a product that's produced by just one 
company, what happens quite often is that the company will decide not to make the 
medicine available for the tender system. Thereby, [providers would] be forced to buy at a 
high price because it's not on tender. They will simply remove it knowing that there's no 
other medicine.” Participant 8-Nonprofit-Pharmacist-Africa 
 
“The company that becomes the sole supplier for prescribed medicines basically has such 
an enormous proportion of the market that other suppliers might decide it’s not worth it 
and not supply.  That’s something that Pharmac (Pharmaceutical Management Agency, 
New Zealand) has to take into account when they do sole supply agreements; to make 
sure their sole supplier is actually in a position to guarantee supply.  There was a problem 
with that, about paracetamol.  People weren’t very happy with the paracetamol that got 
the sole supply.  It wasn’t very pleasant to take, difficult to swallow, and didn’t have the 
coating on it that would make it easier [to swallow].  The other kinds of paracetamol 
became more difficult to get because the sole supply went to that particular company. 
Participant 22-Academic-Sociologist-Western Pacific 
 
2.3.2.7: Wholesaler/Distributor Roles 
Wholesalers and distributors had an important role in ensuring the fluidity and reliability of the 
pharmaceutical supply chain. They had knowledge of the demand and usage of medicines that 
contributed to the national and international supply and distribution of medicines.   
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“You just see the lack of supply at one end, the price changing at the other end, and that’s 
the end of it.  There are a lot of things happening.” Participant 30-Wholesaler-Business 
Management-Western Pacific   
 
“We [the wholesaler/distributor] see the [entire] supply chain market.” Participant 29–
Wholesaler/Distributor-Business Management-Western Pacific  
 
“[Distributors] have supply chain knowledge, by going country to country, town to town, 
village to village.  But it has some costs.  It’s normal that in some countries where they 
have insurance, things are easier, because insurances can pay back the effort of a 
distributor.  [But they] need the supply chain to have transportation, material, employees, 
and [provide for] their own lives. The [distributors] can use their experiences [so that] 
people may [access] more medicines.” Participant 7-Distributor-Pharmacist-Africa 
 
They helped determine and manage supply disruptions in short and long term drug shortages.  
“What is the process when there are shortages and how do the wholesalers and 
manufacturers then restrict stock so that everybody gets a fair share of the stock?  That's 
part of trying to change the supply chain.  At the moment, there's no industry standard of 
how to treat shortages.  Each manufacturer does it their own way, all separately.  There's 
no industry motivation. There's a hospital pharmacist society in Australia but it's more of a 
clinical front.  There's no real industry body on the supply chain side.” Participant 29–
Wholesaler/Distributor–Business Management-Western Pacific   
 
On the other hand, the just-in-time supply model did not allow for flexibility in forecasting.   
“The more you look at the supply chain, the more vulnerability you see.  We create some 
of our own vulnerabilities here with our just-in-time medication, and with our contracting 
processes.  ” Participant 20-Government–Physician-Western Pacific 
 
“[With] distribution into Australia, there are long lead times because we're importing a lot 
of stuff.  We've got distribution challenges: how are we distributing, are we holding stock 
here?  No we can't hold stock here.  Why not?  Because we're actually being asked to 
squeeze our margins because there's less money, because it's a commoditised market.  So 
in the system map flow, we've actually put efficiencies in there in an attempt to save 
money that [instead] has created inefficiency because now we are unable to react.  We've 
gone too deep and the elasticity is too far.” Participant 18–Pharmaceutical Industry-
Pharmacist-Western Pacific 
 
Furthermore, expiry and waste of medicines were unaccounted for and often led to profit losses.  
“[There is limited] space on the shelf in the warehouse. Expiry [of products and] cash tied 
up [are big challenges] because [wholesalers] have to pay the manufacturer, and 
[medicines] just sit there and we’re paying interest on that cash tied up. We've got sheds 
[of products] but the big two costs is the interest on the product tied up and expiry.” 
Participant 29–Wholesaler/Distributor-Business Management-Western Pacific  
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“The market actually works against [EMLs]. As drugs get more scarce and drives less sales 
dollars, you have less priority on them, and that's what some of these essential medicines 
do. Something’s got to give, so you hold less stock because you can’t make the dollars, so 
you have less investment.” Participant 30-Wholesale/Distributor-Business Management-
Western Pacific 
 
“The hospital’s [purchaser] looks at the price [of the medicine], even if it's one or two cents 
the price [of what] the wholesaler is paying.  They don't look at it from what we can see as 
most public hospitals probably hold about 15 to 30 days worth of stock. [Hospitals] write a 
lot of expired stock off.”  Participant 29–Wholesaler/Distributor-Business Management-
Western Pacific 
 
2.4 DISCUSSION 
This study showed the intricate inter-connectivity of stakeholders’ roles and responsibilities 
throughout the pharmaceutical supply chain.  It identified gaps and vulnerabilities in the 
management of the pharmaceutical supply chain due to how key stakeholders interacted. This 
demonstrated that therapeutic decision making was often separated from logistic management 
within the pharmaceutical supply chain, which was likely due to potential conflicts of interest.  
Results showed that inconsistencies (variability) in the supply chain were linked to stakeholders’ 
value of having choice.  Meanwhile, differences between LMIC and HICs demonstrated the impact 
of governance on supporting resources and processes throughout the pharmaceutical supply 
chain.  Therefore, stakeholders involved in the provision of medicines were challenged with 
complex decisions requiring significant collaborative effort. 
2.4.1: Stakeholder Roles  
This study showed that the interconnectivity of stakeholders’ roles and responsibilities highlighted 
the importance of engagement and accountability by stakeholders.  Stakeholders relied on 
processes along each part of the supply chain to run smoothly in order to achieve their own goals 
and perform their functions.   Along this continuum, all stakeholders were valuable (Ellram 1991). 
For example, quantification and forecasting to determine the amount of supply needed to meet 
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demand was a function that health providers, wholesalers, and manufacturers all performed.  
Stakeholders at one end of the supply chain relied on information at the other end (e.g. health 
facility needs or government epidemic planning targets, manufacturer production), in order to 
forecast supply requirements.  On the other hand, evidence-based decisions to reimburse 
medicines could facilitate or inhibit prescribing, effect patient access, and determine whether 
companies would invest in providing a medicine.   
This study demonstrated that selection committees could involve wholesalers and distributors in 
their decision making process to enhance access and information sharing within the 
pharmaceutical supply chain. These wholesalers and distributors offered expertise and capacity 
that could help predict and facilitate supply distribution and disruptions (e.g. forecasting or 
confirming at what level of the system a shortage occurs, redistribution).  Whilst the management 
of each stakeholder’s practice environment was their own responsibility, their decisions and 
actions could influence other areas along the supply chain (Jahre et al. 2012).  Unfortunately, 
stakeholders within health systems tend to operate in silos and lack coherence and transparency 
between them (Meteos 2013, Bigdeli et al. 2013a, Crowe et al. 2013). Participants described some 
of these instances as when medicines were discontinued at the manufacturer level, medicines 
were taken off hospital formularies, there were changes to tendering or contract agreements, or 
there were changes in prescriber preference for another therapeutic option. As a result, 
fragmented decisions and responses occurred throughout the pharmaceutical supply chain.  
As displayed in Figure 2.2 and 2.3, results showed there were many gaps and vulnerabilities in the 
pharmaceutical supply chain involving multiple stakeholders.  Stakeholders considered numerous 
risks and advantages, both independently and collectively. However, unpredictable obstacles 
acted as barriers that permeated through the supply chain, warranting reactivity from each 
member (Jahre et al. 2012, Shah 2004, McBeath 2012).  Similarly, many participants’ confirmed 
that the decisions to improve efficiencies in the supply chain, such as minimising stock holdings or 
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sole supplier contracts, also contributed to the increased reactivity to supply disruptions due to 
less buffers available in the system.  Management strategies therefore, have limited advantage 
when made in isolation or without consultation with other stakeholders. For example, 
participants explained that some stakeholders at the patient level of care felt pressured by the 
timeliness and urgency of supply disruptions, compared to stakeholders who made decisions at 
the policy and manufacturing level.  Some stakeholders felt they were poorly informed or told too 
late about supply disruptions, resulting in risks to patient care or incurred costs.  Their decisions 
needed immediate resolutions for patients at the point of care whether it be for emergency 
situations, result in treatment interruptions of critical therapies, or loss of trust in the system 
(Wilson 2012). Contributing to this dilemma, was the emphasis on advocacy for new or 
individualised patient therapies, which strained suppliers’ capacity to cautiously keep stock.  As a 
result, some stakeholders viewed that strategies to strengthen and ensure capacity throughout 
the overall supply chain was often neglected.   
Another critical gap between stakeholders was the issues of pricing and costs of medicines. 
Stakeholders had highly skewed views around what was considered reasonable cost savings for 
public tenders and individual patients, versus what was considered appropriate profit margins and 
sustainable financial structures.  Meanwhile, even though a medicine was approved for 
reimbursement, frequent changing between suppliers, created gaps along the pharmaceutical 
supply chain. This was compounded by isolated and fragmented management by different 
stakeholders.  This was further complicated by the spike in costs incurred due to unforeseen 
disruptions. In contrast, some participants’ described the mismanagement of funding by 
government workers, sometimes due to corruption, that resulted in failed or late payments to 
suppliers. This caused instability and a cascade of other problems.  Adding to this discourse, 
stakeholders highlighted the high incidence of waste in the pharmaceutical sector. Medicines 
often went expired on the shelf, or manufacturing batches were thrown away if they did not meet 
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regulatory quality assurance standards. This in turn, eroded the global supply of active 
pharmaceutical ingredients (APIs), and consumed substantial financial and material resources by 
suppliers. These events perpetuated waste and could lead to drug shortages. 
This study showed that in some circumstances, there was deliberate avoidance of some 
collaborative alliances.  Results demonstrated that therapeutic decision making and logistics 
management of the pharmaceutical supply chain were often separated, mainly due to conflict of 
interests. This would be in line with criticisms of pharmaceutical companies’  influence on 
physician prescribing (Campbell 2007).  While it was valuable to acknowledge this potential 
conflict of interest, separating these processes came with a cost.  Therapeutic and supply 
decisions made in isolation or without consultation, resulted in fragmentation and continued 
uncertainty in the pharmaceutical supply chain.  Meanwhile, an inclusive and transparent model 
would be difficult to achieve, unless engagement between these two processes were facilitated 
and protected from coercion.  In contrast, results showed that health providers were the common 
interface (overlap) between decision making and pharmaceutical logistic systems; highlighting the 
significance of their role in engaging and communicating with other stakeholders.  Furthermore, 
some participants suggested designating drug shortage experts or liaisons to manage and 
communicate shortages, especially to consumers.  Thus, challenges to collaborative engagements 
needed further investigation. 
2.4.2: Factors Influencing Access to Medicines  
The wide range of views surrounding the management and supply of essential medicines showed 
that stakeholders valued choice. Choice was demonstrated to be a significant driver for the 
demand to provide multiple therapeutic options.  A high degree of choice; therein, contributed to 
inconsistencies and increased complexity and vulnerability in the pharmaceutical supply chain.  
When supply disruptions like drug shortages occurred, it risked patient care, increased costs and 
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consumed additional resources.  On the other hand, where an alternative therapeutic option was 
available, it disputed whether a medicine was accepted as “essential”, or to whom it was essential 
for.  A prescriber may have therapeutic preferences that can change as guidelines or patient 
experiences shape their practice.  Thus, when individuals have choice, it confounds the notion of 
essential.   
Building on the comprehensive theory of collaboration, choice has created inconsistency and 
complexity throughout the pharmaceutical supply chain which has been challenging to manage. 
This was in line with Wood and Gray (Wood and Gray 1991), who argued that increased 
complexity due to individualism and autonomy decreased an organisation’s control over a 
domain. Meanwhile some features of collaboration suggest that collaborative alliances were also 
likely to make systems more complex (Bresser 1988). Hence, providing many therapeutic choices 
in the supply chain decreased a health system’s ability to control formularies, keep up the supply 
of a wide range of products, waste stock, and store adequate supplies in dispensaries and 
warehouses of all products. This disparity demonstrated the change of focus from utilitarian value 
to accommodating individuals’ needs. This phenomenon may occur in any health system. While a 
health system may respect an individual’s choice to determine whether a medicine is essential for 
them; each individual should also be accountable for these decisions and share responsibility for 
having these choices provided. Particularly, when they do not serve public health needs.  On the 
other hand, equitable access to essential medicines should include those that suffer from 
neglected diseases or require specialised care (Reich 2000). For example, orphan essential 
medicines and treatments for rare diseases may risk neglect of some individuals.  Therefore, 
subsidisation schemes need to carefully consider how to provide alternative funding to ensure 
that public health needs are met and that individuals are supported. 
Participants described significant advantages of having complex systems.  For example, multiple 
suppliers for generic products offered governments opportunities to negotiate lower prices for 
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medicines, even in monopsony markets such as the United Kingdom, Australia, Canada, and New 
Zealand (Lexchin and Mintzes 2008, Clement et al. 2009, Manning 2011, Tordoff, Norris and Reith 
2008, Morgan et al. 2006).  Additionally, reliable and responsible management of company 
portfolios to meet population needs fostered trust and relations with other stakeholders and 
global markets. Furthermore, access to alternative supply sources offered solutions and resilient 
strategies to manage unpredictable supply disruptions. Meanwhile, at the point of care, the 
availability of therapeutic alternatives acknowledged the importance and dynamics of patient-
centred care.  In line with Wood and Gray (Wood and Gray 1991), collaboration between 
stakeholders involved in the pharmaceutical supply chain was considered foundational to 
reducing inconsistencies and enhancing fluid management of the system in order to guarantee 
supply of essential medicines. Hence, the impact of drug shortages offered a collaborative 
opportunity and motivation for stakeholders in the pharmaceutical supply chain to provide 
solutions and improve processes that ensure the provision of critical health services.  
While choice is a human right and an empowering attribute; these choices must be governed 
respectfully, ethically, and fairly.   Many stakeholders discussed the importance of trust and 
accountability involved in pharmaceutical supply chain collaborations.  Some stakeholders 
suggested difficulty engaging with other stakeholders.  For example, relationships between 
stakeholders took time to develop. Some participants highlighted that governments were often 
elected every few years, which affected the dynamics of collaborative engagement.  Participants 
explained this was further complicated, when governing bodies themselves were involved in or 
accused of unethical conduct by government workers or pharmaceutical companies, resulting in 
loss of trust by the public and collaborating stakeholders. Similarly, these relationships were 
strained when pharmaceutical companies set exorbitantly high prices for medicines. Stakeholders 
working in LMICs mostly reported concerns regarding unethical conduct and corruption in 
governance and financial interactions as major barriers. However, HIC settings also grappled with 
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transparency around pharmaceutical industry involvement and influences in decision making, and 
disparities in pricing.   Therefore, in order to improve collaboration between stakeholders, 
transparency, communication and accountability must be further addressed. 
As described by participants, situations where the decisions to have many therapeutic choices 
available for treatments were perpetuating constant drug shortages. This was resolved through 
multi-lateral discussions that encouraged prescribers to prioritise their choices, in order to ensure 
supply of the treatments that were critical for the majority of their patient population.  
Stakeholders acknowledged that concessions due to financial restrictions, allowed decision 
makers to establish pathways and management strategies that facilitated consensus amongst 
stakeholders. While these tough decisions cannot align for all individuals’ needs; decision-makers, 
including governments, industry, health providers and consumers, must responsibly support and 
sustain the health system. In accordance to improving collaborative alliances, linking this to 
communication pathways and understanding of the supply chain may facilitate acceptance of 
these decisions.  
2.4.3: Strengths and Limitations  
This study described the views of multiple stakeholders from a wide range of countries and 
regions worldwide. While it explored global perspectives, it did not represent views from every 
country and sector. For example, public and private procurement agencies, as well as wider range 
of health work force staff who also provide consumers medicines (e.g. nurses and pharmacy 
technicians), were not included in this study but could be considered in future investigations. In 
line with qualitative methodology, this study was not intended to be representative of the global 
population. Rather, an in-depth look at the issues considered by international key opinion leaders 
and the context of their roles and environments were explored and compared. This study 
included perspectives from multiple disciplines, in both developed and developing countries. 
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Recruitment of global participants proved to be challenging and time consuming as leaders were 
often very busy and unavailable for correspondence or participation, compounded by 
coordination of different time zones.  This study acknowledged that some participant views were 
of international stakeholders that resided in high income countries, but provide support and 
training in developing countries. Therefore, they may have applied their paradigm onto these 
settings, rather than culturally developed.  Future investigations within regions or a country 
context may provide understanding of different cultural and social interactions between 
stakeholders. Furthermore, future research may explore shared priorities and practical 
collaborative approaches or models. 
2.5 CONCLUSION 
This was the first study to explore the management of essential medicines from a broad range of 
stakeholder views involved in both therapeutic decision making and logistics management.  
Furthermore, it was also one of very few studies to include a HIC context. It showed that the 
complex global pharmaceutical supply chain was vulnerable to shortages and crisis. Findings also 
revealed there were more similarities than differences between health systems in accessing 
medicines in a vulnerable supply chain. Results showed the concepts of EMLs had relevance to 
HICs in promoting multi-stakeholder engagement.  In line with Hogerzeil (Hogerzeil 2004), no 
country has unlimited resources. Therefore, value was demonstrated in aligning medicine 
selection decisions with procurement strategies. Results highlighted the need for engagement 
and accountability by stakeholders to involve integrative and transparent strategies.  This study 
showed that global and national strategies needed to improve communication, supply chain 
management capacity, information sharing, harmonisation of roles between stakeholders, and 
collaborative alliances. Therefore, further investigation was needed to establish a clear 
understanding of what shared priorities were foundational to facilitate collaboration between 
stakeholders that ensured utilisation and access to essential medicines.  
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CHAPTER 3- QUALITATIVE INTERVIEWS EXPLORING WHAT MAKES 
MEDICINES ESSENTIAL FOR STAKEHOLDERS IN A HIGH INCOME 
COUNTRY 
3.1: INTRODUCTION 
The review of the literature in chapter one demonstrated there was inequality of access to 
essential medicines.  On the other hand, EMLs have been shown to provide reliable evidence to 
guide reimbursement decisions, guide education and training, and be useful tools to promote 
advocacy to influence policies and lower prices of medicines for individuals and the population. 
However, findings showed variation of patient access to essential medicines at the health facility 
level.  EMLs have not been strictly adhered to at the prescribing level due to the expanded scope 
of patient needs, and fragmented decision making and procurement practices. This has 
contributed to drug shortages, which have made guaranteeing supply of medicines challenging.  
Furthermore, problems with access to essential medicines have been mainly examined in LMIC, 
and few studies have explored access in HICs, which also experience access challenges in rural and 
remote areas, such as in Australia.  Similarly, primary studies in the area of EMLs have 
predominantly applied quantitative methods. Few qualitative studies have been conducted to 
explore the different influences between stakeholders involved in medicines decision making, 
which caused the inequality of access to essential medicines. 
Findings from chapter two revealed that there were similarities between health systems in 
accessing medicines in a vulnerable global pharmaceutical supply chain. It also demonstrated that 
there was reason to believe that stakeholders involved in therapeutic decision making and 
logistics management of the supply chain were unwilling to collaborate. Yet at the same time, 
their collaboration was necessary to align medicines selection with procurement management.  
In line with Hogerzeil (Hogerzeil 2004), although the Essential Medicines List (EML) concept was 
rarely studied in high income country settings, no country has unlimited resources. Therefore, 
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there was relevance, in a country like Australia, to explore how the EML concept may be used to 
promote access to medicines through multi-stakeholder engagement. In particular, the drug 
shortage situation requires transparency and stakeholder engagement in order to share 
information and solutions between stakeholders. Therefore, further investigation was needed to 
understand what factors were foundational to facilitate collaboration between stakeholders to 
prevent and manage access to medicines.  
The issues discussed in the previous chapters have demonstrated fragmented application of the 
EML concept between a large number of stakeholders, and continued challenges and inequality to 
accessing essential medicines.  Furthermore, essential medicines studies have continually been 
examined in LMICs, and few have explored the essential medicines access situation and/or 
solutions to access challenges in HICs. Therefore, this led to the study outlined in chapter three, to 
explore the perspectives of a diverse group of stakeholders engaged in medicines decision making 
around what constitutes an ‘essential’ medicine, and how the EML concept functions in a high 
income country context (Australia).  
This chapter, published in Plos One, a peer reviewed journal, showed that there were differing 
views of what medicines were deemed essential between stakeholders. Furthermore, these 
different views also contributed to tensions between stakeholders and aversion to some 
collaboration. The notion of essential becomes more fragmented and complex, when moving 
from the health system perspective towards the point of care, where there are variable and 
broader patient needs.  Since stakeholders held different views of what was considered essential, 
this reflected inconsistent management of essential medicines throughout the supply chain and 
willingness to collaborate.  These issues will continue to perpetuate the drug shortage and access 
to medicines situation, and calls for innovative and cooperative approaches to managing a 
sustainable global supply chain.
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Abstract
Objective
To explore the perspectives of a diverse group of stakeholders engaged in medicines deci-
sion making around what constitutes an “essential”medicine, and how the Essential Medi-
cines List (EML) concept functions in a high income country context.
Methods
In-depth qualitative semi-structured interviews were conducted with 32 Australian stake-
holders, recognised as decision makers, leaders or advisors in the area of medicines reim-
bursement or supply chain management. Participants were recruited from government,
pharmaceutical industry, pharmaceutical wholesale/distribution companies, medicines non-
profit organisations, academic health disciplines, hospitals, and consumer groups. Perspec-
tives on the definition and application of the EML concept in a high income country context
were thematically analysed using grounded theory approach.
Findings
Stakeholders found it challenging to describe the EML concept in the Australian context
because many perceived it was generally used in resource scarce settings. Stakeholders
were unable to distinguish whether nationally reimbursed medicines were essential medi-
cines in Australia. Despite frequent generic drug shortages and high prices paid by consum-
ers, many struggled to describe how the EML concept applied to Australia. Instead, broad
inclusion of consumer needs, such as rare and high cost medicines, and consumer involve-
ment in the decision making process, has led to expansive lists of nationally subsidised
medicines. Therefore, improved communication and coordination is needed around shared
interests between stakeholders regarding how medicines are prioritised and guaranteed in
the supply chain.
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Conclusions
This study showed that decision-making in Australia around reimbursement of medicines
has strayed from the fundamental utilitarian concept of essential medicines. Many stake-
holders involved in medicine reimbursement decisions and management of the supply
chain did not consider the EML concept in their approach. The wide range of views of what
stakeholders considered were essential medicines, challenges whether the EML concept is
out-dated or underutilised in high income countries.
Introduction
The concept of “essential medicines” dates back to military tradition, in which therapeutic sup-
plies (such as penicillin) were essential to be carried by soldiers, field medics, and camp infir-
maries, into combat zones. This was also applied to the rationalising of therapeutic restrictions
necessary during wartime economy [1]. Ensuring access to essential medicines has been con-
sidered a basic human right, in line with access to food, water, shelter and education [2]. The
Essential Medicines List (EML) was introduced by the World Health Organization (WHO) in
1977, as a core list of 186 pharmaceuticals deemed necessary to manage the disease burden and
basic health needs of a population (Box 1) [1,3]. Today, the WHO’s Model List of Essential
Medicines (WHO EML) includes 409 active substances, is updated every two years, includes
low and high cost medicines, and is applied to all income settings in 156 countries [4–6].
Nearly forty years since the introduction of the WHO EML, few studies have investigated
the impact of EML policies on access to medicines [7,8]. Although the EML concept appears
simple, it can be complex to implement and maintain. Therefore, the intention of having access
to essential medicines within the context of a functioning health care system remains a work in
progress for many countries [6]. Challenges in managing EMLs are most apparent in low-to-
middle income countries (LMICs), compared to high-income countries (HICs) with sophisti-
cated health care systems and national health insurance schemes [9,10]. Furthermore, the
Access to Medicines Gap reported by the WHO states that one third of the world’s population
still does not have access to medicines, which rises to up to half of the population in some
LMICs [11,12].
A study by Cameron et al [9] showed that despite national EML policies, LMICs still experi-
ence low availability of generic medicines and high prices paid by consumers. Within LMIC
settings these challenges are further complicated by scarce resources, limited availability and
substandard and/or counterfeit products which pose safety risks to consumers [9,13]. Mean-
while, studies have also shown discrepancies between the WHO EML and national medicines
lists in middle to high income countries [14,15]. Whilst disparities exist between how countries
Box 1. TheWHO Definition of Essential Medicines [3]
“Essential medicines are those that satisfy the priority health care needs of the popula-
tion. They are selected with due regard to disease prevalence, evidence on efficacy and
safety, and comparative cost effectiveness. Essential medicines are intended to be avail-
able within the context of a functioning health systems at all times, in adequate amounts,
in the appropriate dosage forms, with assured quality, and at a price the individual and
the community can afford.”
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amongst colleagues or professional organisations in the area of quality use of medicines, medi-
cines policy, medicine distribution, procurement management, manufacturing, or health eco-
nomics. Most participants had professional backgrounds as physicians or pharmacists.
However, consumer representatives, chief executive officers, supply chain managers, and
health economists were also included. Some had broad experiences across multiple and over-
lapping sectors, and/or had international experience working with EMLs in LMICs.
In-depth face-to-face, teleconference and Skype interviews were conducted with partici-
pants. Interviews were conducted prior to the 19th WHO EML, published in May 2015 [4].
Audio recordings of the interviews were de-identified, transcribed verbatim and secondary ver-
ification of the transcripts was conducted to ensure accuracy. De-identified supplementary
field notes were included in the data analysis. Interviews were conducted until thematic satura-
tion was achieved (when several participants repeated similar or recurrent concepts in their
response), as described by Bazeley [32]. Interviews lasted a median time of 63 minutes (IQR:
50–71).
Transcripts and field notes were imported into the qualitative analysis software program
N-Vivo 10 for coding and data management [33]. Sequential analysis was used to explore rele-
vant issues according to participants’ responses [34]. A grounded theory approach was applied
in data analysis to extract themes and key concepts using iterative constant comparative tech-
niques [35]. The grounded theory approach is a well-established research method which has
been widely accepted and supported as a high standard of analysis used in interpreting and
reporting qualitative research [32,35–38]. Accordingly, open, axial and selective coding meth-
ods were used to identify and interpret topics, themes, and concepts [32].
One researcher independently conducted the open coding thematic content analysis to
identify themes and concepts, followed by two researchers conducting axial coding together
that was validated by the rest of the research team. Final selective coding was performed as a
team. While the initial thematic content analysis was performed by one researcher, the contin-
uous consultative approach offered reflexivity and explored relationships between these themes
and concepts. Results derived from the grounded theory approach were applied to the compre-
hensive theory of collaboration to build a conceptual model [39]. As described by Patton [37],
reflexivity of data collection, interpretation and analysis was offered by the researchers’ broad
experiences working across multiple pharmacy, patient care and administrative settings, with
international experiences in both HICs and LMICs. Participants were offered the opportunity
to validate the accuracy and interpretation of their views expressed in selected quotes.
Results
Participants had a broad range of views on the notion of what is meant by an “essential” medi-
cine. Three main concepts were derived from the views of multiple stakeholders on what con-
stituted an essential medicine and how the EML concept applied in the Australian context.
Table 1 illustrates the corresponding quotes reported in the results.
1. The definition and function of an EML in Australia was interpreted
differently amongst stakeholders
All participants considered access to essential medicines as a basic human right that should be
upheld by society [Q1]. However, most participants noted that in principle, the notion of an
“essential” medicine in a HIC like Australia has evolved in terms of the definition and intended
application of an EML [Q2]. Some participants considered the reimbursement of medicines
through the Australian PBS was akin to a functioning EML [Q3]. However, many participants
argued they could not distinguish between reimbursed medicines and essential medicines [Q4]
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amongst colleagues or professional organisations in the area of quality use of medicines, medi-
cines policy, medicine distribution, procurement management, manufacturing, or health eco-
nomics. Most participants had professional backgrounds as physicians or pharmacists.
However, consumer representatives, chief executive officers, supply chain managers, and
health economists were also included. Some had broad experiences across multiple and over-
lapping sectors, and/or had international experience working with EMLs in LMICs.
In-depth face-to-face, teleconference and Skype interviews were conducted with partici-
pants. Interviews were conducted prior to the 19th WHO EML, published in May 2015 [4].
Audio recordings of the interviews were de-identified, transcribed verbatim and secondary ver-
ification of the transcripts was conducted to ensure accuracy. De-identified supplementary
field notes were included in the data analysis. Interviews were conducted until thematic satura-
tion was achieved (when several participants repeated similar or recurrent concepts in their
response), as described by Bazeley [32]. Interviews lasted a median time of 63 minutes (IQR:
50–71).
Transcripts and field notes were imported into the qualitative analysis software program
N-Vivo 10 for coding and data management [33]. Sequential analysis was used to explore rele-
vant issues according to participants’ responses [34]. A grounded theory approach was applied
in data analysis to extract themes and key concepts using iterative constant comparative tech-
niques [35]. The grounded theory approach is a well-established research method which has
been widely accepted and supported as a high standard of analysis used in interpreting and
reporting qualitative research [32,35–38]. Accordingly, open, axial and selective coding meth-
ods were used to identify and interpret topics, themes, and concepts [32].
One researcher independently conducted the open coding thematic content analysis to
identify themes and concepts, followed by two researchers conducting axial coding together
that was validated by the rest of the research team. Final selective coding was performed as a
team. While the initial thematic content analysis was performed by one researcher, the contin-
uous consultative approach offered reflexivity and explored relationships between these themes
and concepts. Results derived from the grounded theory approach were applied to the compre-
hensive theory of collaboration to build a conceptual model [39]. As described by Patton [37],
reflexivity of data collection, interpretation and analysis was offered by the researchers’ broad
experiences working across multiple pharmacy, patient care and administrative settings, with
international experiences in both HICs and LMICs. Participants were offered the opportunity
to validate the accuracy and interpretation of their views expressed in selected quotes.
Results
Participants had a broad range of views on the notion of what is meant by an “essential” medi-
cine. Three main concepts were derived from the views of multiple stakeholders on what con-
stituted an essential medicine and how the EML concept applied in the Australian context.
Table 1 illustrates the corresponding quotes reported in the results.
1. The definition and function of an EML in Australia was interpreted
differently amongst stakeholders
All participants considered access to essential medicines as a basic human right that should be
upheld by society [Q1]. However, most participants noted that in principle, the notion of an
“essential” medicine in a HIC like Australia has evolved in terms of the definition and intended
application of an EML [Q2]. Some participants considered the reimbursement of medicines
through the Australian PBS was akin to a functioning EML [Q3]. However, many participants
argued they could not distinguish between reimbursed medicines and essential medicines [Q4]
Essential Medicines: Essential to Whom?
PLOSONE | DOI:10.1371/journal.pone.0143654 December 9, 2015 4 / 14
Table 1. Stakeholder Comments on the Aim and Function of an EML in Australia.
Concept Signiﬁcance Quotations
1) The deﬁnition and function of an EML in
Australia is interpreted differently amongst
stakeholders.
Access to essential medicines is a basic human right [Q1] “No one should live with infection, serious pain, {or} a
disability that can be treated. The essential elements of
healthcare should be available to everyone whether you
live in rural Australia, the city, on a good wage or without
a job. Everybody has a right to that basic level of
healthcare. That includes access to drugs.” (Participant
31- Consumer)
The notion of an “essential” medicine has evolved [Q2] “When the EML was created, it was about the aspirin
(s), {and the} penicillins. . . things that really were going to
make a difference. These days, it’s no longer the case.
You have to consider is this good value for money? I think
the essential medicines list has evolved and changed.
(Participant 25- Academic)
National reimbursement of medicines through the
Australian PBS is a functioning EML
[Q3] “Ours {PBS list} is bigger than the WHO list, but
that’s appropriate for a wealthy country like Australia. . .
yet it certainly does only encompass a fraction of all the
drugs available. It {the PBS} is a limited list, selected on
the basis of diseases in the country and cost
effectiveness, and that’s the principle of the WHO
list.”(Participant 22-Government)
There lacks a clear distinction between reimbursed
medicines and essential medicines.
[Q4] “I would like to think {the PBS} is an EML, otherwise
why are we funding them? One of the things we need to
do better in Australia is to remove drugs which have been
superseded by other drugs as far as their effectiveness or
cost effectiveness is concerned.” (Participant
30-Consumer)
[Q5] “You tend to get a wish list, and then it becomes
difﬁcult to sort through what really is essential and what’s
would be nice to have. (Participant 23- Non-proﬁt)
An EML can support stakeholders to sustain
fundamental health services.
[Q6] “Today, the EML is the PBS by default. It's far from
essential. . . When securing supplies, we really need to
identify what is essential, and why it's essential. If it's not
essential then acknowledge that it's not. So that in my
day-to-day practice, drugs that I rely on to keep patients
alive are available.” (Participant 6, Healthcare Provider)
Focus on medicines cost and cost-effectiveness diverts
from the notion of essential
[Q7] “The WHO deﬁnes essential medicines in such a way
that cost effectiveness is one of the criteria. I think that’s a
perversion of the idea of an essential medicines list. A
medicine is intrinsically essential. You either need it or you
don’t. The cost of that medicine is not a dimension of
your need or the potential beneﬁt you may derive from
that medicine.” (Participant 14– Government)
2) The selection criteria of medicines and the
context to which the EML concept is applied are
dynamic variables which inﬂuence decision
making.
A medicine is essential at the point of care for the
individual
[Q8] “{Essential medicines} are life-saving, {or} enable
management of a difﬁcult, chronic condition. The
individual consumer of course wants access to the drugs
which will help their individual conditions and needs.”
(Participant 30- Consumer)
A reimbursement system assesses cost effectiveness
and additional beneﬁt of a medicine for some individuals
not the essential need of a medicine for a population.
[Q9] “The PBS is different, because they’re not essential
by deﬁnition. They are {medicines} that have been proven
to be cost effective and the government is willing to pay
to give their citizens access to these medications. Some
could be lifesaving, high-cost drugs, and then that’s a
different program. The structure in a country like Australia
is different because it’s how much you’re willing to pay for
an extra innovation. So the concept is different from an
EML.” (Participant 25-Academic)
Perception that an EML is only used in low middle
income settings
[Q10] “The danger is that you end up saying that an EML
is what less well-off countries have and reimbursement
lists are what wealthier countries have. “(Participant
20-Academic)
(Continued)
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Table 1. (Continued)
Concept Signiﬁcance Quotations
The supply of essential medicines is vulnerable to
disruptions in all country settings.
[Q11] “We live in a complex world where some
pharmaceutical supplies are not guaranteed to any nation.
There's a lot of politics and economics involved in
healthcare decisions that are not necessarily directed at
mutual utilitarian beneﬁts of pharmaceuticals, in terms of
patient outcomes. But having a list of essential medicines
acknowledged can help direct our society to develop
infrastructure and supply chains to protect the most
important medicines.” (Participant 6, Healthcare Provider)
Stakeholders involved in providing medicines in the
supply chain prioritise medicines according to different
principles
[Q12] “1) Medical relevance. Is this product a life-saving
{medicine} versus {a medicine for} long-term disease
improvement {or} symptomatic relief issue? The more life-
saving {the medicine}, it becomes more essential. 2)
Demand. If {a medicine} has either a sporadic or
responsive demand, it becomes an essential product we
need to plan for. Flu vaccines are an essential medicine. It
improves health outcomes, but because {of} it's sporadic
demand you need to plan for its use. 3) Supply. Who else
can deliver this product? If there's four competitors of a
product we don't see it as an essential medicine as a
pharma company. It may be an essential medicine for a
practising pharmacist but that's where the differentiation
starts to occur. 4) To deliver value to shareholders {as} a
publicly listed company {and to} sell {medicine} at a
positive margin. Some items within our portfolio we sell a
lot of which makes a lot of money, and therefore it's a
commercially essential medicine.” (Participant 8 –
Pharmaceutical Industry)
3) Tensions amongst stakeholders are created by
differing views on the function of an EML and
conﬂicting interests surrounding the selection of
medicines.
The notion of essential medicines is highly confounded. [Q13] “What makes a drug essential? You can lay down
some criteria, but they're not absolute and deﬁnitive. You
can prioritise and heavily weigh them with a declining
degree of weight. Then there's a transition between at
what point {is} something essential or non-essential. That
is highly confounded. {Clotrimazole for treating}
candidiasis is an example. Not essential. Damn! Who says
it's not essential? Someone has made that determination
—in this case, other than the consumer. The government
made the decision they were available over the counter,
therefore we {society} wouldn't pay for them. Does that
make them non-essential? Or they're available over the
counter? What is the link between subsidy and essential
medicines?” (Participant 11-Government)
The inﬂuence of cost containment is interpreted
differently amongst stakeholders. Lowering costs of
some medicines allow for expansion of the PBS to
include more medicines
[Q14] “One of the reasons the industry has supported all
the price cut policies they renegotiated with
government. . . is that they are designed to drive down
the price of old drugs so that the health system could
afford to list the new drugs coming through in the future.
The Government {has} got the savings, now we can afford
to bring {other} things on.” (Participant 5, Pharmaceutical
Industry)
The PBS keeps medicine costs affordable for
Australians despite high prices set by pharmaceutical
companies
[Q15] “The PBS has helped {so Australians} can afford all
these new medicines. Drug companies might complain
that the {price listed on the} PBS is too cheap, that they
can't afford to sell medicines to {consumers at such a
price}. It doesn't seem to stop them from registering their
products and listing them on the PBS.” (Participant
1-Healthcare provider)
Demand for improved transparency around the
pharmaceutical industry’s role and inﬂuence in the
decision making process
[Q16] “{The PBS has} got too many alternatives. . . You
have to look at the make-up of the Pharmaceutical
Beneﬁts Advisory Committee (PBAC). I believe the current
PBAC membership has the necessary expertise and looks
appropriately comprehensive. {But} drug companies can
exert inﬂuence directly or through consumers who then
pressure MPs (Members of Parliament). I believe they
could be under a lot of pressure to put new things on the
list which probably should not be on the PBS. It is
important that there are mechanisms to deal with that
pressure.” (Participant 27,Academic)
doi:10.1371/journal.pone.0143654.t001
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[Q5]. While some believed an EML approach could support stakeholders in the supply chain
to sustain fundamental health services [Q6], one participant highlighted that the consideration
of a medicines’ cost and cost-effectiveness were contentious issues that undermined the notion
of essential [Q7].
2. The selection criteria of medicines and the context to which the EML
concept was applied were dynamic variables that influence decision
making
Some participants reflected the selection of medicines for reimbursement has been increasingly
driven by consumer needs [Q8]. Furthermore, some participants explained reimbursement
decisions were driven by cost effectiveness and additional benefit of a medicine for some indi-
viduals rather than the essential need of a medicine by the population [Q9]. Many participants
found it challenging to apply the concept of EML to the Australian context because EMLs were
perceived to be useful for resource scarce settings [Q10]. However, some participants regarded
essential medicines as part of a complex pharmaceutical supply chain. Even in HICs, access
cannot always be guaranteed [Q11]. One participant described the characteristics of medicines
that are categorised as “essential” by the pharmaceutical industry within the supply chain
[Q12].
3. Tensions amongst stakeholders were created by differing views on
the role of an EML and conflicting interests surrounding the selection of
medicines
The selection and supply of reimbursed medicines were complex issues. One participant
reflected that the notion of essential medicines was highly confounded [Q13]. The influence of
cost containment was interpreted differently amongst stakeholders. Some participants thought
decisions about whether a medicine was listed on the PBS included consideration of cost con-
tainment by lowering prices of generic medicines in order to expand the PBS to list new medi-
cines [Q14]. While some participants felt that despite high prices set by pharmaceutical
companies, the PBS has helped keep medicine costs affordable for Australians [Q15]. Many
participants encouraged more transparency around the pharmaceutical industry’s role and
influence in the decision making process [Q16].
Discussion
This study found that stakeholders had a broad range of views surrounding the application
and/or relevance of the EML concept within the Australian context. The findings illustrated a
diversity of perspectives amongst stakeholders, often reflecting their position within the health
care system. Views held by consumers and health professionals with respect to what was
“essential” and what medicines should therefore be accessible and reimbursed, were sometimes
in contrast to the views of supply chain managers or policy makers. This demonstrated the tus-
sle between perceptions of an EML based on a utilitarian approach in the health system for a
population versus an EML established to meet individuals’ needs.
Stakeholders’opinions of what constituted an ‘essential medicine’ differed depending on
whether they were being tasked with making decisions for the population or they were consid-
ering a medicine to be ‘essential’ for an individual. From a consumer’s perspective, a medicine
is considered essential at the point of care. Education can empower consumers to request
access to medicines they deem essential. Individuals want access to the right drug, at an afford-
able price, of safe quality and available at all times within close proximity [40]. On the other
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hand, policy makers within the health system consider medicines to be essential based on a
country’s priority health care needs and cost effectiveness, in order to facilitate wider access to
medicines by the population [12]. Although the notion of ‘essential’ for an individual or health
system is often used interchangeably, results showed that the two perspectives are often diver-
gent and therefore applied as different concepts.
While participants in this study supported the EML concept and were able to explain its
general function, most found it difficult to determine what constituted an essential medicine
due to the confounding nature of individual or utilitarian needs, as described above. Histori-
cally, an EML was once a basic formulary of survival and emergency medicines that adhered to
utilitarian principles [41]. Today, the EML concept has evolved, influenced by human rights’
movements, disease specific epidemics and societal values, to become a much more complex
list used to save and also improve the quality of life for many more individuals [1,41]. Further-
more, the evolution in pharmacotherapy from prescribing for a disease to prescribing for an
individual includes consideration of those with multiple conditions. This could mean that stan-
dard treatment guidelines, which are usually limited to the treatment of a single condition and
informed by data gathered in clinical trials, may not be applicable for patients with multiple
co-morbidities. Adding to this complexity is the continual development of pharmaceutical
products in the market, leading to more choices and alternatives available. This expansion and
evolution of the “EML concept” has led to the development of extensive lists of publicly subsi-
dised medicines in HICs, such as Australia. These lists often have multiple pharmacotherapy
choices available to manage conditions [42,43]. While in some health systems, lists can be sub-
categorised using “vital”, “essential”, or “non-essential” medicine (VEN) models of procure-
ment to identify priority medicines [44]. In line with this trend of list expansion, the 19th
WHO EML includes a range of high cost medicines that address priority diseases in a variety of
settings [4]. For example, Trastuzumab in breast cancer and Sofosbuvir for Hepatitis C [4,5].
Therefore, in HICs like Australia, it remains unclear if the decisions to add and manage medi-
cines on these lists still adhere to the foundational utilitarian principles that were once crucial
to its inception.
Study participants described the PBS accommodated broader individual needs than EMLs.
Some highlighted that consumer engagement in the decision-making process has contributed
to the wide breadth of the PBS to include sometimes rare and costly medicines to meet individ-
ual needs and expand access. The tussle between policy makers and consumer driven decisions
may be explained by the Comprehensive Theory of Collaboration which describes three types
of self-interest: shared, differing, and opposing [39]. Shared self-interests provide clear condi-
tions for a health system to identify and manage national priority medicines. For example, the
utilitarian-type public health program around influenza pandemic planning manages and
ensures continued supply of vaccines and medicines to all Australians. Meanwhile, partici-
pants’ discussed how differing interests contributed to the wide breadth of reimbursement
under the PBS, which can include multiple options within the same drug class. Lastly, tensions
between stakeholders may result from individuals having opposing interests. Participants
described these tensions in the deliberations involved in the selection of high cost medicines
for reimbursement, and negotiations to lower prices of generic medicines. For example, cost
containment may prevent few individuals from accessing rare high cost medicines through
public subsidised funding. At the same time, pharmaceutical companies may have opposing
interests to governments and consumers regarding pricing of their medicines, and may be pres-
sured to lower the cost of products in order to have them listed and utilised. This demonstrates
how individuals’ opposing and differing interests contribute to the expansion and costs of
reimbursement lists in HICs, in contrast to shared (utilitarian) interests around priority
medicines.
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It is often assumed that an EML ensures access to prioritised medicines. Therefore, stake-
holders perceived that applying the EML concept provided access to affordable medicines to
individuals and the health system. Yet, even in a HIC like Australia, access to medicines can be
hindered. Two examples of vulnerabilities highlighted by stakeholders include unforseen drug
shortages and high costs of medicines. Despite reimbursement, essential medicines are part of
a complex global supply network, in which supply cannot always be guaranteed during unpre-
dictable drug shortages [45–47]. This was demonstrated during worldwide shortages of
injectable benzyl penicillin in 2011 and morphine in 2013, causing much strain on the health
system and consumers [48,49].
Secondly, participants described the affordability of medicines for consumers and health
systems was a growing concern as pharmaceutical expenditures continue to rise [17]. Health
systems may need to pay high prices for these medicines and governments must make difficult
decisions as to how these medicines will be paid for. As a national reimbursement scheme, the
PBS negotiates lower prices with manufacturers to provide, “timely access to medicines that
Australians need, at a cost individuals and the community can afford” [26]. There are a range
of therapeutic options available through the PBS, including rare and high cost medicines. Addi-
tional arrangements provide funding and restricted supply for medicines under: the Life Saving
Drugs program, Section 100 (S100) program, or Special Access Scheme for rare or specialised
conditions [50–53]. Despite this, Australia still pays some of the highest prices for generic med-
icines compared to other countries, and up to twenty times more than its neighbouring country
New Zealand, where sole-sourcing and pooled procurement strategies have been applied to
obtain lower prices [17,54,55].
Furthermore, consumers’ inability to afford out-of-pocket expenses can hinder access to
medicines, sometimes leading to “catastrophic drug costs” [56,57]. Although Australia is a
HIC, there is disparity of wealth across the population [58]. Therefore, whilst catastrophic drug
costs are rare due to PBS subsidisation, out-of-pocket expenses (ie. co-payment of $37.70 AUD
for general patients in 2015 [59], which increases annually), can become too much for some
individuals to afford, especially for those on regular multiple medicines [17,60]. Meanwhile,
some medicines deemed essential to individuals and listed on the WHO EML, but may not be
reimbursed under the PBS, leading to out-of-pocket payments by consumers. It should be
noted that in Australia, PBS listed medicines are indirectly paid for by all individuals through
the government income-based taxation system. Additionally, individuals requiring medicines
can pay for them through direct out-of-pocket payments (usually for medicines not listed on
the PBS or those that are priced under the co-payment amount), or through co-payments for
government subsidised medicines. Some may also receive partial reimbursement for high cost,
non-listed medicines through private health insurance. Similar to Cameron et al. [9], HICs also
face challenges to guarantee supply of generic medicines and high prices. Therefore solutions
and approaches in HICs may provide useful to LMIC settings.
All participants acknowledged the PBS as a national reimbursement scheme generally effec-
tive at meeting Australians’ health needs. However, the issues raised above, led them to explore
strategies from the EML concept to prioritise medicines in the supply chain. In line with
Hogerzeil [6] and Wood & Gray [39], applying collective (utilitarian) interests to identify a
core list of medicines needed to maintain the basic functions of a health system, can improve
resilience to supply disruptions and manage rising medicine expenditure. Furthermore, in a US
study, Millar et al. [61] found that WHO EML medicines appeared on most Preferred Drug
Lists (PDLs), suggesting that the EML could function as a core list for PDL development to
guide procurement and decrease prices of medicines.
The comprehensive theory of collaboration was applied as the underpinning theory to
explain the variability in the notion of what is meant by an essential medicine. “Self-interests”
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in collaboration surrounding EMLs influence stakeholders’ views of what they deemed essen-
tial. Hence, multiple factors may influence these self interests which guide individuals to choose
medicines, as represented in S1 Fig. This conceptual model supports that an EML is used at a
health system level, for most people, most of the time. However, for individuals at the point of
care with many options, an EML is often viewed as not relevant. Although, a specific drug on
the EML may be appropriate. The layers in S1 Fig demonstrated the influence of self interest at
different levels of care. As one moves through the levels of the health system from government
policies towards the point of care, the notion of self-interest becomes more focused on the indi-
vidual and less utilitarian. This phenomenon has contributed to the expansion of reimburse-
ment lists. In contrast, when a medicine becomes unavailable, where there are no alternatives
or options are unaffordable for individuals or governments, then this focus shifts back towards
shared priorities in order to ensure the delivery of health services. Hence, this conceptual
model demonstrates the concept of EML becomes fragmented as it moves through the pharma-
ceutical supply chain towards the point of care.
A health system is unable to meet every need of all individuals within a population. Thus, S1
Fig illustrates the disparity between health systems that focus reimbursement schemes on utili-
tarian population needs versus meeting the expanding needs of individuals. This is most appar-
ent between LMIC and HIC approaches to reimbursing medicines. When consumers absorb
the difference in out-of-pocket medicine costs outside of government reimbursement pro-
grams, it can sometimes become exorbitantly unaffordable [57]. Therefore, consumers’ oppos-
ing interests remaining outside population wide reimbursement schemes may need alternative
funding assistance or education programs to address ongoing tensions.
Strengths and Limitations
The results in this study were not meant to be generalisable. Instead, the use of qualitative
methodology allowed researchers the opportunity to explore issues facing decision makers
when creating national medicines lists. The strength of this study lies in offering an in-depth
exploration of a broad range of key stakeholder views through rich qualitative data. This study
gathered the perspectives of leaders and senior management throughout the continuum of a
complex supply chain involved in decision-making surrounding medicines management in
HICs. The study however, did not explore perspectives of primary health care workers, which
should be pursued in future studies. It showed there were a variety of views as to what the term
EML really means and how it relates to policy in a HIC context. While not included in the
scope of this study, future studies could examine how this can be applied in LMICs. Addition-
ally, future studies could examine further each individuals work environment and its effect on
their views.
Conclusions
The EML concept is simple, idealistic, and has been widely received. However, this study
showed that the notion of “essential” is not implicit. Although beneficial in theory, Australian
stakeholders struggled to identify how the EML concept functioned in practice. In Australia,
decision making around reimbursement of medicines has strayed from the fundamental utili-
tarian concept of essential medicines. Instead, focus is on cost-effectiveness of new technologies
and meeting unmet individual needs through expansive reimbursement lists. Interestingly,
many of those involved in medicine reimbursement decisions and management of the pharma-
ceutical supply chain did not consider the EML concept in their approach. Moreover, the
results of this study challenge for whom we consider essential medicines for, and if the term
essential is currently appropriate. Therefore, this challenged whether the EML concept was
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out-dated or underutilised in HICs such as Australia. As medicine expenditures continue to
rise worldwide and global drug shortages remain frequent and problematic, the EML concept
can potentially play a role in managing health resources. Therefore, further investigation is
required to address innovative ways to apply EML concepts in HICs to support population
wide access to prioritised medicines, while strengthening collaborations between pharmaceuti-
cal supply chain stakeholders. Transitioning the EML concept from policy to practice contin-
ues to be a work in progress.
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S1 Fig. Conceptual Model. A core list of medicines reflects shared stakeholder interests to sup-
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CHAPTER 4- DISCUSSION AND CONCLUSION 
 DISCUSSION 
 
The body of research reported in this thesis suggests that there are different perceived functions 
of Essential Medicines Lists (EMLs). These perceived functions seem to be stratified depending on 
whether the decision making context was at a health systems level or at an individual level (i.e. for 
a patient at the point of care). The differing views of diverse stakeholders regarding access to 
essential medicines, highlighted within this research, showcased the complexities of decision-
making processes involved in developing and managing EMLs.   
In contrast to the work conducted by Holloway & Henry (Holloway and Henry 2014) and Cameron 
et al. (Cameron et al. 2009), this study explored a broader context of stakeholders involved in 
decision making processes affecting access to medicines. This involved stakeholders from 
government or policy decision makers through to healthcare providers and consumer groups; as 
well as stakeholders involved in the logistics of the pharmaceutical supply chain, such as 
manufactures and wholesalers.  It offered a variety of opinions regarding what constituted an 
essential medicine and how an EML for reimbursement and procurement should be utilised.  
Building on previous literature (Hogerzeil 2004, Millar et al. 2011, Patel and Pichardo 2012, 
Meteos 2013), this research revealed that the challenges of balancing individual choice and 
system priorities requires innovative and plausible collaborative approaches to achieve 
concessions that minimize supply disruptions and meet individuals’ health needs. 
It was found that the notion of an EML was usually perceived as a systems concept, intended as a 
reimbursement list to increase access to affordable therapeutic options based on utilitarian 
population health needs and evidence based guidelines (WHO 2003). The literature review 
supported that EMLs have provided effective advocacy and evidence at the systems level to select 
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and list medicines with the intention of trying to improve access for a population (Mahmić-Kaknjo 
and Marušić 2015, Burapadaja and Chinawong 2010, Gitanjali and Manikandan 2011, Cheraghali 
and Idries 2009, Cheraghali et al. 2004b).  However, EML studies have mainly focused on low to 
middle income countries (LMICs), and little research has examined their use in high income 
countries (HICs), as discussed in chapter 3 (Duong et al. 2015, Kadić et al. 2014, Jommi et al. 
2013). No country has unlimited resources.  High prices paid for medicines and rising 
pharmaceutical expenditure are challenges across all health systems (Duckett et al. 2013, Bigdeli 
et al. 2013a, Bigdeli et al. 2013b). Therefore, the importance of applying evidence, experience, 
communication, and individual choice to decision-making and provision of essential medicines is 
equally relevant to both HIC and LMIC health systems.  
As stated, it has traditionally been the utilitarian approach of the “greatest good for the greatest 
number of people” (Roberts and Reich 2002), that has driven decision making regarding listing of 
medicines on EMLs (mainly utilised as national reimbursement lists). This research highlighted 
however, that this utilitarian approach could often be in contrast to how an individual would 
define an “essential medicine”. Many participants, particularly consumers and health care 
providers, considered an essential medicine as a medicine that was needed by an individual at the 
point of care (regardless of cost or listing on a reimbursement list). This is in line with patient-
centred care approaches (Greene 2011, Barry and Edgman-Levitan 2012).  Adding to the 
complexity of semantics, the findings from this body of work supported the notion that the EML 
concept has been evolving away from its utilitarian principles, in order to meet broader individual 
needs (Greene 2011, Barry and Edgman-Levitan 2012).  EMLs have therefore expanded from basic 
lists of life-saving medicines to reimbursement lists that encompass many medicines for more 
complex diseases.  Hence, balancing this evolution with limited resources has perhaps left many 
EMLs ambitiously designed to be something to everyone; and therefore, falling short at the 
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implementation and utilisation phases.  This has added to the complexity of the notion of who 
stands to benefit most from an EML.   
In addition, many participants agreed that the logistic complexities of the pharmaceutical supply 
chain, has fed tensions between stakeholders surrounding selection and management of essential 
medicines.  These findings were supported by the literature review which showed huge variability 
of EML policy implementation and suggested EMLs were difficult to use at the point of care due to 
different local priorities (Bertoldi et al. 2012, Mori et al. 2014, Dal Pizzol et al. 2010a).  
Qualitative interviews however, showed that many stakeholders (particularly health providers 
and consumers) valued choice.  Some stakeholders stressed that providing more choices could 
lead to more difficulty in managing lists requiring more responsibility and accountability. 
Conversely, this could allow for more tailored care for individuals as well as contingency or 
“backup” options during drug shortages. It was evident that choice seemed directly related to 
wealth, with HICs such as Australia possessing many more medicines on their reimbursement lists.  
Some qualitative interviews voiced that restricting choice was perceived as taking away an 
individual’s “voice” or their autonomy to choose and influence decisions.  Therefore, multilateral 
agreements and communications need to rationalise individuals’ choices and the capacity to pay 
for those choices. Furthermore, consumer education and empowerment may help individuals 
make more appropriate decisions regarding their care based on evidence of effectiveness 
balanced with price (Barry and Edgman-Levitan 2012, Patel and Pichardo 2012). 
This body of work explored how different health systems focused on or supported priorities of 
access through reimbursement (Millar et al. 2011, Wilson 2012, Morgan et al. 2006, Carapinha et 
al. 2011, Zerda, Salud and Salud 2002). These examples ranged from the expectation of out-of-
pocket expenses in a free market environment with no EML (e.g. US), to broader (albeit limited) 
reimbursement schemes such as those in HICs (e.g. Australia), or to restricted reimbursement and 
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access in resource limited settings like LMICs with EMLs.  In line with Hogerzeil (Hogerzeil 2004), 
managing limited choices rather than emphasising restrictions was needed as many stakeholders 
were still of the view that cheap medicines and prioritised reimbursement lists were for poorer 
countries, and expensive medicines and long reimbursement lists were for richer countries.  
A contemporary finding of this work suggests that consumers have a powerful stakeholder voice 
that can drive pharmaceutical market demand. According to stakeholders, if consumer demand 
and willingness to pay supported the need for a medicine, it will probably be made available to 
them.  Again this supports the notion that an “essential medicine” is deemed essential to the 
individual at the point of care, regardless of listing on a reimbursement list.  Coincidentally, this 
draws attention to what sources of information are available to the public and how direct to 
consumer advertising influences consumers. In some instances, consumers have been successful 
in lobbying governments to add highly expensive medicines to such lists for rare conditions (Nunn 
et al. 2009, WHO 2015a, PBS 2015b, PBS 2015a, Edwards et al. 2015, Vargas-Peláez et al. 2014). 
However, even if lobbying was unsuccessful, many consumers will still access non-reimbursed 
medicines through out-of-pocket payment if they are deemed “essential” to the individual 
(Wagner et al. 2011, Phillips 2009, Knaul et al.). It is therefore apparent that reimbursement of 
medicines has become even more complex with the rise of consumer stakeholder voice in the 
decision making process. 
In short, managing the differences between individual choices and health system priorities has 
proven challenging.  These challenges have been further compounded by the complex, multi-
tiered, and elaborate global supply chain (Rossetti et al. 2011). On one hand, complexities such as 
multiple suppliers, manufacturers, wholesalers, and retailers have been systematically added into 
the supply chain to offer considerable advantages and resilience in the form of lower pricing, 
therapeutic substitutions and backup suppliers (Lexchin and Mintzes 2008, Tordoff et al. 2008, 
Morgan, McMahon and Greyson 2008).   On the other hand, inconsistencies and complex 
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interactions between stakeholders have made the logistics and timely access to medicines 
sometimes difficult to achieve (Quilty et al. 2011, Bresser 1988).  Thus, communication between 
systems may be more likely to fail.  In such cases, participants described that improved supply 
chain resilience would entail concessions made by all stakeholders and willingness to pay for 
contingency planning.  That is, system buffers or resilience planning must account for the cost and 
provision of unpredictable supply disruptions, extra shelf space in pharmacies and warehouses, 
and national redistribution strategies to reduce waste and expiry to rotate or move around 
supply; meanwhile, still meeting consumer needs. Strategies to mitigate or prevent all “eggs in 
one basket” situations must be supported by all stakeholders and considered sustainable, which 
may be in contrast to current trends towards lean processes to improve efficiency (Bhatia et al. 
2013, Sousa et al. 2011).  
Gaps and vulnerabilities in the supply chain have risked supply disruptions (e.g. drug shortages) 
that have threatened patient care and increased costs (Cherici C 2011, McBeath 2012, FDA 2013, 
Bogaert et al. 2015).  It has been cited that improved supply chain management can facilitate 
access to essential medicines by reducing drug shortages (Bogaert et al. 2015, Gray and Manasse 
2012, Quilty et al. 2011). This research found that drug shortages were a common management 
challenge in both LMIC and HIC settings, which in turn threatened patient care and strained 
resources.  Although governments feel empowered by the ability to negotiate lower prices for 
medicines, governments and consumers no longer “get a better deal” when medicines supply is 
not guaranteed (Huff-Rousselle 2012, Tordoff et al. 2008, Cherici C 2011, FDA 2013, Duckett et al. 
2013). Therefore, reactivity in the system has resulted in higher incurred costs of medicines, use 
of resources, and susceptibility to coercion and corruption (Cherici C 2011, Bogaert et al. 2015, 
FDA 2013, Bevilacqua et al. 2011, Dal Pizzol et al. 2010b, Bertoldi et al. 2012). In response to these 
challenges, many participants explored the benefits of the EML approach (e.g. applying utilitarian 
principles to prioritise vital, essential or non-essential medicines) to better manage supply 
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disruptions or secure high priority medicines within the supply chain (Millar et al. 2011, Hogerzeil 
2004). However, this approach would necessitate improved collaboration, communication, 
transparency and coordination between stakeholders throughout the continuum of the 
pharmaceutical supply chain and decision making processes (Meteos 2013).  
This body of knowledge proposed that addressing medicine supply chain problems demanded 
improved collaborative alliances. In line with the comprehensive theory of collaboration and 
Pharma Futures report, management of these supply chain challenges requires collaboration, 
building strategies, identifying shared priorities and establishing agreements on how to manage 
different values (Wood and Gray 1991, Meteos 2013).  However, according to qualitative results 
discussed in chapter two of this thesis, the interconnected stakeholder roles and responsibilities 
lacked cohesion.  Furthermore, it also showed deliberate avoidance of some collaborative 
alliances due to conflicts of interests. Similarly, qualitative interviews discussed in chapter three, 
demonstrated this caused tensions between stakeholders around the function of EMLs and 
conflicting interests around the selection of medicines.  Additionally, the literature review 
described financial and ethical barriers to accessing medicines (Akaleephan et al. 2009, Cohen 
2006).  For example, divergent views on pricing and cost savings of medicines were highly skewed 
and international trade agreements like the Trade Related Intellectual Property Rights (TRIPS) 
agreement further contributed to these tensions.  In line with the comprehensive theory of 
collaboration, the research reported in this thesis demonstrated that identifying and 
understanding stakeholders’ self-interests could facilitate solutions involving multilateral 
agreement and action. This could be achieved through the alignment of selection and 
procurement of medicines. Hence, challenges to the supply and use of EMLs offer an opportunity 
to align the values of health system priorities with individual choice.  
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Strengths and Limitations 
This thesis gathered a broad range of views of many stakeholders from multiple levels of the 
health system. While other studies have focused on one segment of access to medicines, this 
study offered a rare global overview of the access to medicines framework demonstrated in both 
the literature review and qualitative interviews.  In line with qualitative method objectives, the 
results of this study were not intended to be generalisable.   Rather, they were able to explore 
gaps in the literature regarding the influences on access to medicines and report perceived 
challenges that stakeholders experienced.  Furthermore, this unique study highlighted the 
interaction of different stakeholder’s views and gave insight into factors that influenced decision 
makers surrounding the supply and access to medicines.   
Although not all countries, range of health systems, and individual circumstances were 
represented in this study; it was still able to compare views of stakeholders from many HICs and 
LMICs through the vast and overlapping experiences of the participants recruited.  This study also 
acknowledged that while participants had rich experiences across different health systems, many 
were from HICs but worked in LMICs.  Therefore, their paradigm of health may have been 
imposed onto their views of the situation in LMICs rather than culturally developed.  Despite this, 
results showed the views of participants from LMICs were aligned with views of participants from 
HICs when describing the situations in LMICs.  Lastly, complex overlapping stakeholder functions 
and activities were not depicted in this study. Instead, this was presented as simplistic diagrams 
and selected quotes to describe major stakeholder roles and challenges. Other specific strengths 
and limitations have been discussed in previous chapters.  
CONCLUSION 
This is the first body of research to use a qualitative approach in exploring the global use of EMLs 
through comprehensive stakeholder views. The divergence of perspectives gathered in this 
research reflected the complex decision making processes involved in developing and managing 
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national reimbursement lists. Therefore, findings from this body of work challenged whether the 
term “essential” was appropriate to describe national lists, and if “reimbursement” lists were 
more reflective of how lists were used.  This research also confirmed that decision making 
processes around access to medicines are extremely complex. Adding to this complexity, 
consumer demand for therapeutic choices to accommodate individualised care has resulted in 
more logistics to manage and pressure decision makers to add medicines to expanding 
reimbursement lists. This has put increasing pressure on governments to balance what consumer 
demands they are willing to reimburse with the limited available resources. Therefore, 
empowering consumers with information to responsibly and safely guide these decisions could 
direct the provision of medicines within the supply chain.   
Findings confirmed that the access to medicine gap continues to be problematic, and explored 
potential solutions to mitigating supply chain disruptions through multi-stakeholder engagement 
and EML approaches. This is relevant within the climate of globalisation, economic crisis, political 
conflicts, and natural disasters (Bhatia et al. 2013). This research also demonstrated that health 
systems and individuals can look to EMLs to guide advocacy, prioritisation and provision of the 
most “essential” medicines.  Therefore, building on Hogerzeil (Hogerzeil 2004) and Wood and 
Gray (Wood and Gray 1991), these solutions demand innovative and plausible collaborative 
approaches to achieve concession that improve supply disruptions and meet individuals’ health 
needs.  In brief, it is recommended that all stakeholders must work together to carve 
communication pathways that encourage and sustain patient-centred care. In line with the 
Pharma Futures report (Meteos 2013), we recommend improved stakeholder engagement 
through absolute commitment to participate, increased communication, improved transparency, 
timely co-ordination of responses, and practical concessions. Furthermore, this research suggests 
aligning decision making priorities with procurement practices. This should be considered in 
committee decisions or applied to evaluative measures to determine for whom essential 
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medicines are for; stratifying the priority for vital, essential and non-essential medicines; how 
they are managed and communicated throughout the supply chain; contingency planning to 
ensure provision of priority medicines; and consumer communication.  In summary, the 
challenges in this current climate offer decision makers and supply chain managers a valuable 
opportunity to reflect and understand how the current system is functioning, and develop 
foundations for improved processes, and innovative and cooperative platforms to interact and 
network. 
Future Research 
Future investigations within regions or a country context may provide understanding of different 
cultural and social interactions between stakeholders. Furthermore, future research may explore 
how shared priorities identified in collaborative alliances have been successful in providing access. 
Additionally, further research could examine each individual’s work environments and how that 
effects their views. Finally, an extension of this body of work for future investigations could 
identify and test causal variables that determine what makes a medicine essential to 
stakeholders. This would help identify self-interest variables that could be applied to improving 
collaborative alliances and offer insight into how stakeholders weigh evidence, experience, 
choice, and political pressure.  
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Appendix A: Narrative Literature Review Checklist (chapter 1) 
Narrative Review Checklist  
Developed from:  
Elsevier. 2016. Information for Authors - Narrative Review Checklist. Journal of the Academy of  
Nutrition and Dietetics. Available at: http://www.andjrnl.org/content/authorinfo#nar  
 
Section/Topic # Checklist Reported 
on chapter 
or page # 
TITLE    
Title* 1 Identify the report as a Narrative Review of …  
 
Statement 
included in 
Chapter 1: 
Methods 
page 5 
ABSTRACT    
Unstructured 
summary* 
2 Provide an unstructured summary including, as 
applicable: background, objective, brief summary of 
narrative review and implications for future research, and 
clinical practice or policy development. 
Abstract, 
page xii-xiv 
INTRODUCTION    
Rationale/Background 3 Describe the rationale for the review in the context of 
what is already known. 
Chapter 1: 
Introduction  
Objectives 4 Specify the key question(s) identified for the review topic. Chapter 1: 
Introduction  
METHODS    
Research selection 5 Specify the process for identifying the literature search 
(eg, years considered, language, publication status, study 
design, and databases of coverage). 
Chapter 1: 
Methods,  
Discussion/Summary    
Narrative 6 Discuss: 1) research reviewed including fundamental or 
key findings, 2) limitations and/or quality of research 
reviewed, and 3) need for future research. 
Chapter 1: 
Results 
Discussion  
Summary** 7 Provide an overall interpretation of the narrative review 
in the context of clinical practice, policy development and 
implementation, or future research. 
Chapter 1: 
Conclusion  
*adapted from the “journal of the academy of nutrition and dietetics” publication standard to 
thesis format (2016) 
**adapted from the discipline of nutrition for medicine 
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Narrative Overview Rating Scale 
Green, BN, Johnson CD, Adams A. 2006. Writing narrative literature reviews for peer-reviewed 
journals: secrets of the trade. Journal of Chiropractic Medicine.5(3):101-117. 
Circle the number that you feel is appropriate for the paper that you are reading: 
1 = Absent 2 = Present but not complete 3 = Present and complete 
Initial Impression 
1 2 3 Does the review appear to be relevant to an issue of interest (18, 30)? 
 
Abstract 
1 2 3 Is the specific purpose of the review stated (3, 15)? 
1 2 3 Is context for the overview provided? 
1 2 3 Is the type of research design stated? 
1 2 3 Are the search methods clearly summarized? 
1 2 3 Are the important findings clearly discussed? 
1 2 3 Are the major conclusions and recommendations clearly outlined? 
 
Introduction 
1 2 3 Is the specific purpose of the review clearly stated based upon a brief review of the literature 
(1, 3, 18, 24)? 
1 2 3 Is the need/importance and context of this study established (2, 11, 24)? 
1 2 3 Are novel terms defined (10, 29)? 
 
Methods 
1 2 3 Were the electronic databases used to conduct the literature searches identified (MEDLINE, 
CINAHL, etc.) (3, 13, 17)? 
1 2 3 Were the search years stated? 
1 2 3 Were the search terms stated (3)? 
1 2 3 Were standard terms used as search terms, including Medical Subject Headings (17)? 
1 2 3 Were the guidelines for including and excluding articles in the literature review clearly 
identified (10, 18, 22)? 
 
Discussion 
1 2 3 Were the results summarized in a comprehensible manner (3, 10)? 
1 2 3 Was the critical appraisal of each study the same and reproducible (11, 13, 22)? 
1 2 3 Was the quality of the included articles assessed objectively (3, 11, 13)? 
1 2 3 Was the variation in the findings of the studies critically analyzed (1, 10, 13, 22)? 
1 2 3 Were the meaning of the results addressed (3)? 
1 2 3 Do the authors tie in the results of the study with previous research in a meaningful manner 
(1, 3, 10)? 
1 2 3 Were the weak points and untoward events that occurred during the course of the study 
addressed by the authors (1, 3)? 
 
Conclusions 
1 2 3 Was a clear summary of pertinent findings provided (10)? 
1 2 3 Were the authors’ conclusions supported by the evidence provided (1, 3, 13, 18)? 
1 2 3 Were specific directives for new research initiatives proposed? 
1 2 3 Specific implications to the practice environment are addressed (3). 
References 
1 2 3 Are references relevant, current and appropriate in number (11)? 
1 2 3 Are all papers reviewed cited in the references (1)? 
 
Overall Impressions 
1 2 3 Do the merits of this review of the literature outweigh the flaws? 
1 2 3 Were the authors unbiased in their approach to the review (11, 18)? 
1 2 3 Will the results of the paper help me in my philosophical or evidence based approach to 
patient care (11,18)?
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Appendix B – Literature on Essential Medicines (chapter 1) 
Studies were organised according to the WHO Access to Essential Medicines Framework under 
appropriate selection (Table B1), availability and affordability of medicines (Table B2) and quality 
of medicines (Table B3).  Studies were displayed in order of methodology, country (multiple to 
individual countries), WHO region (Europe, Western Pacific, South East Asia, Africa, Americas), 
and author. Where some studies evaluated more than one outcome measure, they were 
described in one section only.  Notably, studies and reviews categorised under multiple countries 
were generally conducted in LMICs, since HICs were not reported in the sample. Facilitators and 
barriers to EML implementation were identified.   
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Table B1: Appropriate Selection of Medicines Study Comparison 
Author Title Country Objective Type of 
Study 
Study Design How does it relate to 
EML? 
Comments 
Greene 
(Greene 2011) 
Making medicines 
essential: The 
emergent 
centrality of 
pharmaceuticals 
in global health 
Multiple 
countries 
To understand what 
practices render a 
medicine essential. 
Literature 
Review 
Historical narrative review. Appropriate use of 
EML could not be 
determined and 
questions what 
renders a medicine 
essential. The 
evolution of practice 
and politics has led to 
the expansion of the 
EML. 
Describe the origin, evolution, goals, 
perceptions, progress, challenges and 
changes in the concept of essential 
medicines and access. 
Ratanawijitrasin 
et al. 
(Ratanawijitrasin, 
Soumerai and 
Weerasuriya 
2001) 
Do national 
medicinal drug 
policies and 
essential drug 
programs improve 
drug use?: A 
review of 
experiences in 
developing 
countries 
 
Multiple 
countries 
To define the 
available knowledge 
regarding drug policy 
effects on drug use, 
identify evidence 
important for future 
policy and research. 
Literature 
Review 
Systematic literature review, 
regulatory interventions 
evaluated. Reviewed 36 
published works (18 journal 
articles, 13 reports, 1 book 
chapter, 1 booklet, 2 theses, 1 
conference presentation). 
Could not determine if 
EML improved quality 
use of medicine due to 
poor quality of studies 
and few categories of 
policy assessed. 
Variability in quality of studies using 
different methodologies; stronger 
research designs required. 
Tran & Bero 
(Tran and Bero 
2015) 
Barriers and 
facilitators to the 
quality use of 
essential 
medicines for 
maternal health in 
low-resource 
countries: An 
Ishikawa 
framework 
Multiple 
countries 
To identify barriers & 
facilitators to 
availability & use of 
oxytocin, 
ergometrine and 
magnesium sulphate 
in pre-eclampsia and 
eclampsia. 
Literature 
Review 
Ishikawa Framework Approach 
applied as analytical framework 
to identify barriers and 
facilitators.  Analysed 
UNFPA/WHO reports. 4 health 
system levels: government, 
pharmaceutical supply, health 
facility and health professional. 
 
Appropriate use and 
availability of 
magnesium sulphate 
was low despite EML 
listing. 
This study identified barriers and 
facilitators to quality use of medicines 
including: STGs, forecasting and 
procurement, availability of antidote, 
storage. Useful tool for rapid 
assessment to guide quality use of 
medicine. 
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Table B1: Appropriate Selection of Medicines Study Comparison 
Author Title Country Objective Type of 
Study 
Study Design How does it relate to 
EML? 
Comments 
Vargas-Peláez et 
al. 
(Vargas-Peláez et 
al. 2014) 
Right to health, 
essential 
medicines, and 
lawsuits for access 
to medicines - A 
scoping study 
Multiple 
countries 
Examined the 
approach to 
judicialisation of 
access to medicines 
and its possible 
impacts. 
Literature 
Review 
A scoping literature review with 
through qualitative thematic 
analysis of 65 articles to 
evaluate social approach to 
judicialisation. 
EML improved right to 
health to support 
appropriate use, 
however, policies were 
distorted during 
implementation 
resulting in poor 
availability of 
medicines. 
Judicial intervention can be a useful 
mechanism for promoting the right to 
health and pushing governments to 
fulfil their constitutional obligations. 
However it induces distortion in the 
implementation of policies which can 
compromise health systems 
sustainability. Have limited impact on 
operations of health services. Judicial 
system in Europe prioritises common 
wealth over individual rights. Whereas 
in Latin America, judicial decisions 
favour individual lawsuits without 
considering the impact on the health 
system and the rest of the population. 
 
Wilson et al. 
(Wilson et al. 
2014) 
 
Process, contexts, 
and rationale for 
disinvestment: a 
protocol for a 
critical 
interpretive 
synthesis 
Multiple 
countries 
To understand 
whether, how & 
under what 
conditions health 
systems decide to 
pursue 
disinvestment, how 
health systems have 
chose to undertake 
disinvestment, and 
how health systems 
have implemented 
their disinvestment 
approach. 
 
Literature 
Review 
Critical interpretive synthesis 
approach using qualitative 
constant comparative method 
applied to a Systematic 
literature review to develop a 
theoretical framework. 
EMLs must be updated 
regularly in order to be 
used appropriately. 
Listing and delisting 
medicines can impact 
adherence to EMLs. 
Use of constant comparative approach 
to identify common themes from 
literature to develops theoretical 
constructs. Used purposive sampling 
of papers to fill in conceptual gaps. 
This study design used qualitative 
techniques to interpret literature to 
design a tool that can be administered 
to stakeholders. 
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Table B1: Appropriate Selection of Medicines Study Comparison 
Author Title Country Objective Type of 
Study 
Study Design How does it relate to 
EML? 
Comments 
Nguyen et al. 
(Nguyen et al. 
2012) 
Indicators of 
quality use of 
Medicines in 
South-East Asian 
countries: a 
systematic review 
Multiple 
countries in 
South East 
Asia 
To identify indicators 
of quality use of 
medicines used in 
the South-East Asian 
region. 
Literature 
Review 
Systematic literature review to 
identify quality use of 
medicines indicators in South 
East Asia. 17 studies in 7 
countries were included. 
The impact of EML in 
south east Asia was 
difficult to determine 
as indicators of quality 
use of medicines were 
limited and lacked 
validity and reliability. 
 
 
QUM was suboptimal and varied 
greatly. WHO indicators most 
frequently used. Existing Indicators 
need to consider validity, reliability, 
feasibility and changing health needs 
in the region (i.e. NCDs). 
Ridge et al. 
(Ridge et al. 
2010) 
Identifying 
barriers to the 
availability  and 
use of Magnesium 
Sulphate Injection 
in resource poor 
countries: A case 
study in Zambia 
Zambia To identify barriers to 
the availability and 
use of magnesium 
sulphate in the public 
health system in 
Zambia. 
Literature 
Review 
Literature review of archival 
data used to develop the 
Ishikawa Fishbone diagram to 
explain barriers to availability of 
Magnesium sulphate injections 
through observations from 
obstetric services at a health 
facility. 
 
 
Poor availability of EML 
listed medicine due to 
poor procurement 
practices. 
Barriers included lack of public 
procurement, demand by health care 
professionals and in-service training in 
using magnesium sulphate. 
Van der Geest 
(Van der Geest 
1982) 
The efficiency of 
Inefficiency: 
Medicine 
distribution in 
South Cameroon 
Cameroon To explain why public 
health services in 
south Cameroon 
function inefficiently. 
Qualitative Participant observations, case 
histories, health reports/files, 
and financial accounts were 
collected. 
Appropriate use of 
EMLs required 
improved education 
and training of health 
care workers, and 
community 
cooperation. 
Education and training of health care 
workers must include the community's 
cooperation and meetings to 
disseminate values.  Community is 
responsible for demand and use of 
services and also a part of the shortage 
cause.  Health care providers need to 
have communication with community. 
Favours, gifts, and relationships are 
very important to understand in 
cultures. 
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Table B1: Appropriate Selection of Medicines Study Comparison 
Author Title Country Objective Type of 
Study 
Study Design How does it relate to 
EML? 
Comments 
Albert et al. 
(Albert et al. 
2007) 
Factors 
influencing the 
utilization of 
research findings 
by health policy-
makers in a 
developing 
country: the 
selection of Mali's 
essential 
medicines 
Mali To explore policy 
makers views on the 
factors influencing 
medicine utilisation. 
Qualitative Qualitative semi-structured 
interviews and discussion with 
national policy makers. Data 
analysis used a Giorgi's 
Phenomenological approach. 
Could not determine 
appropriate use of 
essential medicines 
due to poor quality of 
evidence and 
collaboration to inform 
EML decision making. 
Emerging factors influencing the 
decision making process included: 
Access to evidence, application of 
information, limited resources 
(including staff), competency, requires 
time that competes with other duties, 
trust in research, biased views, 
differing priorities, and accountability. 
Need for more collaboration and 
technical support to assist policy 
makers to make informed decisions. 
 
Mori et al. 
(Mori et al. 2014) 
The role of 
evidence in the 
decision-making 
process of 
selecting essential 
medicines in 
developing 
countries: the 
case of Tanzania 
Tanzania Describe the process 
of updating the STGs 
and EML in Tanzania 
and further examines 
the criteria and the 
underlying evidence 
used in decision 
making. 
Qualitative Qualitative in depth interview 
and document reviews with 18 
key informants. Analysed using 
thematic content analysis. 
Outcome Measures: described 
the criteria and evidence used 
in decision making. 
Appropriate use of 
EML could not be 
determined because of 
the variation of what 
was considered 
evidence and how it 
influenced clinical 
judgement. 
Decision making favoured experience 
and discretionary judgement, rather 
than Evidence. Cost had limited role, 
no consideration of cost-effectiveness 
due to lack of expertise. The process 
and organization requires 
improvement and more discussion. 
Medicines used in a hospital were 
assumed to have clinical evidence. 
Clinical experience and patient 
feedback was also perceived as 
evidence. Identified issues trusting and 
applying evidence balanced with 
experience. Clinical advice can 
informally come from pharmaceutical 
industry through colleague 
discussions. 
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Table B1: Appropriate Selection of Medicines Study Comparison 
Author Title Country Objective Type of 
Study 
Study Design How does it relate to 
EML? 
Comments 
Homedes & 
Ugalde 
(Homedes and 
Ugalde 2005) 
Multisource drug 
policies in Latin 
America: Survey 
of 10 countries 
Multiple 
countries in 
Latin 
America 
To describe different 
country experiences 
in defining and 
implementing 
generic drug policies, 
cost & time of 
registering products, 
and government 
incentives to 
promote use of 
multisource drugs. 
 
Mixed 
Methods 
Mixed Methods: 82 Survey and 
qualitative questions in 10 Latin 
American countries. 22 
participants with min 1 person 
in drug regulatory agency or 
pharmaceutical policy in each 
country and compared with 
archival data. Investigated 
whether definitions were 
appropriate in policies. 
 
Difficult to determine 
EML impact because 
the quality of 
medicines could not be 
evaluated when the 
terms generic and 
bioequivalence were 
used differently. 
Definition of the term "generic" has 
different meaning within and between 
countries. Length of time for drug 
approval in Latin America is 
significantly shorter than developed 
countries, and some can be 
automatically registered if no response 
is received (Peru).  Need to harmonize 
vocabulary and technical procedures 
to ensure quality of pharmaceutical 
products from multiple sources. 
Bazargani et al. 
(Bazargani et al. 
2014) 
Selection of 
Essential 
Medicines for 
Diabetes in Low 
and Middle 
Income Countries: 
A Survey of 32 
National Essential 
Medicines List 
Multiple 
countries 
To examine selection 
of and influencing 
factors around 
essential medicines 
to treat diabetes. 
Quantitative Comparison of national EML of 
32 countries for 
Insulin/analogues and blood 
glucose lowering drugs used in 
diabetes treatment. 
Suboptimal and 
inconsistent availability 
of diabetes medicines 
despite listing on EML. 
Most LMICs listed the minimum 
required diabetes medicines. A median 
of 6 medicines for diabetes treatment 
were listed on National EMLs. 
Suboptimal or inconsistent availability 
of some of these essential diabetes 
medicines require further 
investigation. 
De Lima et al. 
(De Lima et al. 
2007) 
Ensuring Palliative 
Medicine 
Availability: The 
Development of 
the International 
Hospice and 
Palliative Care List 
of Essential 
Medicines for 
Palliative Care 
Multiple 
countries 
To describe how the 
WHO EML for 
Palliative Care was 
created. 
Quantitative Guidelines were developed and 
sent through a modified Delphi 
Process to 112 physicians in 77 
developing countries, followed 
by working groups from 26 
organizations. 
Listing of Palliative 
medicines on WHO 
EML used to improve 
access. 
33 medicines were included on the List 
of Essential Medicines for Palliative 
Care, in which 14 were already 
included on the WHO EML. 
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Author Title Country Objective Type of 
Study 
Study Design How does it relate to 
EML? 
Comments 
Holloway & 
Henry 
(Holloway and 
Henry 2014) 
WHO essential 
medicines policies 
and use in 
developing and 
transitional 
countries: an 
analysis of 
reported policy 
implementation 
and medicines use 
surveys 
 
Multiple 
countries 
To determine if the 
WHO EML policies 
were associated with 
improved QUM. 
Quantitative Surveys from 56 countries, used 
10 validated QUM indicators 
and 36 self-reported policy 
implementation variables from 
WHO databases from 2002-
2008. 
EML policy was 
associated with 
improved appropriate 
use of medicines in 
LMICs, especially in 
education around 
STGs. 
A positive correlation was shown 
between EML policy and QUM in 
LMICs, especially in education around 
STGs. Regression analyses showed 
positive association between QUM 
scores and number of EML policies. 
Logez et al. 
(Logez et al. 
2004) 
Could the WHO 
Model List of 
Essential 
Medicines Do 
More for the Safe 
and Appropriate 
Use of Injections? 
 
Multiple 
countries 
To describe 
injectable medicines 
in the WHO EML and 
examine how it 
addresses access to 
injection devices. 
Quantitative Database using 11th WHO EML 
to give 27 injectable medicines 
using Martindale, expected size 
of syringes needed, and 
medium price per unit. 
WHO EML influenced 
availability and 
appropriate use of 
medicines. 
Outlined the importance of injectable 
essential medicines and need for safe 
and appropriate guidelines for 
procurement, preparation & 
administration. 
Mahmic-Kaknjo 
& Marusic 
(Mahmić-Kaknjo 
and Marušić 
2015) 
Analysis of 
evidence 
supporting the 
Federation of 
Bosnia and 
Herzegovina 
Reimbursement 
medicines lists: 
role of the WHO 
EML, Cochrane 
Systematic 
Bosnia and 
Herzegovina 
To compare the WHO 
EML with the 
national formulary 
list to evaluate the 
evidence supporting 
inclusion of 
additional medicines. 
Quantitative Formulary Comparison: WHO 
EML with national formulary list 
and using Cochrane review and 
HTA reports to support non-
WHO EML drugs included on 
the national formulary list. 
EML provided good 
evidence for 
reimbursement 
decisions especially 
when financial 
resources were scarce. 
30% of medicines included on the 
national formulary list but that were 
not found on the WHO EML did not 
have good enough evidence to justify 
their inclusion on the national 
formulary list. The WHO EML, 
Cochrane systematic review, and HTA 
reports offer high quality evidence to 
assist circumstances with scarce 
resources. This aids decision making 
on medicine reimbursement. 
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Study 
Study Design How does it relate to 
EML? 
Comments 
reviews & 
technology 
assessment 
reports 
Kadić et al. 
(Kadić et al. 2014) 
Using the WHO 
essential 
medicines list to 
assess the 
appropriateness 
of insurance 
coverage 
decisions: a case 
study of the 
Croatian national 
medicine 
reimbursement 
list 
 
Croatia Used the WHO EML 
to evaluate evidence 
basis for medicine on 
the national 
insurance coverage 
list in Croatia. 
Quantitative Compared WHO EML with 
Croatian Institute Health 
Insurance (CIHI) basic list. 
WHO EML was a useful 
quality assurance tool 
to ensure countries 
used appropriate 
evidence to list and 
reimburse medicines. 
WHO EML provided useful evidence 
for reimbursement decision making. 
Jommi et al. 
(Jommi et al. 
2013) 
Multi-tier drugs 
assessment in a 
decentralised 
health care 
system. The 
Italian case-study 
Italy To address gaps 
arising from multi-
tier drug assessment 
processes and how 
these issues are dealt 
with. 
Quantitative Case study: structured multiple 
choice questionnaire for 
regional and hospital 
committee members in Italy. 
Described decision making 
process and considerations for 
policy makers. 
 
Application of EML 
hard to determine 
because decision 
making processes were 
fragmented and not 
transparent. 
The decision making process is 
fragmented and requires regional and 
local assessment. No consideration for 
appeals. Therapeutic committees are 
closed to industry and patient 
associations’ involvement. 
Prioritisation is driven mostly by 
disease severity, clinical evidence, and 
absence of therapeutic alternatives. 
Committees demonstrated low level of 
transparency. 
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Study 
Study Design How does it relate to 
EML? 
Comments 
Chen et al. 
(Chen et al. 2014) 
Does Economic 
Incentive Matter 
for Rational Use of 
Medicine? China's 
Experience from 
the Essential 
Medicines 
Program 
China To measure changes 
in prescribing 
patterns after 
removal of economic 
incentives for 
physicians to 
overprescribe after 
EML implementation 
 
Quantitative Multistage cluster sampling 
surveys, analysed with 
regression methods. Conducted 
in primary healthcare facilities. 
EML did not improve 
appropriate use by 
prescribers. 
No change in prescribing patterns after 
implementation of EML policy was 
shown. Removing prescriber economic 
incentives from pharmaceutical 
companies did not improve 
appropriate use of EML by prescribers. 
Hettihewa & 
Jayarathna 
(Hettihewa and 
Jayarathna 2010) 
Comparison of the 
Knowledge in 
Core Policies of 
Essential Drug List 
Among Medical 
Practitioners and 
Medical Students 
in Galle, Sri Lanka 
Sri Lanka To assess the 
knowledge of EML 
and the attitudes on 
prescribing essential 
medicines by medical 
practitioners and 
students. 
Quantitative Comparative cross-sectional 
survey with 42 medical 
practitioners and 120 medical 
students. 
EML improved 
appropriate use by 
influencing prescriber 
knowledge. 
Medical students had good knowledge 
of EML content, but poor knowledge 
of criteria. Whereas medical 
practitioners had good knowledge of 
selection criteria but were not 
confident about EML content 
especially inclusion criteria such as 
generic names and common ailments. 
Medical practitioners need repetitive 
service training in EMLs and 
Curriculum needs to include criteria 
for EML selection. 
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EML? 
Comments 
Lubinga et al. 
(Lubinga et al. 
2014) 
Impact of 
pharmacy worker 
training and 
deployment on 
access to essential 
medicines and 
health outcomes 
in Malawi: 
protocol for a 
cluster quasi 
experimental 
evaluation 
Malawi To measure impact 
of pharmacy 
assistant training 
program in LMIC on 
access to medicine 
and health 
outcomes. 
Quantitative Cluster Quasi Experimental 
Evaluation: 1) Health centre 
based time motion and patient 
survey 2) population based 
household survey, 3) a model-
based health and economic 
analysis. 150 pharmacy 
assistants trained and worked 
in 18 districts. 4150 surveys. 
Outcome Measures: 
operational efficiency (patient 
wait times); access to ACT, 
antibiotic, ORS; QALY gained, 
DALY averted and costs of 
program. 
 
The availability of 
essential medicines is 
influenced by the 
capacity and 
availability of qualified 
staff. 
This protocol described a guide to 
national and regional human resource 
intervention that impacts cost, health 
outcomes and cost effectiveness. 
Dal Pizzol et al. 
(Dal Pizzol et al. 
2010a) 
Adherence to 
essential 
medicines lists in 
municipalities of 
three Brazilian 
States 
Brazil Assessed adherence 
of prescribers to 
municipal EML. 
Quantitative Survey and Data collection of 
288 prescriptions were 
compared to WHO EML by a 
multi-disciplinary committee, in 
8 city municipalities in 3 states 
associated with tertiary 
educational institution. 
Low availability of 
essential medicines 
due to inappropriate 
use of local EMLs. 
Some cases showed that need for 
"non-essential" medicines were 
justified by the perceived inadequacy 
of the local EML and drug shortages to 
address therapeutic gaps. Of the 10 
most prescribed medicines, 1 or more 
medicines were not part of the local 
EML. Medicines listed on the local EML 
were more likely to be available than 
unlisted medicines. Patients would go 
to private sector and pay out of pocket 
for these frequently prescribed non-
essential medicines. 
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Study Design How does it relate to 
EML? 
Comments 
Rico-Alba & 
Figueras 
(Rico-Alba and 
Figueras 2013) 
The fuzzy line 
between needs, 
coverage, and 
excess in the 
Mexican 
Formulary List: an 
example of 
qualitative market 
width analysis 
Mexico To evaluate coverage 
of basic health needs 
provided by drugs 
included in the 
Mexican national 
formulary and 
reference catalogue 
for national Mexican 
health services, and 
measure the 
rationality of the 
drugs in the list. 
Quantitative Mixed methods: Quantitative 
comparison of the Mexican EML 
to assess therapeutic rationality 
of medicines not included in the 
WHO EML. Qualitative analysis 
using Prescrire Classification to 
rate rationality of medicines 
and degree of usefulness.   
Outcome Measures: 1) Listed 
on WHO EML with standardised 
therapeutic rational, 2) 
Rationality of WHO EML 
unlisted products meet 
Prescrire Classification of 
therapeutic rationality. 
Comparison of WHO 
EML with Mexican EML 
shows twice as many 
products and 
irrationality of missing 
essential medicines. 
Used standardised tools such as WHO 
EML and Prescrire Classification 
system to compare EML and explore 
rationality of listing on the formulary. 
236/771 (30.6%) product listed on 
Mexican EML perfectly matched WHO 
EML. Several essential products to 
treat prevalent diseases were missing, 
while there was also an oversupply of 
other products with little or no added 
therapeutic value (28%). Missing 
medicines were cheap, had no patent 
protection and of poor marketing 
interest. 
 ACT-Artemisinin-based Combination Therapy; DALY-Disability-Adjusted Life Years; EML-Essential Medicines List; HTA-Health Technology Assessment; LMIC-low to middle income country; 
NCD-non-communicable disease; ORS-Oral Rehydration Salts; QUM-Quality Use of Medicines; QALY-Quality Adjusted Life Years; STG-Standard Treatment Guideline;  UNFPA-United Nations 
Fund for Population Activities; WHO-World Health Organization; WHO EML- World Health Organization Model List of Essential Medicines. 
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Table B2: Availability and Affordability of Medicines Study Comparison 
Author Title Country Objective Type of 
Study 
Study Design How does it relate to 
EML 
Comments 
Nunan & Duke  
(Nunan and 
Duke 2011) 
Effectiveness of 
pharmacy 
interventions in 
improving 
availability of 
essential 
medicines at the 
primary 
healthcare level 
Multiple 
countries 
To assess the 
effectiveness of 
pharmaceutical 
system interventions 
in improving the 
availability of 
essential medicines 
at the primary care 
level. 
 
Literature 
Review 
Systematic literature review of 
pharmaceutical interventions’ 
impact on availability of 
medicines in LMICs. 
Availability of EML can 
be improved through 
local pharmacy 
interventions. 
A standardised approach to measuring 
availability of medicines is needed. 
Pharmacy interventions at the primary 
health care level can potentially 
improve medicines availability without 
large scale international cooperation 
or global policy change. 
Mackintosh et 
al. 
(Mackintosh et 
al. 2011) 
 
Can NGOs 
regulate 
medicines 
markets? Social 
enterprise in 
wholesaling, and 
access to 
essential 
medicines 
Multiple 
countries 
To describe and 
assess the activity of 
NGOs and social 
enterprise in 
essential medicines 
wholesaling. 
Qualitative Qualitative semi-structured 
interviews. Senior procurement 
managers of NGOs and social 
enterprise in Europe, India and 
Tanzania. Analysis cross-
referenced ownerships 
structure with aspects of 
reported business behaviour. 
Triangulated data on behaviour 
of competitors and the 
evolution of market 
competition. 
 
Wholesaling improved 
access to good quality 
medicines. 
Social enterprise wholesaling can 
improve access to good quality 
essential medicines in the absence of 
effective government activity and 
regulation. NGO regulatory impact can 
complement but not replace state 
action. 
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Study Design How does it relate to 
EML 
Comments 
Magadzire et al. 
(Magadzire et 
al. 2014) 
Frontline health 
workers as 
brokers: provider 
perceptions, 
experiences and 
mitigating 
strategies to 
improve access to 
essential 
medicines in 
South Africa 
 
Tanzania To compare 
consumers' and 
health care 
providers' 
perceptions of the 
quality of generics to 
the actual quality of 
selected products. 
Qualitative Qualitative cross sectional semi-
structured interviews with 36 
nurses, pharmacy personnel 
and doctors in 6 public health 
centres in 2 districts both rural 
and urban settings. Content 
analysis and grounded theory 
approach, used five 
dimensional framework to 
illustrate connections. 
Availability of EML was 
poor due to logistic 
barriers. 
Barriers to available medicines include: 
logistic bottlenecks in the supply chain, 
poor transport networks, poor 
cohesion between disease programs 
and patient needs, proximity to 
medicine centres, stigma, and 
transport costs. 
Van der Geest 
et al. 
(Van Der Geest 
et al. 2000) 
User fees and 
drugs: what did 
health reforms in 
Zambia achieve? 
Zambia To determine what 
the user fee health 
reforms had 
achieved, and if there 
were improvements 
in the quality of 
health care. 
Qualitative 35 Qualitative semi-structured 
interviews, 25 focus groups and 
observations from a checklist 
were conducted with 
consumers (community leaders 
and users of health centre). 
Conducted in 2 urban and 2 
rural health centres. 
 
Cost sharing did not 
improve availability of 
medicines. 
Cost sharing was not seen to have 
improved the quality of care or 
availability of medicines. The medicine 
supply chain was seen as unreliable, 
therefore the high fees seemed unfair. 
Chen et al. 
(Chen et al. 
2010) 
Availability and 
use of essential 
medicines in 
China: 
manufacturing, 
supply and 
prescribing in 
Shandong and 
Gansu provinces 
China To investigate 
manufacturing, 
purchasing and 
prescribing of 
essential medicines 
Mixed 
Methods 
Quantitative surveys of 
manufacturers, hospitals, and 
retail pharmacies. Prescription 
review of hospital prescriptions. 
Qualitative structured 
interviews with manufacturers 
CEO, hospital/retail pharmacy 
managers.  
Inappropriate use of 
EML, therefore low 
availability and 
affordability of 
essential medicines. 
There was low demand for essential 
medicines and price mark up controls. 
Proportion of essential medicines 
produced was not proportional to 
sales volume (low production). Listing 
on EML did not influence 
manufacturers production or retail 
pharmacy procurement decisions. 
Influencing factors on procurement 
were: market demand, production 
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Study 
Study Design How does it relate to 
EML 
Comments 
cost, price, profit margins, or market 
share. In hospitals, low purchasing of 
EML due to lack of clinical use or 
availability of clinical alternatives. A 
wide range of availability (20-80%). 
 
Carasso et al. 
(Carasso et al. 
2009) 
Availability of 
essential 
medicines in 
Ethiopia: an 
efficiency-equity 
trade-off? 
Ethiopia To determine 
availability and cost 
of essential 
medicines in rural 
health centres and 
explore if the fee 
waiver system 
protected patients 
from paying. 
Mixed 
Methods 
Data was collected from 4 rural 
primary health centres and 7 
private outlets. Availability and 
affordability of medicines 
studied through quantitative 
collection of number, price and 
type of medicines prescribed 
and dispensed upon exit 
interviews. Qualitative semi-
structured interviews looked at 
patients' experience with 
accessing medicines.  
Availability was high in 
private and public 
centres. Low 
availability was due to 
lack of qualified staff. 
Medicines were not 
always affordable to 
low income. Results 
described financial and 
social hardship on 
families who needed 
more support. 
Availability of essential medicines in a 
rural area was high (more than 80%) in 
private and public facilities, and 
highest in public centres. Where 
availability was poor (specialty 
pharmacies), facilities reported 
shortage of qualified staff. Private 
vendors were used as complementary 
services if medicines not available in 
public sector. Qualitative results 
showed patients incurred financial 
burden such as loans from 
relatives/neighbours, selling 
livestock/assets or postponing health 
visits until the illness was very serious. 
Proposed a revolving medicine fund 
for purchasing in private sector. But, 
cautioned in creating a parallel system 
that may leave medicines unavailable 
in public sector. 
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Mujinja et al. 
(Mujinja et al. 
2014) 
Local production 
of 
pharmaceuticals 
in Africa and 
access to 
essential 
medicines: "urban 
bias' in access to 
imported 
medicines in 
Tanzania and its 
policy 
implications 
 
Tanzania To describe the 
nature and benefit of 
local production to 
improve access to 
medicines 
Mixed 
Methods 
WHO/HAI price data on sources 
for 40 medicines in 96 facilities. 
Used NVivo and Stata for data 
analysis. Applied analytical 
framework of "urban bias". 
Measured price data, views on 
role of NGOs in medicine access 
Higher availability of 
locally manufactured 
than imported 
medicines in both rural 
and urban areas. 
Locally produced medicines were more 
accessible than local imports to rural 
areas.  Medicines that are locally 
produced were more available in both 
urban and rural areas than imported 
medicines. Most available medicines 
were for acute conditions. 
Nilseng et al. 
(Nilseng et al. 
2014) 
A cross-sectional 
pilot study 
assessing needs 
and attitudes to 
implementation 
of Information 
and 
Communication 
Technology for 
rational use of 
medicines among 
health care staff 
in rural Tanzania 
 
Tanzania Pilot test of new 
android program to 
assess use of 
information 
communication 
technology amongst 
health workers in 
relation to medicine 
distribution 
practices, stock-outs 
and continuing 
medical information. 
Mixed 
Methods 
Mixed Methods on new 
Android application to improve 
inventory management: 
Qualitative semi-structured 
interviews with 20 health care 
works at 13 health facilities in 2 
districts. Quantitative data 
collected on drug access 
availability and stock-outs. 
Low availability of 
essential medicines 
due to procurement 
practices. 
Severe drug shortages and stock-outs 
were the main problem with medicine 
distribution in this area. Poor access to 
medical information.  Ordering can be 
made more simple and automatic to 
improve staff capacity.  There was 
potential for technology to improve 
and simplify ordering tasks but 
required internet and electricity, as 
well as improved infrastructure and 
transportation for distribution. 
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Babar et al. 
(Babar et al. 
2013) 
The Availability, 
Pricing, and 
Affordability of 
Three Essential 
Asthma 
Medicines in 52 
Low- and Middle-
Income Countries 
Multiple 
countries 
To determine 
availability, price, 
and affordability of 
medicines likely to 
affect access to 
asthma medicines. 
Quantitative WHO/HAI surveys in 52 
countries (85%LMIC) for 3 
asthma medicines. 
Variations in pricing 
and availability even 
though listed on EML.  
Low availability of 
asthma inhalers in 
public sector, better 
availability in private 
sector, and none at all 
in some countries. 
Variations in pricing and availability 
suggest differences between countries' 
commitment to access health care. 
Low availability of inhaled 
corticosteroids and listing on EMLs. 
Salbutamol was mostly listed in EMLs, 
but had low availability in public 
sector, acceptable availability in 
private sector, but not available in 
some countries. 
 
Cameron et al. 
(Cameron et al. 
2009) 
Medicine prices, 
availability, and 
affordability in 36 
developing and 
middle-income 
countries: a 
secondary 
analysis. 
Multiple 
countries 
To describe the 
results of WHO/HAI 
surveys of 
availability, pricing 
and affordability in 
LMICs. 
Quantitative WHO/HAI surveys in 36 LMICs.  
15 medicines presented in 
results and 4 individual 
medicines. Secondary data 
analysis. 
Lower availability in 
public sector. Higher 
availability and Prices 
in private sector. 
Inappropriate use of 
EMLs.  Results 
suggested medicines 
sales may be used to 
subsidise other parts of 
the health care system 
Public sector has consistently low 
availability due to variations in 
products in EML and poor compliance 
with recommendations. Low 
availability in public sector due to 
inadequate funding, lack of incentives 
for maintaining stocks, inability to 
forecast accurately, inefficient 
distribution systems, or leakage of 
medicines for private resale. 
Availability in private sector was high 
comparably with higher prices. Low 
public procurement costs suggest 
some public facilities are using the 
medicine sales to subsidise other parts 
of the health care system. 
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Cameron et al. 
(Cameron et al. 
2011) 
Differences in the 
availability of 
medicines for 
chronic and acute 
conditions in the 
public and private 
sectors of 
developing 
countries 
 
Multiple 
countries 
To investigate 
potential differences 
in the availability of 
medicines for chronic 
and acute conditions 
in LMICs. 
Quantitative WHO/HAI surveys for 15 acute 
and 15 chronic medicines in 40 
developing countries. 
Low availability in both 
public and private 
sectors. Medicines are 
more available for 
acute than chronic 
conditions. 
Results show a gap in access, in which 
generic medicines for chronic 
conditions have significantly less 
availability than acute conditions, in 
both public and private sectors. 
Cameron et al. 
(Cameron et al. 
2012) 
Mapping the 
availability, price 
and affordability 
of antiepileptic 
drugs in 46 
countries 
Multiple 
countries 
To describe 
availability, price and 
affordability of 
antiepileptic drugs 
and whether these 
factors contribute to 
treatment gaps. 
Quantitative WHO/HAI surveys in 46 LMICs. 
Secondary data analysis. 5 
antiepileptic drugs (phenytoin, 
carbamazepine, valproic acid, 
Phenobarbital, and diazepam). 
Low availability and 
affordability (higher 
prices) of antiepileptic 
medicines. 
Low Availability of antiepileptic 
medicines in LMIC, less than 50% 
except for diazepam injections. 
Generic prices in LMICs were higher 
than international reference prices in 
both public and private sectors. This 
may act as a barrier to accessing 
treatment for epilepsy. 
 
Hill et al. 
(Hill et al. 2012) 
Priority Medicines 
for Maternal and 
Child Health: A 
Global Survey of 
National Essential 
Medicines Lists 
Multiple 
countries 
To examine the 
occurrence of 
maternal and child 
health medicines on 
EMLs. 
Quantitative Comparison of WHO List of 
priority medicines for mothers 
and children with 89 country 
EMLs for 28 pharmaceuticals in 
41 dosage forms. 
Poor availability of 
essential medicines 
and inappropriate use 
of WHO EML due to 
low inclusion on EML. 
There was a lot of 
variation between EML 
and WHO EML list. 
Many priority medicines are still not 
listed, making it difficult for policies to 
achieve MDGs. There was variation 
between lists. Recent updates 
promoted higher probability for 
inclusion of priority medicines. 
Paracetamol, oral rehydration salts 
sodium chloride and gentamicin most 
frequently listed (93%). Least 
frequently listed were anti-malarials, 
and injectable and rectal formulations. 
Half the lists had magnesium sulfate. 
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Only 1/4 of lists had been updated 
recently (in last 5 years), and were 
more likely to include misoprosotol, 
zinc, cefixime, nifedipine. 
 
Mendis et al. 
(Mendis et al. 
2007) 
The availability 
and affordability 
of selected 
essential 
medicines for 
chronic diseases 
in six low- and 
middle-income 
countries 
Multiple 
countries 
To assess the 
availability and 
affordability of 
medicines used to 
treat chronic disease. 
Quantitative WHO/HAI surveys in 6 LMICs: 
Brazil, Pakistan, Sri Lanka, 
Bangladesh, Malawi, Nepal.  32 
medicines to treat 
cardiovascular disease, 
diabetes, chronic respiratory 
disease, glaucoma, and 
palliative cancer care. 
Poor availability and 
affordability of EML 
listed medicines. 
Private more 
availability than public 
sector but both still 
poor. 
Cost of brand up to 10 times higher 
than generic medicines. Medicines are 
free in public sector, but their 
availability was poor.  Stock-outs may 
be due to poor estimates or 
consumption and cash-flow 
constraints. If patients cannot afford 
medicines, will forego treatment. 
Private more than public availability 
but still poor. Poor availability of most 
inexpensive drugs (e.g. HCTZ).  
Moon et al. 
(Moon et al. 
2011) 
A win-win 
solution?: A 
critical analysis of 
tiered pricing to 
improve access to 
medicines in 
developing 
countries 
Multiple 
countries 
To examine how 
tiered pricing can  
make medicines 
affordable in LMICs, 
determines who 
should pay for R&D, 
and determine who 
and how pricing is 
decided. 
Quantitative Case studies of ARVs for 
HIV/AIDS, ACT for malaria, 
drug-resistant tuberculosis 
drugs, drugs for visceral 
leishmaniasis, and the 
pneumococcal vaccine.  Used 
international tiered pricing to 
measure affordability of 
medicines (impoverishing effect 
of a medicine). 
Affordability can be 
improved short term 
through tiered pricing. 
Tiered pricing offered short term 
access to products. It does not ensure 
affordability and availability in the 
long-term. In some cases, tiered 
pricing resulted in lower prices than 
competitive production. Tiered pricing 
lowered prices to improve access 
when markets were small, highly 
uncertain, production capacity limited 
and demand low. 
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Niens et al. 
(Niëns et al. 
2010) 
Quantifying the 
impoverishing 
effects of 
purchasing 
medicines: A 
cross country 
comparison of the 
affordability of 
medicines in the 
developing world 
Multiple 
countries 
To estimate the 
impoverishing effects 
of 4 medicines in 16 
LMICs using the 
impoverishment 
method to measure 
affordability. 
Quantitative Measured affordability based 
on proportion of a population 
that would be pushed below a 
poverty line by the purchase of 
a medicine. 4 medicines were 
studied. 
Affordability of 
medicines was 
considered in relation 
to how close they were 
to the poverty line. 
Considered the 
prevalence of disease 
and inability to fund 
medicines. 
Analysed medicine prices, aggregated 
income data, and information on 
income distribution. Showed relative 
impact of medicine purchase in 
relation to proportion of the 
population above/below the poverty 
line before and after medicine 
purchase. Showed that essential 
medicines were unaffordable when 
compared against the poverty line of 
US$1.25 and US$2. Considered price of 
medicines and prevalence rate of 
disease in country. 
 
Niens et al. 
(Niens et al. 
2012) 
Practical 
Measurement of 
Affordability: an 
application to 
medicines 
Multiple 
countries 
To develop two 
practical methods for 
measuring the 
affordability of 
medicines in 
developing countries. 
Quantitative Looked at 2 methods of 
measuring affordability: 1) 
Catastrophic Approach: Ratio of 
expenditures to total household 
resources, and 2) 
Impoverishment Approach: 
Residual income after 
expenditure. 
Affordability of 
medicines considered 
results of out of pocket 
expenditure on low 
income households. 
Should be considered 
in how affordability is 
measured in other 
studies. 
Used ratio of expenditures to total 
household resources and residual 
income after expenditure. Compared 
"catastrophic" with "impoverishment" 
approaches. Considered price of 
treatment of a medicine, a country's 
total population, the aggregate income 
level of a country and proportion of 
the total income earned across income 
groups. Macro and Micro data were 
illustrated. 
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Srivastava & 
McGuire  
(Srivastava and 
McGuire 2014) 
Analysis of prices 
paid by low-
income countries 
- how price 
sensitive is 
government 
demand for 
medicines? 
Multiple 
countries 
To explore the 
variation in 
pharmaceutical 
prices and price 
mark-ups, to 
investigate the price 
sensitivity at the 
government level 
and compute price 
elasticity for sales to 
government 
purchasers, analyse 
relationship between 
estimated price 
elasticity and income. 
 
Quantitative WHO/HAI surveys data from 16 
low income countries of 48 
branded medicines in 18 
therapeutic classes. 
Affordability of 
medicines was difficult 
to determine due to 
price elasticity and 
variation between 
therapeutic classes. 
Prices were variable between 
therapeutic classes. 
Van Mourik et 
al. 
(van Mourik et 
al. 2010) 
Availability, Price 
and Affordability 
of Cardiovascular 
medicines: A 
comparison 
across 36 
countries using 
WHO/HAI data 
Multiple 
countries 
To examine 
availability, pricing, 
and affordability of 
cardiovascular 
medicines in 
developing countries. 
Quantitative WHO/HAI surveys in 36 LMICs. 
Cardiovascular medicines 
(atenolol, captopril, losartan, 
hydrochlorothiazide, 
nifedipine). 
Low availability of 
cardiovascular 
medicines. Private 
more than public 
sector but both still 
poor. 
Low availability of lowest priced 
generic in public sector. Private sector 
had better availability for all medicines 
generic and brands. High income 
regions had better availability than low 
income regions. In high income areas, 
low availability of generic but had high 
availability of brands. Poor availability 
of public sector may mean patients 
must resort to higher priced private 
sector to access treatment. 
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Wagner et al. 
(Wagner et al. 
2011) 
Access to care 
and medicines, 
burden of 
healthcare 
expenditures, and 
risk protection: 
Results from the 
World Health 
Survey 
 
Multiple 
countries 
To assess the 
contribution of 
health insurance and 
a functioning public 
sector to access care 
and medicines on 
household economic 
burden. 
Quantitative World health survey analysed 
on medicine expenditure in 70 
countries. Analysed using 
logistic regression models. 
Households in LMICs 
mostly purchased 
medicines from private 
sector. There was poor 
public perception and 
low  availability and 
quality of medicines in 
the public sector. 
A functioning public sector was related 
to better healthcare access and lower 
burden of expenditures.  The 
perceived and actual availability and 
quality of medicines in the public 
sector were low, fees were high, and 
waiting caused additional opportunity 
costs. 
Carapinha et al. 
(Carapinha et 
al. 2011) 
Health insurance 
systems in five 
Sub-Saharan 
African countries: 
Medicine benefits 
and data for 
decision making 
Multiple 
countries in 
Africa 
To describe the 
structure of medicine 
benefits and data 
routinely available 
for decision making. 
Quantitative Survey to assess program 
structure, medicine benefits 
and data routinely available for 
decision making in 33 health 
insurance programs in Ghana, 
Kenya, Nigeria, Tanzania and 
Uganda. 
Affordability and 
availability of 
medicines required 
data monitoring of key 
elements and 
resources. 
Strategies used were common in high 
income countries (e.g.. formularies, 
generics policies, reimbursement 
limits, or price negotiations). Basic 
data to monitor performance in 
delivering medicine benefits were 
available in most programs; however, 
some key elements and resource data 
was missing. Identified need to 
investigate: 1) most effective 
medicines policy choices due to 
different organisation structures, 2) 
impacts of benefits design on quality 
and affordability of care on health 
outcomes, and 3) a way to facilitate 
use of routine data for monitoring. 
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Robertson et al. 
(Robertson et 
al. 2009) 
What essential 
medicines for 
children are on 
the shelf? 
Multiple 
countries in 
Africa 
To document the 
inclusion of key 
medicines for 
children in EMLs and 
STGs, and to assess 
the availability and 
cost of these 
medicines. 
Quantitative Audit Survey of availability and 
cost of medicines in 20 dosage 
forms for children in 14 African 
countries. 
Appropriate use of 
EML was poor due to 
lack of inclusion on 
local STGs. Low 
availability and poor 
procurement of 
essential medicines. 
Medicines in EMLs were not included 
in local STGs. Conversely, all medicines 
on STGs not included in EML. Although 
CMS stocked essential medicines, they 
were not always available. Half the 
medicines on EML/STG were available 
in surveyed facilities. Variation in 
availability of priority disease 
medicines. Existence of vertical 
programmes for these priority diseases 
may mean that the medicine supply is 
not coordinated with standard supply 
chains in these countries. 
 
Jiang et al. 
(Jiang et al. 
2013) 
Measuring Access 
to Medicines: A 
Survey of Prices, 
Availability and 
Affordability in 
Shaanxi Province 
of China 
 
 
 
China To measure price and 
availability of 
selected medicines 
after health care 
reform in 2009. 
Quantitative WHO/HAI surveys. 47 
medicines from 50 public and 
36 private outlets. Measured 
price and availability. 
Low availability in both 
public and private 
sectors. Unaffordable 
for those with low 
income. 
Availability was low in both public and 
private sectors. High mark-up prices 
were associated with both generic and 
brand medicines. Wide range of prices. 
Medicines can still be unaffordable to 
those with low income. 
Wang et al. 
(Wang et al. 
2014) 
Access to 
Paediatric 
Essential 
Medicines: A 
survey of prices, 
availability, 
affordability and 
China To evaluate prices 
and availability of 
paediatric essential 
medicines. 
Quantitative WHO/HAI surveys. 28 paediatric 
medicines from 30 outlets 
including hospitals. Measured 
price and availability. 
Very low availability of 
EML medicines in both 
public and private 
sectors. Medicines 
were reasonably 
affordable. 
Availability was found to be very low in 
public and private sectors. General 
affordability was found to be 
reasonable. 
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price components 
in Shaanxi 
Province, China 
 
Yang et al. 
(Yang et al. 
2010) 
Prices, availability 
and affordability 
of essential 
medicines in rural 
areas of Hubei 
Province, China 
 
China To determine 
availability of 
essential medicines 
in Hubei province. 
Quantitative WHO/HAI surveys. 39 
medicines from 18 public and 
18 private outlets in rural 
mountainous China. Measured 
price and availability. 
Low availability of EML 
listed medicines in 
public and private 
sector, not affordable 
for low income. 
Low procurement prices and 
availability in public sector. Medicine 
prices were affordable to most of the 
population, but not for low income. 
Zhu et al. 
(Zhu et al. 
2008) 
The influence of 
health insurance 
towards accessing 
essential 
medicines: The 
experience from 
Shenzhen labour 
health insurance 
 
China To evaluate the 
impact of the new 
Shenzhen labour 
health insurance on 
accessing essential 
medicines among 
migrant workers. 
Quantitative Data obtained from medicines 
data base, and revenue 
expenditure reports from 
community health service 
centres. 
EML improved 
affordability and 
availability when 
applied to 
reimbursement lists for 
insurance schemes. 
Essential medicines made up a 
majority of the reimbursement list for 
the health insurance scheme, and 
procurement for outpatients was 
increasing, yet still not high. 
Babar et al. 
(Babar et al. 
2007) 
Evaluating Drug 
Prices, 
Availability, 
Affordability, and 
Price 
Components: 
Implications for 
Access to Drugs in 
Malaysia 
 
Malaysia To evaluate medicine 
prices, availability, 
affordability, and 
structure of price 
components. 
Quantitative WHO/HAI surveys for pricing, 
availability and affordability for 
48 medicines in public and 
private sectors 
Low availability of free 
essential medicines in 
public sector. 
Availability of free essential medicines 
in the public sector was very low. Price 
mark-ups for generics were higher 
than brands. 
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Saleh & Ibrahim  
(Saleh and 
Ibrahim 2005) 
Are essential 
medicines in 
Malaysia 
accessible, 
affordable and 
available? 
Malaysia To assess whether 
people in Malaysia 
had access to 
essential medicines. 
Quantitative WHO/HAI surveys for pricing, 
availability and affordability for 
13 medicines in public and 
private sectors. Measured 
availability, prices and 
prevalence of stock-outs of 
dispensed medicines. 
High affordability and 
availability of 
medicines through 
public sector, but not 
affordable in private 
sector. Rural areas had 
less availability. 
 
The majority of the population in 
Malaysia have access to essential 
medicines through public sector. 
Private sector medicines are not 
affordable. Access in rural areas was 
still a problem. 
 
Akaleephan et 
al. 
(Akaleephan et 
al. 2009) 
Extension of 
market exclusivity 
and its impact on 
the accessibility 
to essential 
medicines, and 
drug expense in 
Thailand: Analysis 
of the effect of 
TRIPs-Plus 
proposal 
 
Thailand To quantify the 
impact of market 
exclusivity and its 
impact on medicine 
expense and 
accessibility. 
Quantitative Data obtained between 2000-
2003 from the Thai FDA and 
drug and medical supply 
information centre. Generic and 
brand medicine prices and 
quantities were compared. 
The TRIPs agreement 
would make medicines 
unaffordable. 
TRIPs-Plus proposal would result in 
significant increase in medicine 
expenditure and delay access to 
generics. 
Burapadaja et 
al. 
(Burapadaja et 
al. 2007) 
Effects of 
essential 
medicines on 
cardiovascular 
products 
available for the 
market in 
Thailand 
 
Thailand To examine if the 
EML concept affects 
the patterns and 
values of 
cardiovascular 
products available on 
the market in 
Thailand. 
Quantitative Cross-sectional study of generic 
cardiovascular medicines 
available from national Thai 
EML. Comparison with Thai FDA 
and Thailand Index of Medical 
Specialties. Analysed with 
descriptive statistics and simple 
regression. 
EML improved 
availability of generic 
cardiovascular 
essential medicines. 
There was a greater proportion of 
essential medicines products with 
more generics available than non-
essential medicines. Domestic 
production was greater than foreign 
producers. Demonstrated advantages 
to using EML to promote generics and 
guide procurement. 
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Burapadaja & 
Chinawong  
(Burapadaja 
and Chinawong 
2010) 
Response of a 
government 
hospital to 
prescription cost 
savings through 
its hospital 
formulary in 
Thailand 
Thailand To determine a 
measure reflecting 
the response of a 
government hospital 
to prescription cost 
savings by looking at 
hospital formularies 
and additions to it. 
Quantitative Thai EML was compared to a 
hospital formulary. 
EML improved 
appropriate use, 
availability and 
lowered cost of 
medicines. 
There were more essential medicines 
on the formulary than non-EMs which 
influenced prescribing with generics to 
lower costs.  Broad price range was 
evident for single availability of generic 
or brand drugs, while dual availability 
(have both generic & brand) narrowed 
the price. Prescription cost savings 
were demonstrated by high proportion 
of essential medicines prescribed off 
the formulary. 
 
Gitanjali & 
Manikandan  
(Gitanjali and 
Manikandan 
2011) 
Availability of five 
essential 
medicines for 
children in public 
health facilities in 
India: A snapshot 
survey 
 
India To describe 
availability of 5 
paediatric essential 
medicines in public 
health facilities in 
India. 
Quantitative Snapshot survey for 5 
paediatric medicines in 129 
health facilities. 
Average availability of 
paediatric medicines in 
private sector and very 
low in public sector. 
There was a reasonable availability of 
most paediatric medicines, except zinc 
sulphate which still had very low 
availability in the public sector (36%). 
Kotwani et al. 
(Kotwani et al. 
2007) 
Prices and 
Availability of 
common 
medicines at six 
sites in India 
using a standard 
methodology 
 
India To measure price and 
availability of 
medicine in public 
and private sectors. 
Quantitative WHO/HAI surveys. 27 
medicines at 6 sites 
Low availability and 
affordability in public 
sector. 
Public sector had low procurement 
prices and poor availability of 
medicines. 
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Kotwani A 
(Kotwani 2013) 
Where are we 
now: Assessing 
the price, 
availability and 
affordability of 
essential 
medicines in Delhi 
as India Plans free 
medicine for all 
 
India To determine price, 
availability and 
affordability of 
essential medicines 
in public and private 
sectors in Delhi, 
India. 
Quantitative WHO/HAI surveys. 50 
medicines in public and private 
sectors in Delhi. 
Low availability or 
medicines despite cost 
sharing policies. 
Cost sharing was not seen to have 
improved the quality of care or 
availability of medicines. The medicine 
supply chain was seen as unreliable; 
thus, the high fees seemed unfair. 
Cheraghali et 
al. 
(Cheraghali et 
al. 2004a) 
Evaluation of 
availability, 
accessibility and 
prescribing 
pattern of 
medicines in the 
Islamic Republic 
of Iran 
Iran To evaluate 
prescribing, 
dispensing, 
availability and 
affordability of 
essential medicines, 
and the availability of 
health information. 
Quantitative WHO/HAI surveys. 12 
medicines, in 100 primary 
health care centres in 5 
provinces. 
Average to high 
affordability and 
availability in public 
sector. Inappropriate 
use of EML shown 
through poor 
adherence to STGs and 
high use of antibiotics. 
 
Essential medicines are generally 
available (60-95%) and affordable 
(85% subsidised) in public sector. But 
long periods of stock outs (e.g. average 
29 days). Very low adherence to STGs. 
Dabare et al. 
(Dabare et al. 
2014) 
A national survey 
on availability, 
price and 
affordability of 
selected essential 
medicines for non 
communicable 
diseases in Sri 
Lanka 
 
Sri Lanka To determine 
availability, price and 
affordability of non 
communicable 
diseases. 
Quantitative WHO/HAI surveys. 50 
medicines at 9 sites. Total 109 
surveys. Measured price and 
availability. 
High availability and 
affordability of 
essential medicines in 
both public and private 
sectors. 
Most medicines were available in both 
public and private sectors. Generic 
medicines were affordable to lowest 
income earners. 
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Ganga 
Senarathna et 
al. 
(Ganga 
Senarathna et 
al. 2011) 
 
Medicine prices, 
availability and 
affordability in Sri 
Lanka 
Sri Lanka To determine the 
prices, availability, 
and affordability of 
medicines in the Sri 
Lankan private sector 
without price 
controls. 
Quantitative WHO/HAI surveys. 28 
medicines at 15 sites. 
High availability and 
affordability of generic 
medicines in private 
sector. 
Low cost generics of essential 
medicines were highly available (more 
than 80%) in private sector. 
Cheraghali & 
Idries  
(Cheraghali and 
Idries 2009) 
Availability, 
affordability, and 
prescribing 
pattern of 
medicines in 
Sudan 
Sudan To address gaps 
arising from multi-
tier medicine 
assessment 
processes and how 
these issues are dealt 
with. 
Quantitative WHO/HAI surveys. 15 
medicines in 36 health facilities, 
in 6 geographic regions. 
Generally high 
affordability and 
availability in public 
sector. Inappropriate 
use of EML shown 
through poor 
adherence to STGs for 
diarrhoea and malaria, 
and high use of 
antibiotics. 
 
Essential medicines are generally 
available in the public sector. Low 
adherence to STGs for diarrhoea and 
malaria. 
Mouala et al. 
(Mouala et al. 
2009) 
Essential 
medicines and 
access to primary 
health care in the 
medical district of 
Mambere-Kadei 
 
Central 
African 
Republic 
To assess if people 
had access to 
medicines in primary 
healthcare settings. 
Quantitative WHO/HAI surveys. 14 generic 
medicines in 14 public health 
care centres, in central African 
republic. 
Average availability 
and affordable of 
generic medicines. Low 
affordability for those 
with low income. 
Reasonable availability and 
affordability of generic essential 
medicines in this district. Still 
unaffordable to the very poor. 
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Maiga & 
Williams-Jones  
(Maiga and 
Williams-Jones 
2010) 
Assessment of 
the impact of 
market regulation 
in Mali on the 
price of essential 
medicines 
provided through 
the private sector 
 
Mali To assess the impact 
of the 2006 
government decree 
on the evolution of 
market prices, 
availability and 
access to essential 
medicines in Mali. 
Quantitative Cross-sectional descriptive 
study of 49 medicines in 16 
wholesalers and 30 private 
drugstores. Assess availability 
and prices of medicines to 
evaluate fixed maximum pricing 
policy in the private sector. 
Lowering prices was 
not shown to increase 
availability of essential 
medicines. 
No change to availability of medicines 
before and after maximum medicine 
pricing policy. Prices of medicines 
were decreased. Unable to show that 
market regulation had a negative 
impact on availability. 
Mikkelsen-
Lopez et al. 
(Mikkelsen-
Lopez et al. 
2014) 
Essential 
medicines in 
Tanzania: Does 
the new delivery 
system improve 
supply and 
accountability? 
Tanzania To assess if reform of 
the Tanzanian 
delivery system from 
a central "push" kit 
system to a 
decentralized 'pull' 
integrated logistics 
system has improved 
medicines 
accountability. 
 
Quantitative Inventory data was collected 
using the push kit system and 
applied inventory ordering 
program. Compared 11 
medicines in 6 health facilities 
in Rufiji district in coastal south 
east Tanzania. 
Could not determine if 
inventory program was 
able to improve 
availability of 
medicines or 
accountability by 
suppliers. 
No uniform improvements in 
availability, no increased 
accountability due to uncertainty, 
incompleteness and inaccuracies of 
available information. Needed to 
reconcile demand of medicines with 
supply to improve accountability of 
resources. 
Bertoldi et al. 
(Bertoldi et al. 
2008) 
Medicine access 
and utilization in 
a population 
covered by 
primary health 
care in Brazil 
Brazil To describe medicine 
utilisation and access 
in the population. 
Quantitative Cross sectional, survey 
structured interviews with 2988 
subjects living in one Brazilian 
city on their medicine use in the 
previous 15-day period. 
Described medicine utilisation 
patterns, evaluated access to 
medicines, and assessed 
proportion of medicines 
obtained at no charge. 
 
High availability of 
medicines, but many 
paid out of pocket. 
68% with low income 
received medicines for 
free but 26% paid out 
of pocket. Poor local 
use of EML. 
Generally, there was good access to 
medicines. Small proportion of people 
unable to obtain their medicines, and 
half were able to get it for free. 80% of 
essential medicines were not included 
on the municipal basic medicines list. 
Poor local use of EML. 
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Bertoldi et al. 
(Bertoldi et al. 
2012) 
Is the Brazilian 
pharmaceutical 
policy ensuring 
population access 
to essential 
medicines? 
Brazil To evaluate medicine 
availability, price, 
and affordability in 
Brazil across 3 types 
of medicines: 
originator brands, 
generics, or similar 
medicines (brand 
generics). 
Quantitative WHO/HAI surveys. 50 
medicines in 56 pharmacies 
across 6 cities in southern 
Brazil. 
Moderate availability 
but low for poorer 
regions. Affordability 
was high for generics 
in public sector and 
lower in private sector. 
Moderate access to medicines in all 
cities (69% in public, 74% in private), 
but poorer access than other regions 
of Brazil. Only generics found in public 
sector facilities. Generics were 
approximately half the price of 
originator brands, but there were still 
cases of unavailable essential 
medicines, and out of pocket 
purchases at private vendors. 
 
Santos Pinto et 
al. 
(Santos Pinto et 
al. 2010) 
Medicine prices 
and availability in 
the Brazilian 
Popular Pharmacy 
Program 
Brazil To analyse the 
performance of the 
Brazilian Popular 
Pharmacy Program in 
the public and 
private sectors via 
availability and cost 
of medicines treating 
hypertension and 
diabetes. 
Quantitative WHO/HAI surveys. 4 medicines 
in 30 cities. 
Reimbursement 
program with "co-
payments" had higher 
availability of essential 
medicines than both 
public and private 
sectors and shown to 
be affordable. People 
turn to alternative 
programs due to Low 
availability of public 
sector and high prices 
of private sector. 
Reimbursement program with "co-
payments" had higher availability than 
both public and private sectors and 
shown to be affordable. People turn to 
alternative programs due to Low 
availability of public sector and high 
prices of private sector. 
Anson et al. 
(Anson et al. 
2012) 
Availability, prices 
and affordability 
of the WHO’s 
essential 
medicines for 
children in 
Guatemala 
Guatemala To measure 
availability, price and 
affordability of 
children's medicines 
in Guatemala. 
Quantitative WHO/HAI surveys. 27 
medicines and 1 device, in 
urban and rural areas, in 50 
outlets 
Lower availability of 
children’s formulations 
in public than private 
sector. Lower medicine 
availability for chronic 
than acute conditions. 
Generally, unaffordable, low 
availability of children’s formulations, 
lower availability of essential 
medicines in public than private 
sector, and lower for chronic 
conditions than acute conditions. 
139 
 
Table B2: Availability and Affordability of Medicines Study Comparison 
Author Title Country Objective Type of 
Study 
Study Design How does it relate to 
EML 
Comments 
Madden et al. 
(Madden et al. 
2010) 
 
Measuring 
Medicine Prices in 
Peru: Validation 
of key aspects of 
WHO/HAI survey 
methodology 
Peru To assess possible 
bias due to the 
limited target list and 
geographic sampling 
of the WHO/HAI 
Medicines Prices and 
Availability survey 
used in >70 countries 
since 2001.  
Quantitative Validate WHO/HAI surveys. 
Addressed bias due to small 
sample of purposely selected 
facilities (excluded remote 
areas), specific case types of 
therapeutic classes, and 
restriction of data collection of 
originator brand and lowest 
priced generic products. Study 
included 38 medicines, 
rural/remote centres -52 public, 
96 private. Medicine prices 
included in 3 expanded 
therapeutic classes with all 
product versions. Availability 
measured by physical presence 
in an outlet at time of survey. 
Price per unit recorded in local 
currency in recommended pack 
size. Affordability measured by 
comparing lowest paid 
government worker wage with 
treatment cost/month/episode. 
 
EML products had 
similar low availability, 
better affordability in 
public sector due to 
lower public prices due 
to generic use, and 
higher retail prices. 
There were no 
statistically significant 
differences in rural and 
urban regions in this 
study due to sufficient 
distribution systems. 
Use of comprehensive global data 
across WHO member countries for 
select therapeutic classes to assess 
country versus WHO EML price, 
relative affordability and availability. 
Compared median retail prices with 
wholesale prices from IMS data. 
Validation study showed no 
statistically significant difference in 
bias. The WHO/HAI Prices and 
Availability survey can play an 
important role for advocacy for 
pharmaceutical policy in LMICs. 
ACT-Artemisinin-based Combination Therapy; ARV-Antiretroviral Therapy; CMS-Central Medical Stores; EML-Essential Medicines List; FDA-Food and Drug Administration; HCTZ-
Hydrchlorothiazide; LMIC-low to middle income country; MDG-Millennium Development Goals;  NGO-Non-governmental Organisation; R&D-Research and Development; STG-Standard 
Treatment Guideline; TRIPS-Trade Related  Aspects of International Property Rights; WHO-World Health Organization; WHO/HAI-World Health Organization Health Action International; 
WHO EML- World Health Organization Model List of Essential Medicines. 
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Table B3: Quality of Medicines Study Comparison  
 
Author Title Country Objective Type of 
Study 
Study Design How does it relate to 
EML 
Comments 
Caudron et al. 
(Caudron et al. 
2008) 
Substandard 
medicines in 
resource-poor 
settings: a 
problem that can 
no longer be 
ignored 
Multiple 
countries 
To describe key 
concerns to assure 
quality of medicines 
in relief programmes 
in LMICs. 
Literature 
Review 
Pubmed plus bibliographic 
literature search. 
Quality of essential 
medicines has been 
susceptible to 
substandard and 
counterfeit products 
due to lack of 
standardisation in 
regulation and 
resources to address 
the problem. 
 
LMICs are vulnerable to substandard 
medicines due to lack of standardised 
regulation and lack of resources by 
regulatory agencies in these countries 
to address the problem. 
Wilson et al. 
(Wilson et al. 
2012) 
The make or buy 
debate: 
Considering the 
limitations of 
domestic 
production in 
Tanzania 
Tanzania To examine the 
"make or buy" 
dilemma and critical 
limitations of 
domestic 
manufacturing 
through Tanzania 
case study of ARVs. 
Qualitative Qualitative semi structured 
interviews with key informants, 
observation and review of 
documents. 
Quality and availability 
of essential medicines 
can be improved by 
building local 
manufacturing 
capacity. 
There is a lack of coherent policy 
strategy to develop the 
pharmaceutical industry and 
manufacturing. Required improved 
capacity building and incentives. 
Khan et al. 
(Khan et al. 
2011) 
Perceptions and 
practices of 
pharmaceutical 
wholesalers 
surrounding 
counterfeit 
medicines in a 
developing 
country: a 
baseline survey 
Cambodia To investigate the 
risk of counterfeit 
medicines in the 
Cambodian medicine 
supply chain. 
Mixed 
Methods 
Quantitative cross sectional 
surveys. Qualitative semi-
structured interviews with 62 
wholesalers around counterfeit 
issues, observational data of 
warehouses. 
Quality of essential 
medicines was not 
reinforced at the 
wholesaler level. 
Most wholesalers were not properly 
informed on counterfeit medicines 
issues and how to handle these 
situations. 
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Table B3: Quality of Medicines Study Comparison  
 
Author Title Country Objective Type of 
Study 
Study Design How does it relate to 
EML 
Comments 
Patel et al. 
(Patel et al. 
2012) 
Quality of generic 
medicines in 
South Africa: 
Perceptions 
versus Reality - A 
qualitative study 
Tanzania To describe the 
process of updating 
STGs and EMLs with 
consideration of 
criteria and 
underlying evidence 
used in decision 
making. 
Mixed 
Methods 
Qualitative semi-structured 
interviews with 15 healthcare 
providers and 12 consumer 
focus groups. 135 products 
from public and private sector 
tested in vitro for quality. 
Poor understanding of 
what warrants quality 
medicines can impact 
appropriate use and 
availability of 
affordable generics. 
All formulations passed the in vitro 
test. Poor and variable 
understanding/misconception of what 
quality was (confused with efficacy, 
side effects, recognisable, reputation, 
brand image, trust). Need for 
improved education and consumer 
and healthcare provider engagement 
to address needs and information on 
medicines. 
Nakyanzi et al. 
(Nakyanzi et al. 
2010) 
Expiry of 
medicines in 
supply outlets in 
Uganda 
Uganda To determine main 
contributing factors 
to expiry of 
medicines in 
medicine supply 
outlets in Uganda. 
Mixed 
Methods 
Quantitative cross sectional 
surveys. Qualitative semi 
structured questionnaires with 
13 closed questions on expiry. 
One participant from each of 
the 38 sites was interviewed. 
Poor quality medicines 
take up shelf space but 
cannot be given to 
consumers. Therefore, 
the availability of 
medicines was lowered 
due to waste of 
expired medicines. 
Medicines were prone to expiry if used 
for vertical programs, donated, or had 
slow turnovers. While bulk purchasing 
can improve negotiated prices for 
medicines, it can lead to overstocking 
and exacerbate expiry and waste. 
Need for improved coordination and 
implications or logistics feasibility of 
lean supply and stock rotation. 
 
Lauffenburger 
et al. 
(Lauffenburger 
et al. 2011) 
A public-health 
approach to site 
specific formulary 
management: 
addressing 
deficient drug 
supplies in 
Malawi 
 
Malawi To assess and 
address deficiencies 
in a clinic's medicine 
supply using 
formularies. 
Quantitative Conducted in NPOs supporting 
orphans and community. 
Inventory compared to clinic 
logbooks and WHO EML. Prices 
compared in local medicine 
stores and wholesalers. 
Inappropriate use of 
EML and expiry 
contributing to 
lowered availability of 
essential medicines. 
High proportion (over half) of expired 
stock, many medicines not generally 
prescribed. Need to use a formulary 
for targeted international donations 
when resources are limited. 
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Table B3: Quality of Medicines Study Comparison  
 
Author Title Country Objective Type of 
Study 
Study Design How does it relate to 
EML 
Comments 
Bevilacqua et al. 
(Bevilacqua et 
al. 2011) 
Procurement of 
generic medicines 
in a medium size 
municipality 
Brazil To analyse the 
financial impact of 
medicine 
procurement with 
the required 
bioavailability and or 
bioequivalence tests 
for the basic 
pharmaceutical 
services component. 
Quantitative Retrospective study. Looked at 
competitive procurement bids 
that occurred with (2007) and 
without (2008) the requirement 
of bioequivalence and/or 
bioavailability tests were 
analysed. 
To keep medicine 
prices affordable and 
available, quality of 
medicines have been 
compromised and 
allowed to stay in the 
system. Therefore, 
there are poor quality 
medicines offered at 
cheap prices. 
In 2007 and 2008 respectively, 2.6% 
and 56.9% of items failed to pass tests. 
Medicine purchases increased 60% for 
some and decreased 29.3% for others. 
Procurement costs doubled. Bio-
equivalency/availability tests increased 
costs by more than 100%. Due to the 
high percentage of failed items, a third 
bidding process was necessary for 
which the bioavailability and/or 
bioequivalence tests were not 
required due to the risk of catastrophic 
stock-outs in the health system. 
ARV-Antiretroviral Therapy; EML-Essential Medicines List; LMIC-low to middle income country; NPO-Non-Profit Organisation; STG-Standard Treatment Guideline;  WHO EML- World Health 
Organization Model List of Essential Medicines
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Appendix C - Ethics Approval (chapter 2,3) 
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Appendix D - Participant Information statement for research (chapter 2,3) 
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Appendix E - Participant Consent form for participation in research,(chapter 
2,3) 
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Appendix F - Coreq 32 check list (chapter 2,3) 
 
Consolidated criteria for reporting qualitative studies (COREQ): 
32-item checklist 
 
Developed from: 
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 
32-item checklist for interviews and focus groups. International Journal for Quality in Health Care. 
2007. Volume 19, Number 6: pp. 349 – 357 
 
 
No.  Item  
 
Guide questions/description Reported on Page # 
Domain 1: Research 
team and reﬂexivity  
  
Personal Characteristics    
1. Interviewer/facilitator Which author/s conducted the 
interview or focus group?  
Mai Duong 
2. Credentials What were the researcher’s 
credentials? E.g. PhD, MD  
Mai Duong,  
BSc.Pharm,BHSc(Hons), 
RPh, M.Phil Candidate 
 
Rebekah J. Moles,  
PhD,DipHPharm,BPharm, 
Senior Lecturer 
 
Betty Chaar,  
PhD,MHL,BPharm, 
Senior Lecturer 
 
Timothy F. Chen,  
PhD,DipHPharm,Pharm, 
MPS,MSHP,Associate 
Professor 
 
3. Occupation What was their occupation at the time 
of the study?  
Pharmacist, M.Phil 
student, Teaching 
Assistant 
4. Gender Was the researcher male or female?  Female  
5. Experience and 
training 
What experience or training did the 
researcher have?  
Methods - 
The researcher gathered 
data from hospital 
interviews in Costa Rica 
in a study at the 
University of Toronto in 
2006. She participated in 
ACSPRI qualitative 
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research methods 
training courses in 
Australia in 2013.  
Relationship with 
participants  
  
6. Relationship 
established 
Was a relationship established prior to 
study commencement?  
No 
7. Participant knowledge 
of the interviewer  
What did the participants know about 
the researcher? e.g. personal goals, 
reasons for doing the research  
Participant information 
sheet and Consent Form  
8. Interviewer 
characteristics 
What characteristics were reported 
about the interviewer/facilitator? e.g. 
Bias, assumptions, reasons and 
interests in the research topic  
Methods 
Domain 2: study design    
Theoretical framework    
9. Methodological 
orientation and Theory  
What methodological orientation was 
stated to underpin the study? e.g. 
grounded theory, discourse analysis, 
ethnography, phenomenology, 
content analysis  
Methods 
Participant selection    
10. Sampling How were participants selected? e.g. 
purposive, convenience, consecutive, 
snowball  
Methods 
11. Method of approach How were participants approached? 
e.g. face-to-face, telephone, mail, 
email  
Methods 
12. Sample size How many participants were in the 
study?  
Methods 
13. Non-participation How many people refused to 
participate or dropped out? Reasons?  
Methods 
Setting   
14. Setting of data 
collection 
Where was the data collected? e.g. 
home, clinic, workplace  
Methods 
15. Presence of non-
participants 
Was anyone else present besides the 
participants and researchers?  
No 
16. Description of sample What are the important characteristics 
of the sample? e.g. demographic 
data, date  
Methods 
Data collection    
17. Interview guide Were questions, prompts, guides 
provided by the authors? Was it pilot 
tested?  
Methods 
18. Repeat interviews Were repeat inter views carried out? If 
yes, how many?  
No 
151 
 
19. Audio/visual recording Did the research use audio or visual 
recording to collect the data?  
Methods 
20. Field notes Were ﬁeld notes made during and/or 
after the inter view or focus group? 
Methods 
21. Duration What was the duration of the inter 
views or focus group?  
Methods 
22. Data saturation Was data saturation discussed?  Methods 
23. Transcripts returned Were transcripts returned to 
participants for comment and/or 
correction?  
Methods 
Domain 3: analysis and 
ﬁndings  
  
Data analysis    
24. Number of data 
coders 
How many data coders coded the 
data?  
Methods 
25. Description of the 
coding tree 
Did authors provide a description of 
the coding tree?  
Methods 
26. Derivation of themes Were themes identiﬁed in advance or 
derived from the data?  
Methods 
27. Software What software, if applicable, was used 
to manage the data?  
Methods  
28. Participant checking Did participants provide feedback on 
the ﬁndings?  
Methods 
Reporting    
29. Quotations presented Were participant quotations presented 
to illustrate the themes/ﬁndings? Was 
each quotation identiﬁed? e.g. 
participant number  
Results 
30. Data and ﬁndings 
consistent 
Was there consistency between the 
data presented and the ﬁndings?  
Discussion 
31. Clarity of major 
themes 
Were major themes clearly presented 
in the ﬁndings?  
Results 
32. Clarity of minor 
themes 
Is there a description of diverse cases 
or discussion of minor themes?       
Results 
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Appendix G- Interview protocol (chapter 2,3) 
 
Interview Guide 
Title: The Management and Supply of Essential Medicines  
Country:  ________________________________________________ 
Occupational Setting:   ____________________________________ 
Profession: ______________________________________________ 
Number of Years Practiced: ________________________________ 
Gender: M  /  F 
Age:  _______________ 
PBI Code: ____________ 
Date:  __________________________ 
Time Started:__________ Time Completed: ______________ 
Location: __________________________________________________ 
Interaction Type:   Face-to-Face  Teleconference Skype 
 
The Role and Application of the Essential Medicines List: 
1. Are you familiar with the Essential Medicines List in your country? 
 
2. What does the concept of having an Essential Medicines List mean to you? 
 
3. What makes a drug essential? 
 
4. How is the concept of the Essential Medicines List applied in your practice setting?  
 
5. Please describe examples of effective use of the Essential Medicines List in your practice 
setting. 
 
6. Please discuss some barriers to the effective use of the Essential Medicines List in your 
practice setting. 
 
The Appropriate use of the Essential Medicines List: 
7. What factors influence how essential and non-essential medicines are used in your 
practice setting? 
 
8. How does the essential medicines list affect your practice? 
 
The Availability of the Essential Medicines List: 
9. Have you encountered any difficulties obtaining any medicines from the Essential 
Medicines List?  
Please describe your experience. 
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10. Please describe the availability of medicines from the Essential Medicines List in your 
practice setting. 
 
The Affordability of the Essential Medicines List: 
11. How does the Essential Medicines list effect costs for individuals, health care 
professionals, health facilities/institutions, governments, and pharmaceutical 
manufacturers? 
 
 
The Quality of Medicines from the Essential Medicines List: 
12. Please describe the quality of essential medicines available in your country.  
 
Other: 
13. How does the essential medicine list effect patients and their health care experience? 
 
14. In your opinion, what are the key issues surrounding the Essential Medicines List? 
 
Additional Comments: 
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Appendix H- Society of Hospital Pharmacists (SHPA) Poster (chapter 3) 
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Appendix I- International Pharmaceutical Federation (FIP) Poster (chapter 
2) 
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Appendix J- IPJ - FIP International Pharmacy Journal (chapter 2,3) 
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Appendix K- Global Home – Access to Essential Medicines Newsletter 
(chapter2,3) 
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